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Abstract 
Acute ST-segment elevation myocardial infarction (STEMI) and its 
associated co-morbidities are among the leading causes of death and disability 
worldwide. We used multi-parametric mapping by cardiovascular magnetic 
resonance (CMR) to provide insights into the pathological processes underlying 
the ischaemic insult and LV remodelling. 
In Chapter 4 we showed that T1 mapping could quantify the AAR as well 
as T2 mapping. Secondly, the presence of a hypo-intense core on T1 or T2 
maps performed equally well to detect intramyocardial haemorrhage (IMH). 
Lastly, we showed that post-contrast T1 maps could accurately delineate acute 
MI size.  
In chapter 5, we found that 6 standard deviations (SD) was the most 
accurate semi-automatic method both for acute and chronic MI size 
quantification using paired CMR scans. However, all 4 of the promising semi-
automated techniques assessed (5-SD, 6SD, full width half maximum and Otsu) 
were equally precise.  
In chapter 6, we showed that the majority of patients with IMH had 
residual iron at follow-up and the latter was associated with adverse LV 
remodelling. Adverse LV remodelling itself was associated with delayed 
resolution of oedema in the MI zone. The remote extracellular volume fraction 
(ECV) was higher in the STEMI patients within the first week, when compared 
to controls, but only remained elevated in those patients who developed 
adverse LV remodelling.  
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3 
In Chapter 7, we obtained the minimal detectable changes for 
percentage change in LV end-diastolic volume (%ΔLVEDV – 12%) and %Δ in 
LV end-systolic volume (%ΔLVESV – 13%) in paired acute and follow-up 
STEMI patients. Combining %ΔLVEDV and %ΔLVESV revealed 4 patterns of 
LV remodelling.  
In conclusion, T1, T2 and T2* CMR mapping complement each other, 
and provide valuable insights into the pathophysiology of STEMI and adverse 
LV remodelling. These parameters could be used to risk-stratify, assess 
response to treatment and for prognostication in reperfused STEMI patients. 
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2 Introduction 
Since the introduction of thrombolysis and primary percutaneous 
coronary intervention (PPCI), mortality due to acute ST-elevation myocardial 
infarction (STEMI) has declined over the past 4 decades (1), and 1-year 
mortality  has reached a plateau at around 11%.(2) However, despite a decline 
in mortality, morbidity post-myocardial infarction (MI) remains significant.(3-7) 
Morbidity and mortality post-STEMI is closely related to the final MI size. A 
recent meta-analysis of 2,632 patients showed that MI size measured by 
cardiovascular magnetic resonance (CMR) or Technetium-99m Sestamibi 
single photon computed tomography (SPECT) within 1 month post-PPCI was 
strongly associated with 1-year hospitalisation for heart failure and all-cause 
mortality.(8) For every 5% increase in MI size, there was a 20% increase in 
relative hazard ratio for 1-year hospitalisation for heart failure and all-cause 
mortality. At present, for patients presenting with an acute STEMI, the most 
effective therapy for limiting MI size, preserving left ventricular (LV) function, 
and reducing the onset of heart failure and subsequent mortality is timely 
reperfusion by PPCI.(9-12) Although, the process of myocardial reperfusion by 
PPCI has been optimised by advances in stent technology, new anti-platelet 
drugs (e.g. prasugrel, ticagrelor, and abciximab), and novel anti-thrombotic 
agents (e.g. bivalirudin therapy), the restoration of coronary blood flow comes at 
a price, paradoxically inducing myocardial injury and cardiomyocyte death, and 
has been termed myocardial reperfusion injury. 
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2.1 Myocardial reperfusion injury  
Whether myocardial reperfusion injury exists in man has been a topic of 
intense debate over past decades.(13) In 1960, Jennings et al (14) first 
postulated the existence of myocardial reperfusion injury in a canine model of 
reperfused MI, characterised by cellular swelling, myofibril contracture, 
disruption of sarcolemma and calcium phosphate particle appearing within the 
mitochondria. However, the differentiation of the ischaemic component from the 
reperfusion component of the acute myocardial injury in the pre-clinical and 
clinical setting is not possible but the existence of myocardial reperfusion injury 
has been proven indirectly. In 2005, Staat et al. (15) first provided some 
evidence of the existence of myocardial reperfusion injury in the clinical setting. 
They showed that ischaemic postconditioning (using four 1-minute low-pressure 
inflations and deflations of the angioplasty balloon following direct stenting of 
the culprit lesion) led to a 36% reduction in MI size in PPCI-treated STEMI 
patients. The ability for a therapeutic intervention, applied at the onset of 
reperfusion, to reduce MI size has provided indirect evidence that the 
phenomenon of myocardial reperfusion injury exists in man.  As a result, 
myocardial reperfusion injury has emerged as a promising target for 
cardioprotection.(16)  
Four types of myocardial reperfusion injury have been described:  
1. Reperfusion-induced arrhythmias: these occur on reperfusing a previously 
ischaemic myocardium and comprise of idioventricular rhythm and 
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ventricular arrhythmias. The vast majority of these arrhythmias are self-
terminating or are easily treated.(17) 
2. Myocardial stunning: this refers to the reversible contractile dysfunction that 
occurs on reperfusing the acutely ischaemic myocardium and is believed to 
be due to myocardial oxidative stress and intracellular calcium overload.(18) 
3. Coronary no-reflow and microvascular obstruction (MVO): coronary no-
reflow in the infarct-related artery following PPCI is indicative of underlying 
MVO – defined as the “inability to reperfuse a previously ischaemic 
region”.(19) Some of the major contributing factors include capillary 
compression by swollen cardiomyocytes and endothelial cells, thrombogenic 
and vasomotor substance release, neutrophil plugging, capillary damage, 
impaired coronary vasodilatation, coronary microembolisation from the 
atherosclerotic plaque, and platelet micro-thrombi as illustrated in Figure 
2-1.(20, 21) Intracoronary agents such as nitrates, calcium channel blockers, 
adenosine and nicorandil have been used to treat coronary no-reflow and 
improve myocardial reperfusion – although none of these have been shown 
to reduce MVO or improve clinical outcomes.(22)  
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4. Lethal myocardial reperfusion injury: Reperfusing a previously ischaemic 
cardiomyocyte induces cytosolic and mitochondrial calcium overload, 
oxidative stress, rapid restoration in intracellular pH, which on a background 
of relative adenosine triphosphate depletion, culminates in the opening of 
the mitochondrial permeability transition pore and irreversible cardiomyocyte 
hypercontracture – the hallmark of lethal myocardial reperfusion injury.(23)  
 
Crucially, there is currently no effective therapy for reducing either MVO 
or lethal myocardial reperfusion injury. Therefore, novel therapeutic 
interventions are required to protect the heart from acute myocardial 
reperfusion injury in STEMI patients, in order to improve clinical outcomes.
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Figure 2-1: Factors contributing to the development of 
MVO 
This figure illustrates some of the factors contributing to the 
development of MVO, namely external compression of capillaries by 
interstitial and cellular oedema, by swollen cardiomyocytes and 
endothelial cells, cellular plugging, capillary damage with 
extravasation of red blood cells, coronary microembolisation of 
debris and in-situ thrombosis. 
 
2.2 The need for cardioprotection 
The consequence of myocardial reperfusion injury is the death of 
cardiomyocytes that were still viable at the end of the index ischaemic insult, 
and which accounts for up to 50% of the final MI size, thereby mitigating the 
benefits of reperfusion, and making lethal myocardial reperfusion injury a 
therapeutic target for cardioprotection (Figure 2-2).  
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Figure 2-2: This hypothetical scheme depicts the 
magnitude and clinical impact of myocardial reperfusion injury 
in patients with ischaemic heart disease who are subjected to 
acute ischaemia/reperfusion injury.  
The thick blue curve shows the extent of myocardial salvage 
(which equates to the area-at-risk subtract the myocardial infarct 
size and is expressed as the % of the left ventricular mass) in a 
theoretical patient presenting with an acute ST-segment elevation 
myocardial infarction (STEMI) reperfused by primary percutaneous 
coronary intervention (PPCI) or thrombolysis. As expected in the 
absence of reperfusion the extent of myocardial salvage declines 
with time. Although myocardial reperfusion is essential for 
myocardial salvage following a STEMI, the process of restoring 
coronary blood flow within the infarct-related artery, can 
paradoxically induce cardiomyocyte death – a phenomenon that has 
been termed ‘myocardial reperfusion injury’. As a result, following 
reperfusion, the extent of myocardial salvage is actually smaller 
than expected given the duration of acute myocardial ischaemia – 
this attenuation in myocardial salvage is due to the presence of 
myocardial reperfusion injury, which can contribute up to 50% of the 
final myocardial infarct size. 
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In this regard, ‘ischaemic conditioning’, in which the heart is rendered 
tolerant to acute ischaemia/reperfusion injury  (IRI) by subjecting it to cycles of 
brief ischaemia and reperfusion, provides an endogenous form of 
cardioprotection. 
The therapeutic potential of ischaemic conditioning, a collective term 
given to the different forms of endogenous cardioprotection, include ischaemic 
preconditioning, ischaemic postconditioning, remote ischaemic conditioning and 
pharmacological conditioning. 
 
Ischaemic preconditioning (IPC) 
In 1986, Murry et al (24) made the intriguing observation that following 
an acute coronary artery occlusion the resultant MI size could be significantly 
reduced by ‘preconditioning’ the heart with brief episodes of ischaemia and 
reperfusion. As a cardioprotective strategy for protecting the heart against acute 
myocardial reperfusion injury, its clinical application has been limited by the 
need to apply the IPC stimulus directly to the heart, and prior to the index 
ischaemia, which is not possible in the clinical setting.  
 
Ischaemic postconditioning 
In 2003, Zhao et al (25) discovered that by interrupting myocardial 
reperfusion with several short-lived episodes of myocardial ischaemia, this led 
to a reduction in MI size to a similar extent as IPC – a phenomenon which has 
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been termed ‘ischaemic postconditioning’ (IPost). It has also provided 
confirmatory evidence for the existence of lethal myocardial reperfusion injury in 
man. However, IPost requires the intervention applied directly to the heart, 
which may not always be feasible or practical depending on the clinical 
situation. 
 
Remote ischaemic conditioning 
In 1993, Przyklenk et al. (26) made the interesting observation that the 
cardioprotective effect of IPC was not restricted to one particular coronary artery 
territory and it could be transferred to another coronary artery territory. This 
gave rise to the concept of ‘remote ischaemic conditioning’ (RIC), the term 
given to the cardioprotection induced by applying cycles of brief ischaemia and 
reperfusion to an organ or tissue away from the heart.  
 
Pharmacological conditioning  
The elucidation of the signal transduction pathways underlying ischaemic 
conditioning has resulted in the identification of new targets for cardioprotection, 
some of which can be modulated by pharmacological agents.(27, 28) However, 
pharmacological conditioning strategies that have shown promise in the 
preclinical setting or small proof-of-concept studies have failed to consistently 
show a benefit in the clinical setting.(29)  
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2.3 Challenges facing clinical cardioprotection research  
There are a number of challenges facing clinical cardioprotection 
research. Firstly, the translation of novel cardioprotective therapies into the 
clinical setting for patient benefit has been extremely difficult. Over the last 30-
40 years a vast number of therapies with proven efficacy for preventing 
myocardial reperfusion injury and reducing MI size in experimental animal 
studies (e.g. such as glucose-insulin-potassium (30, 31), cyclosporine (32, 33) 
and erythropoietin (34-36)), have produced disappointing results when 
investigated in the clinical setting as adjunctive therapy to reperfusion.(37) More 
recently, a number of promising interventions to reduce MI size in STEMI 
patients have also failed to meet their primary endpoint of cardioprotection - 
these have included studies investigating therapeutic hypothermia (38, 39), 
targeting mitochondrial function (40, 41), and modulation of nitric oxide 
signalling (42, 43) as adjuncts to myocardial reperfusion. The reasons for this 
failure to translate cardioprotection into the clinical setting have been attributed 
to a number of factors including the use of inappropriate animal MI models and 
poorly designed clinical studies.(44-47) 
A second challenge facing clinical cardioprotection research is that 
clinical outcomes of STEMI patients following PPCI continue to improve, making 
it increasingly difficult to demonstrate an improvement in clinical outcomes with 
a novel cardioprotective therapy. However, although mortality following STEMI 
is in decline, the number of patients surviving STEMI and going on to develop 
heart failure remains significant. There remains, therefore, an unmet need to 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
32 
discover novel therapeutic strategies capable of preventing myocardial 
reperfusion injury and reducing MI size, so as to preserve LV systolic function 
and prevent the onset of heart failure in reperfused STEMI patients. 
Last but not least, it may be possible that some of the therapeutic 
strategies did not consistently show a cardioprotective benefit in the pre-clinical 
setting using different animal models and their translation to the clinical setting 
was premature. One such example is cyclosporin that was summarised in a 
meta-analysis by Lim et al.(48) They identified 20 pre-clinical studies involving 4 
animal species. Cyclosporin failed to consistently reduce MI size in studies 
using the porcine model of MI. The porcine model is considered a closer match 
to human physiology (49) and therefore given the inconsistent findings of 
cyclosporin on MI size reduction in that model, it is likely that failure of this drug 
to show an improvement in outcomes in the clinical setting (32) may have been 
due to a lack of efficacy. 
 
2.4 Optimising the clinical translation of cardioprotection 
The failure to translate promising cardioprotective therapies from bench to 
bedside has been the subject of several recent review articles.(44-47) There are 
certain factors that need to be taken into account whilst designing clinical 
studies in order to improve the chances of reaping their maximum benefit in the 
clinical environment. In the setting of STEMI patients undergoing PPCI, these 
key points need to be taken into account: 
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• Patients that are most likely to benefit from the cardioprotective therapy 
should be recruited: large area-at-risk (AAR) (>30% of the LV)(50); no 
coronary collateralisation (Rentrop<1); occluded artery prior to PPCI 
(thrombolysis in myocardial infarction flow grade 0 or 1); those 
presenting within 2-3 hours of symptoms onset.(51, 52) 
• Only therapies having shown conclusive cardioprotection in pre-clinical 
studies should be tested. 
• The therapy should be administered prior to myocardial reperfusion via 
PPCI. 
• Confounding factors such as age, pre-infarct angina, diabetes mellitus, 
hypertension, dyslipidaemia and concomitant medications (nitrates, 
morphine, nicorandil, sulphonamides), which can interfere with 
cardioprotection, should be taken into consideration when performing 
power calculation.(53) 
• Relevant clinical endpoints for assessing cardioprotective efficacy should 
be selected. These include: MI size (enzymatic or CMR); myocardial 
salvage index; MVO; LV remodelling, LV ejection fraction (LVEF); 
cardiac death; and hospitalisation for heart failure. 
 
Although the points listed above might theoretically identify a group of 
patients who would most likely benefit from a cardioprotective therapy, using 
these strict criteria in the clinical setting is not realistic. A large number of 
patients would need to be screened prior to recruiting only a handful of them 
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and this approach would make such a trial impractical and not cost-effective. 
Furthermore, any potentially therapy found to be effective would not be 
applicable to the general cohort of STEMI patients. 
 
2.5 The role of CMR in cardioprotection studies 
CMR is a well-established tool for the quantification of focal and diffuse 
fibrosis.(54) Late gadolinium enhancement (LGE) by CMR is considered the 
gold standard for MI size quantification.(55-57) CMR can also provide 
information on LV function, MVO and the AAR (to calculate myocardial 
salvage). MI size (8, 58, 59), MVO (60, 61) and myocardial salvage (62, 63) 
assessed by CMR performed in the first few days following PPCI in STEMI 
patients have all been shown to be strongly associated with prognosis. With the 
recent availability of T1, T2, T2* and extracellular volume fraction (ECV) 
mapping, more in-depth insights can be obtained into various biological 
processes such as oedema, intramyocardial haemorrhage (IMH), MVO, and 
changes in the remote myocardial interstitial space following an acute STEMI. 
As a result, CMR is increasingly being used as a tool, providing several 
surrogate endpoints, in randomised controlled trials assessing novel 
cardioprotective therapies for reducing MI size in reperfused STEMI 
patients.(64)  
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2.5.1 Area-at-risk (AAR) 
2.5.1.1 Importance of knowing the AAR 
To assess the effectiveness of a cardioprotective intervention, the actual 
MI size needs to be compared to the hypothetical MI size if the artery was not 
promptly reperfused, that is, the AAR. In the pre-clinical setting, the AAR can be 
obtained by measuring the regional myocardial blood flow with microspheres 
during coronary occlusion in vivo.(65) In the post-mortem setting, the AAR can 
be obtained by the injection of Evans blue dye during re-occlusion of the 
coronary and MI size can be obtained with triphenyl tetrazolium chloride 
staining.(65)  
Once the AAR and MI size are known, myocardial salvage (Figure 2-5) 
and myocardial salvage index (MSI) can be calculated using the formula below: 
MSI = (AAR - MI size)/AAR 
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Figure 2-3: Schematic representation of the AAR (blue), 
infarct size (grey) and the salvaged myocardium (yellow) 
 
 
MSI is considered a more sensitive measure to assess the effectiveness 
of a cardioprotective strategy than a reduction in absolute MI size or MI size as 
a percentage of the LV alone.(66, 67) Figure 2-4 below illustrates 2 patients 
with similar MI size in grams and as a percentage of the LV. However, Patient A 
has a smaller AAR but a greater transmural extent of MI than patient B. 
Therefore, it is clear that Patient B has a greater myocardial salvage and MSI 
than A. This example highlights the superiority of MSI over MI size, as a 
percentage of the LV or in grams; to be used as a surrogate endpoint in future 
studies. 
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Figure 2-4: 2 patients with similar MI size as a 
percentage of the LV but different MSI 
 
However, the accurate assessment of the AAR in the clinical setting 
using a technique that is easily accessible, reproducible, affordable and 
practical has been difficult and currently there is no established method. 
 
2.5.1.2 Non-CMR based method for assessing the AAR 
The well-validated method to assess the AAR in the clinical setting is by 
99Technetium-sestamibi SPECT.(68) However, this requires injection of 
99Technetium-sestamibi prior to reperfusion of the culprit artery and performing 
a SPECT study within 4 to 6 hours of injection. Furthermore, in order to obtain 
the MI size, a second scan has to be performed at a later stage, usually after 5 
to 7 days (69), for an estimation of the MI size. Recently, injection of the tracer 
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up to 2 hours post-reperfusion has also been shown to be successful in 
delineating the AAR.(70) However, this is logistically difficult to perform, 
involves radiation exposure, is expensive, and is not widely available.(67) 
The electrocardiogram has been used to estimate the AAR by using a 
combination of the ST-segment abnormalities and QRS complex scores but still 
underestimated the AAR by SPECT.(71) Furthermore, it performs less well in 
anterior STEMIs when compared to inferior STEMIs.(72) This technique is not 
robust when compared to SPECT(73) and has therefore failed to be widely 
adopted. 
The circumferential extent of the segments with abnormal contractility by 
left ventriculography at the time of PPCI has also been used to assess the AAR 
in some cardioprotection studies (50, 74-76) but lacks prior robust validation, 
and can be confounded by abnormal contractility due to myocardial 
stunning.(77)  
Three angiographic score models have been developed and can be used 
to assess the AAR. The Duke Jeopardy Score (78) divides the coronary tree 
into six segments. All segments distal to the culprit lesion are assigned 2 points 
and considered to be part of the AAR. The Bypass Angioplasty 
Revascularization Investigation (BARI) score (79) takes into account the 
vessels’ diameter and length and grades them according to specific criteria. The 
scores of the vessels subtended beyond the culprit lesion are summed and 
divided by the total score of the whole left ventricle and expressed as a 
percentage of the LV. The Alberta Provincial Project for Outcome Assessment 
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in Coronary Heart Disease (APPROACH) score is based on previous human 
post-mortem studies and divides the LV according to the relative proportion of 
myocardium perfused by each coronary artery. This model then assigns scores 
to the vessels based on the location of the culprit lesion as proximal, mid, or 
distal and the size of the vessels.(80)  
Ortiz-Perez et al (81) (83 patients) showed that the BARI and 
APPROACH scores matched the AAR derived by the infarct endocardial 
surface area (ESA) (R=0.90 and 0.87 respectively). However, Wright et al (82) 
(108 patients) showed that the BARI score only moderately correlated (R=0.42) 
with infarct-ESA but had a better correlation (R=0.77) with black blood T2-
weighted short tau inversion recovery (STIR) CMR.(82) Likewise, Fuernau et al. 
(83) (197 patients) showed a moderate correlation between APPROACH score 
and infarct ESA (R=0.44) and better correlation with black blood triple inversion 
recovery T2-weighted imaging (R=0.87). 
 
2.5.1.3 Assessment of the AAR by T2-weighted CMR  
Due to the limitations of the above techniques for delineating the AAR, 
CMR has recently emerged as a promising tool for the assessment of both the 
MI size and the AAR in one single scan. Higgins et al (84) in the 1980s were the 
first investigators to study myocardial T2 in a canine model of MI. Interestingly, 
both T2 and T1 were shown to change similarly in the setting of an acute MI. 
The observed changes were theoretically consistent with myocardial oedema 
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and correlated with the measurements of myocardial water content estimated 
by wet-weight to dry-weight ratios. The changes in T2 have been described to 
be due to a combination of an increase in absolute tissue water, movement of 
water from the extracellular to the intracellular compartment, and the conversion 
of protein-bound water to free water.(85) In animal models of MI, Garcia-Dorado 
et al (86) (porcine models of MI), Boxt et al. (87) and Aletras et al. (88) (both 
using canine models of MI) confirmed that T2-weighted CMR images 
represented the AAR. Tilak et al. (89) used a canine model of permanent 
coronary ligation and showed that the AAR depicted by first pass perfusion on 
day 1 agreed well with the hyper-intense zones on T2-weighted images 
performed on day 2.  
In the clinical setting, Friedrich et al (90) (92 patients) showed that T2-
weighted images of acute MI in patients had hyper-intense regions in the 
distribution of the culprit coronary artery and that the hyper-intense zones were 
typically transmural in extent, and significantly larger than the acute MI size and 
could be used to assess myocardial salvage. Carlsson et al (91) (16 patients) 
injected sestamibi in STEMI patients prior to PPCI and imaged with SPECT to 
validate T2-weighted images. They found an excellent correlation between the 
AAR derived by SPECT and T2-weighted imaging. However, dark blood T2-
weighted imaging has several limitations including the subjective interpretation 
of the images, variations in regional myocardial intensity due to changes in 
sensitivity of surface coils, blood-pooling artefacts at the subendocardial border, 
its relatively low contrast-to-noise ratio between normal and abnormal 
myocardium, and its susceptibility to breathing and motion artefacts.(66, 92) 
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Therefore, to overcome these limitations, bright blood T2-weighted SSFP-based 
sequences using a T2 preparation (93) or a turbo spin echo – SSFP hybrid 
approach were developed.(94) These bright blood T2-weighted sequences 
provide more robust image quality while preserving the contrast-to-noise ratio 
when compared to the dark blood T2-weighted imaging. Berry et al (95) (50 
patients) used the bright-blood T2 magnetisation-preparation based sequences 
to delineate the AAR and compared it with angiographic measures of the AAR 
in patients with recent acute MI. The oedema-based AAR correlated with the 
APPROACH score, with a bias of about 2.5% on Bland-Altman analysis.(95) 
Payne et al (96) (64 patients) subsequently showed that bright blood T2-
weighted imaging had higher diagnostic accuracy that dark blood T2-weighted 
imaging to identify and delineate the AAR.  
Further progress was made in this field by Giri et al (97) developed the 
T2 mapping technique. They found that T2 mapping was more robust than T2-
weighted imaging to detect oedema and the former did not suffer from the 
above limitations. Furthermore, the T2 values can be directly obtained from the 
pixel-wise T2 maps and does not require manual adjustment of the window 
settings. Verhaert et al (98) (27 patients) showed that T2 mapping performed 
better than T2-weighted STIR images to detect acute myocardial injury in 
STEMI patients, confirming the superiority of T2 mapping over T2-weighted 
STIR imaging. Most recently, McAlindon et al (99) (40 patients) showed that the 
detection of the AAR by T2 mapping was similar to T2-weighted STIR imaging, 
but the former was more reproducible. 
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2.5.1.4 Controversies surrounding the use of T2-weighted imaging for the AAR 
However not all pre-clinical and clinical studies have support the notion 
that the areas of hyper-intensity on the T2-weighted images represent the 
AAR.(100) Johnston et al (101) and Miller et al (102) (both using canine models 
of MI) showed that T2-weighted MR images demonstrated mostly 
subendocardial hyper-intense regions compared to a transmural reduction in 
blood flow by radioactive microspheres as the reference for the AAR. Ryan et al 
(103) (using different occlusion times in a canine model of MI) showed that 
those with MI on histology had areas of hyper-intensity on T2-weighted MR 
images, whereas the canines without MI did not have any T2 abnormalities, 
despite displaying regional systolic dysfunction. In the pre-clinical setting, Kim 
et al (104) reported that T2-weighted imaging did not depict the AAR in 
anaesthetised dogs that were subjected to different durations of coronary 
occlusion.  MI size by LGE was compared to the gold standard (triphenyl 
tetrazolium chloride staining) and AAR by fluorescent microspheres to T2-
weighted imaging after 4±1 days reperfusion. The T2-weighted hyper-intensity 
correlated better and matched in shape with the MI size than with the AAR and 
these findings were confirmed in a small group of acute STEMI patients. 
Although the findings from the canine model of MI may be due to the presence 
of well-developed collaterals in that species, the findings in their small group of 
patients is in contrast with all other clinical studies published so far using T2-
weighted imaging in reperfused STEMI. 
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In the wake of the above controversies surrounding whether T2 
abnormalities depict the irreversibly injured myocardium only, or the reversibly 
injured (salvaged) myocardium as well, in a porcine model of MI, Ubach et al 
(105) showed that the AAR derived from T2-weighted imaging matched that 
from SPECT, both in animals with and without LGE. Recently, using hybrid 
positron emission tomography (PET)/MR imaging, we showed that the area of 
reduced 18F-fluorodeoxyglucose uptake was significantly larger than the MI 
size and closely matched the AAR delineated by T2, supporting the notion that 
T2 mapping does delineate both the reversibly and the irreversibly injury 
myocardium within the AAR.(106) Hammer-Hansen et al (107) provided some 
further insights on this topic, using a canine model of MI and T2 mapping CMR. 
They showed that the T2 signal was elevated in the MI zone and salvaged 
myocardium when compared to the remote myocardium, and the T2 values 
were higher in the MI zone when compared to the salvage myocardium. 
Furthermore, animals with CMR performed at 2 hours had higher T2 values in 
both the infarct and salvaged myocardium compared to those who had the scan 
at 48 hours, highlighting that the extent of myocardial oedema is dynamic.  
The dynamic nature of oedema post-MI has been previously described in 
the pre-clinical setting. Johnston et al (108) showed in a serial study involving a 
rabbit model of non-reperfused MI that T2 relaxation times measured by nuclear 
magnetic resonance increased at 3 days and returned to baseline at 2 months. 
Using a porcine model of reperfused MI, Foltz et al (109) showed that T1 and 
T2 were elevated at 1 hour post reperfusion and were nearly normal at Day 2. 
On Day 7, T2 increased while T1 decreased.  The partition coefficient was 
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elevated by >150% at all time points. These animals had IMH on histology and 
the fluctuations in T1 and T2 were explained by a combination of oedema and 
subsequently oxidative denaturing of haemoglobin to methaemoglobin. 
Recently, Fernandez-Jimenez et al (110) built on this work and looked at the 
interplay between myocardial water content (using desiccation) and T2 
relaxation times in a similar porcine model of reperfused MI. They reported a 
‘bimodal’ pattern of oedema, appearing at 2 hours and resolving by 24 hours 
and reappearing on day 4 and peaking at day 7. The first wave of oedema was 
attributed to reperfusion injury and the second wave of oedema was put down 
to inflammation during the tissue-healing phase.(111) However, they did not 
take the presence of MVO and IMH into account, which could have interfered 
with their T2 measurements, and the overall sample size for each time point 
was 5 pigs. Recently, Carrick et al (112) showed that although the T2 and T2* 
of the core of the MI followed a bimodal pattern in those with IMH assessed by 
T2* and in those patients without IMH, the T2 relaxation time progressively 
increased in the MI zone. The extent of myocardial oedema (% of the LV) in 
their study followed a unimodal pattern and peaked at day 3 in patients both 
with and without IMH. It was previously believed that oedema is stable in the 
first week of an MI based on the study by Carlsson et al (91) and Dall'Armellina 
et al (113) However both these studies only performed T2-weighted imaging on 
days 1 and 7 and the peak shown by Carrick et al (112) on day 3 was most 
probably missed. 
Nordlund et al (114) recently provided some indirect evidence that there 
was no bimodal pattern of oedema in the clinical setting. They combined data 
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from 2 studies involving 215 patients and showed there was no difference in 
size, quality of the T2-weighted images and the ability to detect the culprit 
territory when patients having a CMR study on Day 1 to Day 6 onwards were 
compared. 
The utility of T2-weighted imaging for measuring the AAR has also been 
put into question because certain cardioprotective therapies have been shown 
to reduce not only MI size but the extent of myocardial oedema as well. 
Ischaemic postconditioning (115) and remote ischaemic conditioning (using 
transient arm or leg ischaemia and reperfusion)(116, 117) has been shown to 
reduce MI size and the extent of oedema delineated by T2 mapping and T2-
weighted imaging, leading to an underestimation of the AAR by this technique. 
However, these were small studies of reperfused STEMI patients and were not 
adequately powered to assess that endpoint. Intuitively, the fact that a 
cardioprotective therapy can reduce the extent of myocardial oedema, which 
itself is the result of myocardial reperfusion injury, should not be unexpected. 
However, in a recent large study of 696 STEMI patients by Eitel et al (118), 
ischaemic postconditioning or a combination of remote ischaemic conditioning 
and ischaemic postconditioning did not lead to a reduction in myocardial 
oedema as compared to those without any conditioning intervention. 
Furthermore, drugs such as metoprolol (119, 120) and exenatide (121, 122) 
that were effective at reducing MI size did not reduce the extent of myocardial 
oedema. Therefore, further studies are required to investigate the reasons for 
these mixed results. 
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2.5.1.5 Other CMR-based techniques for delineating the AAR 
The infarct-ESA (81) has been proposed to assess the AAR, based on 
the assumption that the lateral borders of an MI are already established early 
after an MI, and the wave-front of ischaemic injury begins in the 
subendocardium and progresses in the radial direction.(123) O’Regan et al 
(124) (15 patients) compared the transmural and circumferential extent of T2 
abnormalities and LGE. They found that the main difference between the 2 
methods was in the transmural direction. Ortiz-Perez et al (81) used the infarct-
ESA (Infarct-ESA = summed endocardial hyper-enhanced infarct length/total LV 
endocardial length x 100) in 83 patients for the AAR and showed good 
correlations with BARI and APPROACH angiographic scores. However, Wright 
et al (82) (108 patients) showed that, although black blood T2-weighted 
correlated well with infarct-ESA (R=0.77), the AAR by T2 was 8% larger than 
that derived from ESA.(82) Ubach et al (125) (37 patients) subsequently also 
showed that the AAR by infarct-ESA was significantly smaller than the AAR 
derived from T2-weighted imaging. In particular, there were a small proportion 
of patients with no LGE and therefore infarct-ESA could not be applied to those 
patients. Therefore, infarct-ESA is not considered a reliable method for the 
AAR, especially in those with no or very small MI.  
Contrast-enhanced steady state free precession (CE-SSFP) cine 
imaging is another modality proposed to delineate the AAR. The SSFP-cine 
imaging technique is dependent on the T2/T1-weighted contrast, and in the 
setting of acute MI, it can sometimes display intrinsic contrast signal in the 
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areas of oedema due to the higher T2/T1 ratio. This ratio is further increased 
following gadolinium administration due to a reduction in T1 (predominantly). 
Therefore, this technique has shown promise to delineate the AAR but still 
relies on the presence of oedema in the salvaged myocardium. Sorensson et al 
(126) (16 STEMI patients) showed good correlation (R2=0.78) between the 
AAR derived from SPECT and CE-SSFP images. Ubach et al (127) (21 
patients) subsequently showed good agreement between T2-weighted imaging 
and CE-SSFP cines. Most recently, Nordlund et al (114, 128) in a much larger 
cohort of patients showed good agreement between contrast-enhanced SSFP 
cines and T2-STIR imaging to delineate the AAR. Although there was no bias 
between the 2 methods, the correlation was moderate (R2 0.71) and the limits of 
agreement were wide at ±12%.(114)  The advantage of CE-SSFP imaging over 
T2-weighted imaging was that out of 200 patients with T2-STIR data, only 65% 
had images of diagnostic quality compared to 97% of the SSFP images being 
diagnostic. Furthermore, no additional breath-hold imaging, specifically for the 
AAR, is needed. 
Early gadolinium enhancement (EGE) imaging has been proposed to 
assess the AAR. Matsumoto et al (129) (34 patients) showed that EGE 
performed 2 minutes post-contrast extended transmurally, and was consistently 
larger than the LGE extent. Furthermore, the AAR derived from EGE correlated 
well (R=0.86) with T2-weighted imaging with minimal bias (-0.8%), but the limits 
of agreement were quite wide at 11.8%. Hammer-Hansen et al (130) (37 
patients) provided some insights into this observation using serial T1 mapping. 
Post contrast T1 between the salvaged and infarcted myocardium was similar at 
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4 minutes but different at 8 to 20 minutes post-contrast. Therefore, performing 
EGE before 8 minutes would also enhance the salvaged myocardium and this 
explains the findings from Matsumoto et al(129) However, McAlindon et al (99) 
(40 patients) showed that the AAR by EGE was significantly lower than that by 
T2 mapping and its quantification was also less reproducible. 
 
2.5.1.6 T1 mapping for the delineation of the AAR 
Native T1 mapping CMR is another modality proposed to assess the 
AAR. Although native T1-weighted imaging assesses the longitudinal relaxation 
time of the tissue compared to T2 mapping, which measures the transverse 
relaxation time, T1 mapping is also heavily influenced by the T2 properties of 
the tissue and can also detect oedema. Using a canine model of MI with 
microspheres as the reference standard for the AAR, Ugander et al (131) 
showed that native T1 mapping performed equally well along with T2 mapping 
to delineate the AAR. In the clinical setting, Dall’Armellina et al (132) (41 
patients) confirmed that T1 mapping performed equally well to delineate the 
AAR when compared to T2-weighted imaging in STEMI and was superior to T2-
weighted imaging to delineate the AAR in non ST-segment elevation myocardial 
infarction. Langhans et al (133) (n=14) found that the AAR by T1 and T2 
mapping CMR at 1.5T correlated well with that obtained by SPECT but direct 
comparison between T1 and T2 mapping was not performed. T2 mapping is 
considered to be the most robust method to delineate the AAR so far. Although 
T1 mapping has also shown promise, the diagnostic performance of T1 
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mapping against T2 mapping in the clinical setting has not been performed. If 
T1 mapping performs equally well to detect the AAR as shown by the animal 
data, then this may help to keep scanning time to a minimum by not acquiring 
T2 mapping in cases when T1 mapping for ECV data is already being acquired. 
 
2.5.2 Microvascular obstruction (MVO) and Intramyocardial haemorrhage 
(IMH) 
MVO, which manifests clinically as coronary no-reflow in the infarct-
related artery following PPCI, is defined as the “inability to reperfuse a 
previously ischaemic region”.(19) IMH has been shown to be a consequence of 
the process of reperfusion itself (134, 135) and occurs after a period of 45 
minutes of coronary occlusion in a porcine model of MI.(136) MVO is closely 
linked with the development of IMH (137) and clinical studies have supported 
the notion that MVO precedes the development of IMH in a subset of patients 
and is considered a more severe form of microvascular injury.(138)  
 
2.5.2.1 Incidence and clinical significance of MVO and IMH 
Despite the introduction of PPCI as the reperfusion strategy of choice in 
STEMI, nearly 50% of patients still develop MVO (61), and 35-40% have IMH 
(60, 139), as detected by CMR. The presence of MVO following PPCI, 
assessed by TIMI flow post-PPCI (140), a combination of ST-segment 
resolution and myocardial blush grade (141), myocardial contrast 
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echocardiography (142) and CMR (143-145), have all strongly been linked to 
poor outcomes.(21) In a recent meta-analysis (61) of more than 1000 STEMI 
patients reperfused by PPCI, there was a graded reduction in event-free 
survival in patients with MI size < 25% of the LV, with and without MVO, and 
those with MI size > 25% of the LV, with and without MVO, assessed by CMR. 
Both MVO and IMH are associated with larger MI size, adverse LV remodelling 
and poor clinical outcomes as recently summarised in 2 meta-analyses.(60, 61) 
Carrick et al (139) (228 patients) recently showed that both these processes are 
dynamic and distinct from each other, and IMH assessed by T2* mapping was 
more closely associated with adverse events than MVO.  
 
2.5.2.2 Mechanisms underlying MVO and IMH  
Several factors may (21) to be responsible for the development of MVO: 
pre-existing coronary microvascular dysfunction; individual susceptibility; the 
ischaemic injury; myocardial reperfusion injury; and distal embolisation of 
plaque and thrombus microemboli. The first 2 factors are non-modifiable. The 
ischaemic injury is dependent on the total ischaemic time, the AAR, TIMI flow 
pre-PPCI, and collateral blood flow. Tremendous efforts have already minimised 
the chest pain onset to balloon time. Therefore, the main focus of research to 
minimise the burden of MVO has been to target myocardial reperfusion injury 
and distal coronary embolisation. From these 2 perspectives, a number of 
mechanisms have been described to contribute to the occurrence of MVO as 
described above and illustrated in Error! Reference source not found..(20) Two 
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theories regarding the association of MVO with IMH have been proposed. 
Firstly, MVO leads to destruction of the endothelium and results in the 
extravasation of blood. Secondly, there is destruction of the capillaries as a 
direct result of myocardial reperfusion injury, which leads to IMH, the presence 
of which induces further external compression of the remaining microcirculation 
and exacerbates MVO.(60) 
2.5.2.3 Detection of MVO by CMR 
MVO by CMR can be divided into early MVO and late MVO. Early MVO 
can be assessed using first pass perfusion (FPP) or EGE performed with a 
fixed, high inversion time (TI) (e.g. 440 to 500ms at 1.5T), acquired at 1-4 
minutes post contrast.(22, 146) Although FFP has superior temporal resolution 
to EGE, it suffers from relatively lower spatial resolution and full LV coverage is 
not currently possible.(146) On the other hand, EGE using single shot SSFP 
imaging, full LV short axis coverage can be achieved within one acquisition and 
enables more accurate quantification of early MVO.(22) Late MVO can be 
identified as a dark core within the areas of hyperenhancement on conventional 
LGE sequences acquired at 10 to 20 minutes post contrast injection.(22)  
In 1995, Judd et al (147), using a canine model of MI, first reported areas 
of “dark zones” within areas of hyperenhancement on LGE and this correlated 
with areas of no-reflow by pathology. Subsequently Lima et al (148) reported 
similar findings by CMR in patients with large MI.  Since then, several studies 
(149) have looked at the prognostic significance of MVO. Both early MVO and 
late MVO have been associated with adverse LV remodelling and MACE as 
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recently summarised in 2 comprehensive meta-analyses.(60, 61) Van 
Kranenburg et al (61) in a large meta-analysis of more than 1000 patients 
showed that the presence of MVO was an independent predictor of major 
adverse clinical outcome (MACE) at 2 years in STEMI patients, whereas MI size 
was not independently associated with MACE. In the meta-analysis by Hamirani 
et al (60), they showed that there was a weaker correlation of IMH with early 
MVO (R=0.30) than with late MVO (R=0.89 to 0.93). In most studies included in 
that review, IMH was identified only in the presence of late MVO, except in 
Kandler et al (150) and Husser et al (151), where some patients (5% and 9% 
respectively) had IMH without late MVO. However, these studies did not report 
whether these patients without late MVO and IMH had early MVO. Intuitively, 
these patients are likely to have relatively less extent of microvascular injury, 
and would display early MVO and with contrast eventually washing-in from the 
LV cavity by the time the LGE images are acquired. Interestingly, Carrick et al 
(139) in 286 patients did not observe any patients without MVO that had IMH. 
The potential explanation could be that the definition of MVO was different in 
these three studies. Kandler et al (150) and Husser et al (151) defined MVO on 
LGE images acquired at 10 to 15 minutes post contrast whereas Carrick et al 
(139) defined MVO on the early gadolinium enhancement images acquired at 1, 
3, 5 and 7 minutes post-contrast injection. Furthermore the CMR was performed 
at a mean of 2.8 days in Kandler et al (150) and a median of 6 days in Husser 
et al (151) whereas in Carrick et al (139) the CMR scan was performed sooner 
at a mean of 2.1 days.  
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Therefore, based on both these meta-analyses (60, 61) and the recent 
study by Carrick et al (139) on 286 patients, our current understanding is that 
early MVO occurs in around 60-65%; late MVO in around 50-55%; and IMH in 
around 35-40% of reperfused STEMI patients. However, the detection of MVO 
and IMH is dependent on the CMR techniques, timing of imaging and definitions 
used. We believe that those with IMH but no late MVO are likely to have early 
MVO as illustrated in Figure 2-5 below: 
 
Figure 2-5: Prevalence of early MVO, late MVO and IMH  
This Venn diagram depicts the prevalence of early MVO, late 
MVO and IMH by CMR in reperfused STEMI patients. 
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2.5.2.4 T2* for the detection of IMH 
T2* imaging has been shown to detect IMH in animal models of acute MI 
within the first week.(152, 153) Ghugre et al (152), using a porcine model of 
AMI, showed that T2 elevation in those pigs with IMH was blunted by the 
haemorrhagic by-products and manifested as a hypo-intense core on the T2* 
imaging. Furthermore, the reduction in T2* in the MI zone at 2 weeks was 
associated with IMH. Using a porcine model of AMI with IMH, Payne et al (154) 
showed that bright-blood T2-weighted imaging could detect IMH with high and 
similar diagnostic accuracy to T2* imaging when compared to histology. Using 
T2 mapping, dark blood T2-weight imaging and T2*-weighted imaging in a 
canine model of MI, Kali et al (153) showed that T2* imaging was superior than 
T2-weighted imaging to detect IMH due to its relative insensitivity to oedema. In 
the clinical setting, Kandler et al (150) (151 patients) showed that detection of 
IMH by T2*-weighted imaging, defined by a hypo-intense core with T* < 20ms, 
was superior to T2-weighted imaging. 
A threshold value of T* < 20ms has subsequently been used in several 
clinical studies as the reference for IMH (139, 150, 155, 156) except by Zia et al 
(138), where they used a cut-off for T* of < 30ms. Although T2* CMR imaging is 
currently the reference standard for the detection of IMH, it is prone to motion, 
flow and off-resonance artefacts.(157) In a recent study by Carrick et al (139) 
involving 286 patients, only 86% of patients had analysable T2* data.  
 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
55 
2.5.2.5 T2-weighted imaging for the detection of IMH 
We know from brain imaging data that the degradation of the 
extravasated erythrocytes to oxyhaemoglobin, deoxyhaemoglobin, and 
methaemoglobin (strongly paramagnetic) is dynamic and would exhibit different 
T1 and T2 properties at various stages as previously described by Bradley et 
al(158) T2 is better at identifying deoxyhaemoglobin, whereas T1 is better at 
detecting methaemoglobin.(158) Breakdown of the erythrocyte membrane 
eventually leads to ferritin and haemosiderin deposits within macrophages.(146) 
Although T2-STIR imaging has been shown to have a lower diagnostic 
performance for detecting IMH when compared to T2* CMR imaging (150, 153), 
in the absence of T2* imaging or to keep scanning time to a minimum, several 
studies have also used T2-weighted STIR imaging rather than T2* imaging to 
detect IMH as the presence of a hypo-intense core within the AAR.(159-161) 
However, T2-weighted imaging has several limitations as already described and 
leads to a large number of non-diagnostic images.  
 
2.5.2.6 Other methods to detect IMH 
Susceptibility-weighted CMR imaging has been shown to improve the 
detection of IMH at 1.5T (162) and 3T (163), but this method still requires the 
acquisition of the T2*-weighted imaging. The hypo-intense core on the T1 (156, 
164) and T2 maps (138, 153, 165) acquired for the detection of the oedema-
based AAR has been associated with IMH and MVO. However, the diagnostic 
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performance of T1 and T2 maps to detect the presence of IMH and MVO 
following STEMI in the clinical setting has not been directly compared. If the T1 
and T2 maps could identify IMH with good diagnostic accuracy, this may help to 
keep scanning time to a minimum in unwell STEMI patients who are not able to 
tolerate a comprehensive CMR scan, when T1 or T2 mapping is already being 
acquired as part of the study to depict the AAR. Furthermore, in cases when 
T2* imaging were acquired but not interpretable, the T1 or T2 maps could be 
used as a surrogate to detect IMH and would minimise dropout of patients from 
future studies. 
2.5.3 MI size by CMR 
CMR is considered the gold standard imaging modality for quantifying MI 
size (55, 56) and can detect small subendocardial MI (as little as 1 gram) with 
good accuracy.(55, 166, 167) Conventionally, MI can be identified by LGE with 
inversion recovery (IR) T1-weighted sequences and manual adjustment of the 
TIs to null the remote normal myocardium.(133) Gadolinium chelate is an 
extracellular agent and therefore it cannot cross cell membranes that are intact. 
In normal myocardium, the cells are densely packed. Following acute 
myocardial necrosis, the cell membranes are ruptured and together with 
interstitial oedema there is an expansion in the extracellular space. In the 
chronic setting, there is also expansion of the extracellular space due to the 
collagen deposits. Therefore, following gadolinium chelate administration, there 
is wash-in and wash-out of contrast and at equilibrium, a higher concentration 
of contrast is distributed in acute or chronic infarct tissue (leading to significant 
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shortening of T1) than in normal myocardium. Therefore, with appropriate 
nulling of the remote myocardium, the infarct territory appears bright.(64) 
Both acute and chronic MI by CMR has been shown to be a stronger 
predictor of outcome than ejection fraction or LV volumes. (58, 168-171) 
Therefore, due to the robustness of CMR to assess MI size (55, 166, 167), its 
ability to predict outcomes (58, 168-171) and its high reproducibility (56, 172, 
173) which helps to reduce sample size, both acute and chronic MI size by 
CMR is increasing being used as a surrogate endpoint for randomised control 
trials assessing the effectiveness of new cardioprotective therapies.  
 
2.5.3.1 Optimal timing of the acute CMR post-STEMI 
 The optimal timing of the CMR scan following STEMI in clinical 
cardioprotection studies, is a topic of ongoing research. Acute MI size has been 
shown to be dynamic and to decrease significantly in size between Day 1 and 
Day 7 post-STEMI.(174, 175) In a recent study by Carrick et al (112), MI size 
was similar between day 1 and 3 and reduced in size by day 10. Furthermore, 
late MVO have also been shown to reduce in size within the first week (139, 149, 
175) and those with MVO persisting at one week following STEMI was 
demonstrated to be more prognostic.(149) Recently, the detection of IMH has 
been shown to peak at day 3 and reduced in incidence by day 10 post-STEMI, 
and the latter was demonstrated to be more prognostic than MVO.(139)  
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2.5.3.2 Optimal method for MI size quantification 
Several different techniques have been proposed for quantifying acute 
and chronic MI size including manual contouring (176) and semi-automated 
threshold techniques such as a signal intensity threshold of 5 standard 
deviations (SD)(177) or 6-SD (to identify signal intensities of 5-SD and 6-SD 
above the mean normal remote myocardium respectively)(178) above the 
normal remote myocardium, the Otsu technique (to identify the intensity 
threshold from the signal intensity histogram using the value with minimal intra-
class variance between low and high intensities)(179, 180), and the full width 
half maximum (FWHM - to identify signal intensities that are above 50% of 
maximal signal intensity of the reference region of interest)(181-183) technique 
but have shown inconsistent results.  
The consensus document from the Society for Cardiovascular Magnetic 
Resonance Board of Trustees Task Force on Standardized Post Processing 
recommends the semi-automated threshold technique of 5-SD for MI size 
quantification as it may improve reproducibility. Manual contouring is 
considered the gold standard (57, 176) but may be time consuming (183, 184) 
and subjective. FWHM has emerged as the technique having the lowest 
variability(182, 183), but others have shown FWHM to underestimate acute and 
chronic MI size.(180) (185) Recently FWHM45% and 6SD were found to 
perform well in paired acute and follow-up scans at 3T but they did not include 
Otsu in their comparison.(185) However, no studies have compared the 4 
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promising semi-automated techniques (5-SD, 6-SD, Otsu, FWHM) in paired 
acute and follow-up scans at 1.5T. 
 
2.5.3.3 Quantification of MI size from post-contrast T1 mapping 
The quantification of MI size is dependent on the accurate nulling of the 
remote myocardium. Using conventional magnitude reconstructed inversion 
recovery images, the choice of the optimal TI is done manually. Furthermore, a 
comprehensive CMR including information on oedema, IMH, MI size, MVO and 
extracellular volume fraction for research purposes in an acute STEMI patient 
can be challenging to perform as it may last more than an hour and requires 
multiple breath-holds. Therefore, keeping scanning time to a minimum with 
minimal user input would optimise the CMR protocol for these patients to make 
it more tolerable. Post-contrast T1 mapping has shown promise to detect acute 
MI in a small cohort of predominantly non-reperfused acute MI (186) and 
chronic MI patients.(186, 187) Refinements of the T1 Modified Look Locker 
Inversion recovery (MOLLI) prototype using inversion recovery (IR) images at 
different TIs initially designed to improve motion correction (188, 189), can also 
retrospectively create “synthetic” IR LGE images, namely magnitude-
reconstructed IR (MagIR) and phase sensitive IR (PSIR) outputs. These 
synthetic read-outs have recently been shown to accurately detect chronic MI 
size in a small cohort of 17 patients.(190) To date, no studies have assessed 
the performance of post-contrast T1 mapping and synthetic LGE in quantifying 
acute MI size with full LV coverage in a cohort of reperfused STEMI patients.  
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2.5.4 LV remodelling post STEMI 
CMR is considered the gold-standard imaging modality not only for 
quantifying MI size (57), but also for measuring LV volumes and LVEF (57, 
191), given its high reproducibility.(57, 192) Adverse LV remodelling following 
STEMI has been conventionally defined as ≥ 20% increase in LV end-diastolic 
volume (LVEDV) from baseline. This cut-off value was determined using 
echocardiography, and was based on the upper limit of the 95% confidence 
interval of intra-observer variability for the percentage change (%Δ) in LVEDV 
following STEMI.(193, 194) Reverse LV remodelling has been defined as ≥10% 
decrease in LV end-systolic volume (LVESV) by echocardiography following 
cardiac resynchronization therapy, and was derived using receiver operator 
characteristic (ROC) curves for the optimal cut-off for the %ΔLVESV to predict 
mortality.(195) So far, no cut-off values for adverse and reverse LV remodelling 
following STEMI have been defined by CMR, and studies using CMR to assess 
post-STEMI LV remodelling have relied upon using these cut-off values defined 
by echocardiography.(196-198) Other groups have used an arbitrary cut-off of 
≥15% increase in LVESV to define adverse LV remodelling by CMR.(63, 199) 
Post-MI LV remodelling refers to the intricate changes occurring in both 
the infarcted and remote myocardium on a molecular, structural, geometric and 
functional level (200) and its occurrence predisposes to heart failure. The three 
partially overlapping phases during post-MI LV remodelling are the 
inflammatory phase, the proliferative phase and the maturation phase.(201) 
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Numerous anti-inflammatory agents such as glucocorticoids, monoclonal 
antibodies, C1 esterase inhibitors, metalloproteinase inhibitors, 
phosphoinositide-3-kinase inhibitors and immunoglobulin have had promising 
results in the experimental setting, but have failed to be translated into the 
clinical setting.(202)  
 
2.5.4.1 Imperfect link between MI size and adverse LV remodelling 
Infarct size has been linked with adverse LV remodelling.(58, 203, 204) 
The conventional belief has been that a larger MI leads to higher LV wall stress. 
The LV dilates to maintain the stroke volume as a compensatory mechanism 
(via the Frank-Starling principle). However, LV dilation, as described by the 
Laplace relationship, leads to further wall stress and begets more LV dilation. 
Westman et al (205) recently proposed that there was an imperfect link 
between MI size and adverse LV remodelling (defined as >10ml/m2 increase in 
indexed LVEDV).  By re-analysing previously published data (58), they showed 
that in 122 STEMI patients, 15% of those with MI size < 18.5% developed 
adverse LV remodelling and 40% of those with MI size ≥ 18.5% developed 
adverse LV remodelling. They postulated that an excessive inflammatory 
response together with MI size played an important role in the development of 
adverse LV remodelling. 
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2.5.4.2 Residual iron and inflammation 
There are some emerging data that IMH leads to residual iron during the 
convalescent phase on an MI and may be a source of prolonged inflammation 
and may be pro-arrhythmic.(206) Kali et al (207) showed in a small cohort of 15 
STEMI patients and in 20 canines that IMH resulted in residual myocardial iron 
within the MI zone, which can be a source of prolonged inflammatory burden in 
the chronic phase of MI. Roghi et al (208) found higher levels of non-transferrin 
bound iron in 7 out of 15 STEMI patients with MVO and postulated that IMH 
could be a source of cardiotoxicity in these patients. In a small number of 
STEMI patients, T2 in the infarct related territory have been shown to remain 
elevated on CMR performed 6 months post-PPCI.(91, 209) So far, no studies 
have assessed the relationship between persistently elevated T2 in some 
patients and residual myocardial iron and the subsequent development of 
adverse LV remodelling. 
 
2.5.4.3 The role of the remote myocardium in post-MI LV remodelling 
Whether changes in the extracellular matrix (ECM) in the non-infarcted 
remote myocardium in STEMI patients reperfused by PPCI is linked to adverse 
LV remodelling remains incompletely understood.(197, 210-213) It has been 
suggested that primary changes in the ECM that occur acutely in the non-infarct 
zone also contribute to LV remodelling.(214) In an experimental rat model of MI, 
Anversa et al (215) showed that infarcts with 50% loss of mass resulted in 83% 
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expansion of the spared myocardium. In a mouse model of MI, Tsuda et al 
(211) demonstrated that small infarcts without mechanical overload stimulated 
myocardial fibrosis development in the non-ischaemic myocardium distant from 
the infarct site as early as 72 hours. In the clinical setting, Volders et al (210) 
provided post-mortem histological evidence of an increase in interstitial collagen 
in the remote myocardium of infarcted patients when compared to control. 
However, the time course of acute changes and remodelling in the non-infarct 
zone in humans is not well understood, in part due to a prior lack of an in vivo 
imaging modality that could detect ECM expansion and quantify diffuse fibrosis. 
Furthermore, Marijianowski et al (212) challenged the existence of these 
compensatory changes in the remote myocardium. They showed that post-MI 
LV remodelling in patients with end-stage heart failure undergoing transplant 
was not associated with interstitial fibrosis in the remote myocardium.  
From the tissue characterization point of view, Chan et al (213) used 
post-contrast T1 in 25 acute STEMI patients and found evidence of early 
remote expansion of the ECM, which persisted in the chronic stage. Carrick et 
al (197) demonstrated that native T1 of the remote myocardium of reperfused 
STEMI patients on the acute CMR was associated with change in LV end-
diastolic volume from baseline to 6 months and was independently associated 
with adverse cardiac events in 267 STEMI patients after a median follow-up of 
845 days. The assessment of the extracellular space in vivo by CMR can be be 
done by performing native and post-contrast T1 mapping and calculating ECV, 
after correcting for haematocrit. The availability of automated ECV map has 
provided a more accurate method to quantify not only focal fibrosis but also 
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diffuse interstitial expansion.(216, 217) The native and post-contrast T1 maps 
are co-registered and motion-corrected, which significantly improves the quality 
of the generated automated maps.(218) Whether automated ECV maps may 
provide valuable insights into the changes occurring in the remote myocardium 
during post-MI LV remodelling is not known and warrants further investigation. 
 
2.6 T1 and T2 mapping CMR 
Over the last few years, parametric mapping techniques by CMR have 
emerged as being superior to non-quantitative techniques to interrogate a range 
of pathologies as they are more objective, less prone to the sequence 
parameters and surface coil profiles and can detect both global and focal 
changes in the myocardium. These parametric maps have proven to be 
valuable in the field of STEMI and play a major part in this thesis. In this section, 
we provide a brief overview of T1 and T2 mapping techniques. 
 
2.6.1 T1 mapping 
2.6.1.1 The need for T1 Mapping 
Cardiovascular magnetic resonance (CMR) is the gold standard for the 
non-invasive detection of focal fibrosis using gadolinium-based contrast 
agents.(219-222) This technique cannot be used to quantify diffuse fibrosis and 
endomyocardial biopsy (EMB) remains the gold standard despite being prone to 
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sampling error.  Biopsy also carries with it inherent procedural risk and provides 
no information on the extent of ventricular involvement.(223, 224) With the 
introduction of T1 mapping, diffuse processes can now be detected and 
quantified – particularly for infiltrative and storage processes where the signal is 
high and for quantification of diffuse fibrosis which is difficult to perform, but 
potentially has greater impact. It offers numerous promises such as early 
detection of specific conditions; a surrogate marker in drug development trials; 
and as a prognostic marker in certain diseases. However, this is still a rapidly 
evolving field and numerous factors are currently precluding its 
standardization.(225)  
 
2.6.1.2 T1 mapping: past and present  
Late gadolinium enhancement (LGE) imaging was an advance on T1-
weighted imaging in that the operator selects a tissue that was “normal” and 
nulls it – exaggerating the signal from any tissue with a different T1, identifying 
focally abnormal regions such as scar (e.g. infarction), edema or amyloid. T1 
mapping requires the quantification of the exact T1 of a particular tissue and 
can be performed without contrast. Different tissues have specific ranges of T1 
(milliseconds) at a particular magnetic field strength (226) and can be used to 
detect pathology.  
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2.6.1.3 Native T1 or non-contrast myocardial T1 
The native T1 or non-contrast myocardial T1 is the longitudinal relaxation 
time (T1) of a given tissue without a GBCA. This provides intrinsic signal from 
both the myocytes and the interstitium.(227) Our current understanding is that 
T1 is prolonged with fibrosis (228), edema (229) and amyloid (230) and reduced 
in lipid accumulation (Anderson-Fabry disease) (231), cardiac siderosis (232), 
and hemorrhage in acute infarction.(233) However, as techniques advance, 
potentially other trends may be found. It does appear that pseudo-normalization 
of native T1 also occurs when two processes cancel out co-existing fibrosis and 
iron (sickle cell disease) or lipid (Anderson-Fabry disease).(234) 
 
2.6.1.4 Post contrast T1 for extracellular volume quantification 
The extracellular matrix (ECM) is a complex architectural network made 
up of structural and non-structural proteins contributing to strength and 
plasticity.(235) The matrix is hydrated with extracellular fluid – measurement of 
this, the extracellular volume (ECV) approximates the ECM. The ECM and ECV 
may expand with fibrosis, edema or amyloid.  
The gadolinium contrast agent does not cross cell membranes. Post 
contrast T1 mapping therefore partly measures the extracellular space. 
However, factors such as renal excretion rate, altered wash-in and wash-out 
kinetics of the contrast agent in diseased myocardium(236), volume of 
distribution and acquisition time (237) are influencing factors. The ECV 
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technique intrinsically corrects for this. ECV measurement is done when the 
concentration of contrast is equal in the water between cells in the myocardium 
and in blood – a sufficient equilibrium exists, either by a primed infusion or after 
a bolus and sufficient time (15 minutes is adequate for all but massive interstitial 
expansion).(238) The ratio of a pre to post contrast signal change in 
myocardium and blood reflects the relative ECV of blood and myocardium – the 
partition coefficient. As the blood ECV is one minus the haematocrit (from a 
simple blood test, this can be substituted in to obtain the myocardial ECV.(238) 
The ECV is (1-hematocrit) x ΔR1myocardium/ΔR1blood), where R1 = 1/T1. 
There is no real need to use an infusion – the bolus only method(239) 
works for conditions with ECV < 0.4, but progressively reads a higher ECV in 
high interstitial expansion diseases.  An alternative approach is to perform 
multiple T1 measurements during contrast washout rather than awaiting 
equilibrium.(240) The accuracy and relative precision of these approaches are 
not known – and currently most centers do a single pre- and post-contrast 
measurement. Newer approaches are to automatically register the pre- and 
post-contrast T1 maps to create ECV maps.(218) 
 
2.6.1.5 Measuring the T1: techniques and sequences 
2.6.1.5.1 The Look-Locker based maps 
Initial methods of T1 measurement involved multiple breath-holds to 
obtain the recovery curve from different time points. The Look–Locker 
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sequence was introduced (241) to measure the T1 relaxation time at multiple 
time points after an initial excitation pulse and then subsequently adapted as 
the MOLLI (242) sequence. Colour pixel-wise “T1 maps” whereby each pixel 
carries the measured value of T1 can now be generated. Since this MOLLI 
approach, multiple incremental improvements have been made including better 
inversion pulses, sampling schemes, image reconstruction (236, 242), curve 
fitting (making shorter breath-holds) and the introduction of error maps to 
provide confidence in measured results.(243)  
 
2.6.1.5.2 Non-linear curve fitting 
An SSFP readout is used for the MOLLI approach. The SSFP readout 
allows the IR to recover quicker and reaches steady state at a lower level (the 
apparent T1, referred to as T1*) than the equilibrium magnetization (the actual 
T1). Due to the influence of the readout, the IR curve follows a 3-parameter fit 
exponential model, S(t) = A –  B exp(− t/T1*), where t represents the inversion 
time, and T1* is the apparent T1. The measured values may be fitted to this 
model to estimate A, B, and T1* and they can be used to approximate T1 as 
T1* (B/A – 1). (B/A – 1) is referred to as the “ Look- Locker” correction 
factor.(189)  
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2.6.1.5.3 Motion correction and PSIR synthetic imaging 
One of the approaches to improve image reconstruction was the 
development of motion correction, to reduce artifacts from respiratory motion 
despite breath holds. A typical MOLLI sequence acquires 2 or 3 consecutive 
Look-Locker experiments in the same cardiac phase. Although this approach 
would suppress most of the influence of cardiac motion, the myocardium may 
not always remain still across all acquired images predominantly due to patient 
breathing inadvertently.(188) This would be more of a problem for subjects who 
are poor breath-holders. Respiratory motion due to a diaphragmatic movement, 
if not accounted for, could lead to errors in the pixel-wise estimation of T1 and 
produce poor final maps. Therefore, respiratory motion correction is necessary 
for accurate T1-mapping to avoid partial volume cancellation at the boundaries 
of tissues of different T1 resulting from the images being out of phase. Using 
simple pairwise image registration models is an option but can be challenging 
when this is applied to inversion recovery images acquired at different inversion 
times due to large variations in image contrast, in particular, close to the signal 
nulling point. A better motion-correction algorithm is now possible by firstly 
estimating motion-free PSIR synthetic images followed by motion correction. 
The PSIR synthetic images have similar contrast to original MOLLI data and are 
derived by using the actual polarity of the data for the initial estimate of T1 by 
using a partial differential equation to solve a variational energy minimisation 
problem (unlike magnitude reconstruction, when the negative values occurring 
at short TIs are reconstructed as positive to generate the single shot 
images).(244) The MOLLI image with the longest TI is used as a reference to 
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remove background phase on a pixel-by-pixel basis and the resulting images 
have the correct polarity of the MOLLI images. To minimise the impact of the 
initial misalignment on the registration process, an initial motion correction is 
applied to the last images of each IR experiments. A deformation field is then 
applied to all other images of the first IR experiment and this leads to a 
reduction in phase error. These images can then be registered in a frame-by-
frame manner using a fast variational non-rigid image registration 
framework.(245) This process is now fully automated and can be done inline by 
the scanner to generate more accurate and robust T1 maps.(244) 
 
2.6.1.6 Other types of T1 maps 
New approaches have also been developed including saturation 
recovery single-shot acquisition (SASHA) sequence (246) and hybrid schemes 
(e.g. SAPPHIRE), which is heart rate independent and uses a combination of 
saturation and inversion pulses.(247, 248) Table 2-1 summarises the main 
differences in the T1 mapping techniques. Each technique is implemented 
differently by different scanner manufacturers (189, 249, 250) and there is a 
lack of clarity currently on which improvements are valuable or even how to 
measure this value. Intuitively, the best sequence would be the one that most 
accurately measures T1 – but even this is difficult and it is likely that precision 
(compared to the disease signal) and robustness across a health-care system 
(which is not yet done) may be more important than accuracy. Reflecting this, 
current advice is to have locally produced reference range from healthy 
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volunteers, although quality control and standardization systems are being 
constructed. 
 
Table 2-1: Comparison of the various T1 mapping 
techniques.  
Adapted from Kellman et al (189), Taylor et al (251), Roujol et al (249). 
++ denotes good; + denotes fair; - denotes poor 
 
Multi-BH 
IR-
FLASH 
Segmented 
Look-
Locker 
MOLLI ShMOLLI 
MOLLI 
variants 
SASHA 
(3p-fit) 
SAPPHIRE 
T1 prep type IR IR IR IR IR SR SR/IR 
Readout GRE GRE SSFP SSFP SSFP SSFP SSFP 
Influenced by 
T2 effects 
Negligible Negligible Yes Yes Yes No No 
Acquisition 
time 
10 BH ≈ 20 HB 17 HB 9 HB 9-12 HB 11 HB 17 HB 
HR 
insensitivity 
- - - + + ++ ++ 
Few image 
artifacts 
- - - ++ ++ - - 
Absolute 
accuracy 
- - - - - ++ ++ 
Precision ++ ++ ++ ++ ++ - - 
Reproducibility - - - ++ ++ - - 
IR: inversion recovery; SR: saturation recovery; 3p-fit: 3 parameter fit; GRE: gradient echo; BH: breath-
hold; HB: heart beats; FLASH: fast low angle shot; MOLLI: modified Look-Locker sequence; SASHA: 
saturation recovery single shot acquisition; ShMOLLI: shortened modified Look-Locker technique; 
SSFP: steady-state with free precession imaging.  
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2.6.2 T2 mapping 
The T2 or spin-spin relaxation property of a tissue refers to the 
exponential decay of transverse magnetisation time constant. The T2 relaxation 
time is dependent on the water content and can be measured by T2-weighted 
imaging or T2 mapping techniques. Myocardial edema can be detected in 
patients with acute myocardial infarction, myocarditis (98), stress 
cardiomyopathy (252), cardiac sarcoidosis (253), and cardiac transplant 
rejection.(254) T2-weighted imaging has several limitations including the 
subjective interpretation of the images, variations in regional myocardial 
intensity due to changes in sensitivity of surface coils, blood-pooling artefacts at 
the subendocardial border, its relatively low contrast-to-noise ratio between 
normal and abnormal myocardium, and its susceptibility to breathing and 
motion artefacts.(66, 92) T2 mapping technique can provide direct T2 relaxation 
times quantification and is considered more robust. Multi echo spin echo 
(MESE) is widely accepted as the reference technique (255), but it involves 
long scanning times and is prone to motion and flow artefact. An alternative 
method to quantify the T2 relaxation time is by using a gradient and spin echo 
(GRASE) sequence (256) but the as it uses an echo-planar-imaging (EPI) 
readout, it is susceptible to T2* weighting and can underestimate the T2 
relaxation times. Furthermore, each echo is sampled at slightly different cardiac 
phase and could be a source of error.(257) T2 preparation technique using a 
balanced SSFP readout is more suitable for clinical application as it is relatively 
insensitive to flow and can be acquired within one breath-hold. The T2 maps 
are generated using a similar principle to that used for T1 maps. A T2 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
73 
preparation pulse is applied to impart T2 signal contrast, and a subsequent 
readout is performed by using an SSFP sequence that has less sensitivity to 
turbo spin-echo artefacts.(258) A series of images is acquired at different T2 
preparation times (typically echo times of 0, 24ms and 55ms) to calculate the T2 
decay curve. A coloured T2 map consisting of pixel-wise T2 values can be 
generated following motion correction and fitting of the T2 decay times either in-
line, by the scanner or off-line.  
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3 Hypotheses and Aims 
3.1 T1 mapping to quantify the AAR, IMH and MI size in acute 
STEMI patients 
Although tissue characterisation by CMR provides valuable information in 
acute STEMI patients, performing all the parametric maps can be time-
consuming and distressing for them. Native and post-contrast T1 mapping may 
provide the possibility to acquire information on the AAR, IMH and MI size and 
will be investigated by the research questions below. 
 
3.1.1 T1 mapping and T2 mapping CMR to quantify the AAR in reperfused 
STEMI patients 
Ugander et al (131) showed that T1 mapping performed as well as T2 
mapping to detect the AAR in a canine model of acute STEMI. Whether this is 
also the case in clinical patients has not yet been specifically looked at. The 
result from this sub-study has the potential to provide an alternative tool to 
measure the AAR instead of T2 mapping in acute STEMI patients.  
Research question: Can T1 mapping quantify the AAR as well 
as T2 mapping in STEMI patients at both 1.5T and 3T? 
Hypothesis: T1 mapping can quantify the AAR as well as T2 
mapping in STEMI patients at both 1.5T and 3T. 
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3.1.2 T1 mapping versus T2 mapping for the detection of IMH  
The current gold standard to detect IMH is by T2* imaging. However, T2* 
imaging is not routinely used in clinical studies due to its long breath hold to 
acquire the images, especially in patients who have recently suffered a STEMI 
and also due to the fact that the images are prone to breathing, motion and 
susceptibility artefact. In order to keep the scanning time short, IMH were being 
identified as a hypo-intense core on the T2-weighted images. However, T2-
weighted imaging has its own inherent limitations. So far, the direct comparison 
of the diagnostic performance of T1 and T2 mapping to detect IMH, using T2* 
mapping as the reference standard, has not been performed. Therefore this 
study has the potential to provide an alternative modality for the detection of 
IMH. 
Research question: Can the presence of a hypo-intense core 
within the area of oedema on the T1 and T2 maps be used to detect 
IMH in the setting of acute reperfused STEMI? 
Hypothesis: In the absence of T2*-weighted imaging, a hypo-
intense core on the acute T1 and T2 maps can be used to detect 
IMH. 
 
3.1.3 Infarct size quantification by T1 mapping 
Conventionally, MI can be identified by LGE with inversion recovery T1-
weighted sequences and manual adjustment of the TIs to null the remote 
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normal myocardium.(133) Post-contrast T1 mapping has also shown promise to 
detect acute MI in a small cohort of predominantly non-reperfused acute (186) 
and chronic MI patients.(186, 187) The T1 MOLLI prototype (188, 189), can 
also retrospective create “synthetic” IR LGE images, and have recently been 
shown to accurately detect chronic MI size in a small cohort of 17 patients.(190) 
To date, no studies have assessed the performance of post-contrast T1 
mapping and synthetic LGE in quantifying acute MI size with full LV coverage in 
a cohort of reperfused STEMI patients.  
Research question: can we quantify acute MI size using post-
contrast T1 maps and post-contrast T1 mapping-derived synthetic 
inversion recovery imaging?   
Hypothesis: Acute MI size can be accurately quantified from 
the post-contrast T1 maps and the post-contrast T1 mapping-derived 
synthetic LGE images 
 
3.2 Semi-Automated Quantification Techniques for Assessing 
Acute and Chronic Myocardial Infarction by CMR 
 
Several different techniques have been proposed for quantifying acute and 
chronic MI size including manual contouring (176) and semi-automated 
threshold techniques such as a signal intensity threshold of 5 standard 
deviations (SD) (177) or 6-SD (178) above the normal remote myocardium, the 
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Otsu technique (180), and the full width half maximum (FWHM)(182, 183) 
technique but studies published so far have shown inconsistent results. FWHM 
has emerged as the technique having the lowest variability (182, 183) but 
others have shown FWHM to underestimate acute and chronic MI size.(180, 
185) However, no studies have compared these 4 promising semi-automated 
techniques in paired acute and follow-up scans at 1.5T. 
Research question: Which of the 4 most promising semi-
automated techniques would perform best against manual MI size 
quantification in paired acute and follow-up scans at 1.5T? 
Hypothesis: the technique that performs best against manual 
quantification of MI size in paired acute and follow-up CMR scans 
should be the method of choice when a semi-automated method is 
required or preferred. 
 
3.3 Multi-parametric mapping CMR to provide insights into the 
pathophysiology of adverse LV remodelling post-reperfused 
STEMI  
As discussed in the introduction, LV remodelling post-MI refers to the 
intricate changes occurring in both the infarcted and remote myocardium on a 
molecular, structural, geometric and functional level (200) and its occurrence 
predisposes to heart failure. IMH and its iron degradation products have been 
shown to result in residual myocardial iron within the MI zone and have been 
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proposed to have cytotoxic and pro-inflammatory effects on the 
myocardium.(207, 208) 
Furthermore, whether expansion of the extracellular matrix (ECM) in the 
non-infarcted remote myocardium in STEMI patients reperfused by PPCI is 
linked to adverse LV remodelling remains incompletely understood.(197, 210-
213)  
We aimed to use multi-parametric mapping CMR to provide further 
insights into the pathophysiology of adverse LV remodelling post reperfused 
STEMI.  
Research question: Do STEMI patients with post-MI LV 
remodelling more likely to have IMH, develop residual iron and 
develop remote myocardial interstitial changes as assessed by 
automated ECV maps? 
Hypothesis: STEMI patients with IMH are more likely to have 
residual iron and develop subsequent adverse LV remodelling. 
Furthermore, those with adverse LV remodelling are also more likely 
to have higher ECV in the remote myocardium compared to those 
without.  
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3.4 Redefining left ventricular remodelling by CMR 
 
Adverse LV remodelling following STEMI has been conventionally 
defined as ≥ 20% increase in LVEDV from baseline (193, 194) and reverse LV 
remodelling has been defined as ≥ 10% decrease in LVESV by 
echocardiography.(195) So far, no cut-off values for adverse and reverse LV 
remodelling following STEMI have been defined by CMR, and studies using 
CMR to assess post-STEMI LV remodelling have relied upon using these cut-off 
values defined by echocardiography for adverse (196, 197) and reverse LV 
remodelling.(198)  
Therefore, the first aim of this chapter was to perform intra-observer and 
inter-observer measurements of LV parameters in paired acute and follow-up 
CMR scans in reperfused STEMI patients, in order to determine the minimal 
detectable changes (MDCs) that could be used as cut-off values for defining 
post-MI remodelling.  
Secondly, we aimed to identify the cut-off values for clinically important 
%ΔLVEDV and %ΔLVESV. This would be defined as the cut-off value for 
%ΔLVEDV and %ΔLVESV to predict an LVEF <50% (cut-off value at follow-up 
by CMR previously used to define an abnormal LV function (169)).  
Finally, cut-off values for %ΔLVEDV and %ΔLVESV would then be 
applied to a large cohort of STEMI patients with paired acute and follow-up 
scans to assess different patterns of post-STEMI LV remodelling. 
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Research question: what is the cut-off for %ΔLVEDV and 
%ΔLVESV by CMR to define LV remodelling post-MI, taking into 
account inter-observer and intra-observer measurement errors? 
Could the CMR definition be used to provide further insights into the 
different patterns of LV remodelling post STEMI? 
Hypothesis: the cut-off values %ΔLVEDV and %ΔLVESV 
used to define adverse and reverse LV remodelling by CMR is likely 
to be lower that that used by echocardiography due to the superior 
reproducibility of the former technique. 
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4 General methodology 
4.1 Study Population 
There are 2 main cohorts of patients included in this thesis. Approval was 
obtained from the UK National Research Ethics Service (reference 
05/Q0502/102) and all patients were prospectively recruited and provided 
informed written consent.  
4.1.1 First cohort of patients – 1.5T cohort 
50 STEMI patients reperfused by PPCI (diagnosis and treatment as per 
current guidelines)(259, 260) were prospectively recruited between August 
2013 and July 2014 from The Heart Hospital, London.  
Study exclusion criteria were previous MI and standard recognised 
contraindications to CMR (e.g. ferromagnetic implants, claustrophobia, 
estimated glomerular filtration rate <30mL/min).  
All participants were scanned on a 1.5 Tesla scanner at the Heart 
Hospital (Magnetom Avanto, Siemens Medical Solutions) using a 32-channel 
phased-array cardiac coil. 48 patients completed the acute scan at 4±2 days 
post-PPCI and 40 of these patients had a follow-up scan at 5±2 months. 2 
patients developed unexpected claustrophobia during the acute scan and were 
excluded. Figure 4-1 shows the screening and recruitment process. 
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Figure 4-1: Flow diagram showing the screening and 
recruitment of the 1.5T cohort 
 
 
4.1.2 Second cohort of patients – 3T cohort 
18 STEMI patients treated by PPCI were prospectively recruited between 
August 2013 and March 2014 from The Heart Hospital, London and were part 
of a PET/MR study.(106) 
As they were part of the PET/MR study, exclusion criteria were as 
follows: ≤45 years of age (to attenuate any theoretical higher risk from ionizing 
radiation in younger patients); diabetes mellitus (as pre-existing metabolic/ 
glycaemic derangement may affect clarity of initial results); previous MI; and 
standard recognised contraindications to CMR.  
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All patients completed the initial CMR at 5 (4– 6) days on a 3.0 Tesla 
scanner at the Nuclear Medicine Department, University College London 
Hospital (Biograph mMR; Siemens Healthcare, Erlangen, Germany). 12 
patients returned for a follow-up scan at 1 year. Figure 4-2 shows the patients’ 
screening and recruitment process. 
 
 
Figure 4-2: Flow diagram showing the screening and 
recruitment of the 3T cohort 
 
4.2 Imaging acquisition 
The CMR acquisition protocols for both cohorts are shown in Figure 4-3.  
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Figure 4-3: CMR protocols for the 2 cohorts 
 
4.2.1 1.5T cohort CMR acquisition details 
In the 1.5T cohort, the T1, T2 and T2* maps were part of a Work in 
Progress #448B package from Siemens via a research agreement. The CMR 
acquisition protocol (apart from cines, EGE and LGE) for the acute and follow-
up CMR also included the following: 
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• All patients had full LV coverage T2 maps acquired from base to apex 
during the acute scan and 3 LV short-axis (base, mid and apex) T2 maps 
at follow-up. 
• 30 patients had full LV coverage native and post-contrast MOLLI T1 
maps from base to apex both during the acute scan and at follow-up. 
The remaining 18 patients had 3 LV short-axis (base, mid and apex) 
native and post-contrast T1 maps. 
• All patients had 3 LV short-axis (base, mid and apex) T2* maps on both 
acute and follow-up scans. 
 
Native T1 mapping 
T1 maps were acquired using an SSFP-based MOLLI sequence. A 5s 
(3s) 3s modified MOLLI sampling protocol was used to ensure more complete 
recovery of the inversion pulse at higher heart rates by acquiring a set of 
images for at least 5 seconds after the first inversion pulse, followed by a 3-
second pause and then acquiring a set of images after the second inversion 
pulse for at least 3 seconds(189). The acquisition parameters are provided in 
Table 4-1. Motion correction and a non-linear least-square curve fitting were 
performed with the set of images acquired at different TIs to generate a pixel-
wise coloured T1 map in-line, by the scanner. Each slice was acquired during 
one breath hold. 
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T2 mapping 
T2 maps were acquired as previously described.(97) In brief, 3 single-
shot images at different T2 preparation times (0ms, 24ms, and 55ms, 
respectively) using the following parameters provided in Table 4-1. A coloured 
T2 map consisting of pixel-wise T2 values was generated following fitting to 
estimate T2 relaxation times and motion correction in-line, by the scanner. Each 
slice was acquired during one breath hold. 
 
T2* mapping 
T2* maps were obtained using the parameters provided in Table 4-1. A 
colored pixel-wise T2* map was generated in-line, by the scanner. Each slice 
was acquired during one breath hold. 
 
Early gadolinium enhancement (EGE) 
EGE images were acquired 1-2 minutes after the injection of 0.1 mmol/kg 
of Gadoterate meglumine (Gd-DOTA marketed as Dotarem, Guerbet S.A., 
Paris, France) using inversion recovery single shot SSFP T1-weighted 
sequence at a fixed high TI of 440ms and a full LV short axis stack was 
acquired.(261) 
 
Late gadolinium enhancement (LGE) 
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LGE imaging was acquired with a standard segmented ‘fast low-angle 
shot’ two-dimensional inversion-recovery gradient echo sequence or a 
respiratory motion-corrected, free-breathing single shot SSFP averaged phase 
sensitive inversion recovery sequence (262, 263) at 10-15 minutes after the 
injection of 0.1 mmol/kg of Gadoterate meglumine (Gd-DOTA marketed as 
Dotarem, Guerbet S.A., Paris, France). 
 
Post-contrast T1 mapping 
Post contrast T1 maps were obtained using the 4s (1s) 3s (1s) 2s 
sampling protocol (to improve the accuracy of T1s in the 200-600ms range as 
previously described)(189) 15 minutes after contrast injection (0.1 mmol/kg of 
Gd-DOTA) using similar acquisition parameters as for native T1 maps as 
provided in Table 4-1. 
 
ECV maps 
The previously described and validated automated method for producing 
a pixel-wise ECV map was used.(218) In brief, this method corrects for 
respiratory motion due to poor or inconsistent breath-holding as well as patient 
movement between breath-holds and relies on co-registration of the native and 
post-contrast T1 pixel maps. Each patient had haematocrit checked at the time 
of the scan and the ECV was estimated using the formula(264): 
ECV = (1–haematocrit) x (1/T1myocardium post)  - (1/T1myocardium pre) 
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                                     (1/T1blood post) - (1/T1blood pre) 
An off-line software (ECV Mapping Tool Version 1.1) subsequently 
generated pixel-wise ECV maps using a variety of post processing steps as 
recently described.(218)  
 
The coloured look up tables used for the T1, T2, T2* and ECV maps 
throughout this thesis are shown in Figure 4-4 below: 
 
Figure 4-4: Colour scales for the various maps 
included in this thesis 
 
4.2.2 3T cohort CMR acquisition details 
This cohort of patients underwent a CMR protocol at 3T and was a sub-
study of the PET/MR study(106) recently reported. The CMR maps were part of 
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a Work in Progress #699 package from Siemens as part of a research 
agreement. The acquisition protocols included cines, full LV coverage for T1 
and T2 maps, EGE and LGE. 
The acquisition parameters for the T1 and T2 maps are provided in Table 
4-1. EGE and LGE were acquired as per the 1.5T protocol except for using a 
fixed TI of 500ms for the EGE images at 3T. 
Table 4-1: Acquisition parameters of the T1/T2/T2* 
maps at 1.5T and 3T 
 1.5T 3T 
 T1 map T2 map T2* map T1 map T2 map 
WIP #448B #448B #448B #699 #699 
Sampling 
protocol 
5s(3s)3s for 
native T1 
4s(1s)3s(1s)2s 
for post-
contrast T1 
maps 
3 T2 
preparation 
times: 0ms, 
24ms and 
55ms 
8 TEs: 2.7ms, 
5ms, 7.3ms, 
9.6ms, 11.9ms, 
14.2ms, 
16.5ms and 
18.8ms 
5(3)3 for 
native T1 
4(1)3(1)2 
for post-
contrast T1 
maps 
3 T2 
preparation 
times: 0ms, 
24ms and 
55ms 
Voxel size 1.5x1.5x6.0 2.0x2.0x6.0 1.6x1.6x8.0 1.6x1.6x6.0 2.1x2.1x6.0 
TE/ ms 1.1 0, 24, 55 x8 – as above 1.1 0, 24, 55 
Flip angle/ 
degrees 
35 70 18 35 65 
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FoV/ mm Variable (320-
420) 
Variable 
(320-420) 
400 Variable 
(320-420) 
Variable 
(320-420) 
Matrix size 256x144 116x192 256x192 256x144 116x192 
Bandwidth/ 
Hz/pixel 
977 930 814 1028 930 
Acceleration 
factor 
2 2 None 2 2 
Slice 
thickness/ 
mm 
6 6 8 6 6 
Slice 
gap/mm 
4 4 2 4 4 
Temporal 
Resolution/ 
ms 
227 190 146   
Acquisition 
time 
11 RR/ 11 
seconds 
7 RR 15 RR 11 RR 7 RR 
 
 
4.3 Imaging analysis 
Specific details pertaining to each topic are provided in their respective 
chapters. 
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Cines 
All volume analysis was performed using CVI42 software (Version 
5.2.2[340], Calgary, Canada). Semi-automated contours were drawn on the 
short-axis cine images using the threshold segmentation option for the 
epicardial border and the automatic detection option for the endocardial border, 
with minimal manual adjustment when required. The LVEDV, LVESV, LV mass 
(LVM) and LVEF were quantified using rounded endocardial contours and 
excluded the trabeculae and papillary muscles as part of the LVM and were 
included as part of the LV volume. The basal cine slice was included if at least 
50% of the cavity circumference was surrounded by ventricular myocardium 
and this principle was used for both end-systole and end-diastole.  
 
T1 and T2 maps 
The T1 and T2 maps from the 3T cohort were analysed using an in-house 
macro written in ImageJ (Version 1.45s, National Institute of Health, USA). The 
in-house macro used in this study was written by Drs Steven K White, Andrew 
Flett and Steven G Casson. All the maps from the 1.5T cohort were analysed in 
CVI42 (Version 5.2.2[340], Calgary, Canada). These 2 different methods were 
used as at the time the 3T cohorts were analysed CVI42 was not yet available. 
Analysis of the maps was subsequently much easier with CVI42 and ImageJ 
was subsequently dropped. 
For the 3T cohort, the endocardial and epicardial borders of matching LV 
short axis T1 maps and T2 maps were manually segmented (excluding the 
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papillary muscles) to obtain the myocardium volume. The basal slice with LVOT 
and the apical slice with no identifiable LV cavity were excluded. All subsequent 
quantification was performed on the pre-segmented images.  
For the 1.5T cohort, the endocardial and epicardial borders were 
manually traced on the T2 maps and copied to the T1 maps with minimal 
manual adjustments using CVI42. The basal slice with LVOT present and the 
apical slice with no identifiable LV cavity were excluded. All subsequent 
quantification was performed on the pre-segmented images. 
 
MI quantification 
All LGE quantifications were performed using CVI42. 
The endocardial and epicardial borders were manually drawn on 
all the LGE images. The basal slice with LVOT present and the apical 
slice with no identifiable LV cavity were excluded. MI size was quantified 
using Manual contouring by HB (2 and a half years experience in STEMI 
CMR scans analysis) and expressed as the %LV. Manual MI size 
quantification was performed by manually drawing a contour around the 
area of high signal intensities. On the acute scan, when areas of grey 
peri-infarct zones were present, these were excluded as part of the MI 
zone. Areas of hypo-intense core of MVO were included as part of the MI 
zone. Minimal adjustments were also performed if artefacts were present 
in the remote myocardium and these artefacts were manually excluded.  
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Thresholds of 5-SD, 6-SD, Otsu and FWHM were applied on these LGE 
images with pre-drawn endocardial and epicardial borders to obtain 
corresponding MI sizes and expressed as %LV.  
For 5-SD and 6-SD (to identify signal intensities of 5-SD and 6-SD above 
the mean normal remote myocardium respectively), a ROI was identified in the 
normal remote myocardium using the automatic option from CVI42, with 
minimal manual adjustment when required to minimise intra-observer variability.  
For the FWHM technique (to identify signal intensities that are above 
50% of maximal signal intensity of the reference ROI)(181), the automatic 
option was also used to delineate an ROI in the area of hyper-enhancement by 
LGE.  
The Otsu technique (to identify the intensity threshold from the signal 
intensity histogram using the value with minimal intra-class variance between 
low and high intensities)(179) did not require any additional ROIs but did require 
user input to identify slices with no LGE as normal.  
 
4.4 Statistical analysis 
The detailed imaging analysis descriptions will be provided in each 
relevant chapter. In brief, statistical analysis was performed using SPSS 
Version 22 (IBM Corporation, Illinois, US). Normality was assessed using 
Shapiro-Wilk Test. Continuous data was expressed as mean ± standard 
deviation (SD) or median (interquartile range) and categorical data was 
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reported as frequencies and percentages. Groups were compared using paired 
Student t-test/ Wilcoxon signed rank test or unpaired Student t-test/ Mann 
Whitney U test where appropriate. Correlation was assessed using either 
Pearson’s correlation coefficient for normally distributed data or Spearman’s rho 
for non-normally distributed data. Bland-Altman analysis was performed for 
inter-method measurements comparison and agreement. Inter-observer and 
intra-observer variability was assessed using intra-class correlation coefficient 
(ICC) when required. When assessment of the diagnostic performance of a 
parameter was required, ROC curve analyses were performed. All statistical 
tests were two-tailed, and P<0.05 was considered statistically significant.  
 
4.5 Sample size 
No formal sample size calculation was performed for the studies included 
in this thesis and is a limitation. I acknowledge the importance of having an 
appropriately powered study. Although a small sample is desirable, it would 
give results that are underpowered to detect a difference between two groups 
and the study may turn out to be falsely negative, leading to a type II error. On 
the other hand, a very large sample size is not recommends as it would be a 
waste of time and resources and not ethical for the patients.(265) 3 basic 
factors should be considered when performing sample size calculation; the type 
I or alpha error (failure to accept the null hypothesis when it is true, by 
convention set at 5%); the type II or beta error (failure to reject the null 
hypothesis when it is not true, usually set at 20%, power = 1 - type II error); and 
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the effect size (the larger the expected effect size, the small the sample size 
required).(266) A small sample size can also lead to only a small number of 
patients required to change their status from a non-event to an event to render 
a previously statistically significant result to a non-significant result. The lower 
this number, the more fragile the results and this is also known as the Fragility 
Index.(267) The sample size included in this thesis was small as recruitment 
was affected due to the merging of The Heart Hospital (where the initial work 
began) with Barts Heart Centre.   
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5 T1 mapping for the detection of the AAR, IMH and MI 
size 
5.1 Background 
T2-weighted STIR imaging, which has been used to delineate the AAR in 
reperfused STEMI patients, has also been used to detect IMH as the presence 
of a hypo-intense core within the AAR.(159-161) However, STIR imaging has 
been shown to have a lower diagnostic performance for detecting IMH when 
compared to T2* CMR imaging.(150, 153) Recently, native T1 mapping CMR 
(referred to as T1 mapping or T1 map throughout this chapter for simplicity) has 
been found to be superior to T2-weighted CMR in detecting myocardial oedema 
in the context of acute myocarditis (268) and acute myocardial infarction.(132) 
T1 mapping CMR has recently been reported to accurately quantify the AAR in 
the canine heart subjected to acute myocardial infarction.(131) Langhans et al 
(133) found that AAR by T1 and T2 mapping CMR at 1.5T correlated well with 
that obtained with SPECT. The direct comparison of T1 mapping against T2 
mapping to quantify the AAR, to our knowledge, has not yet been performed in 
the clinical setting.  
IMH can also manifest as a hypo-intense core on the T1 (156, 164) and 
T2 maps.(138, 153, 165) However, the diagnostic performance of T1 and T2 
maps to detect the presence of IMH following STEMI has not been directly 
compared. 
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Conventionally, MI can be identified by LGE with inversion recovery (IR) 
T1-weighted sequences and manual adjustment of the inversion times (TI) to 
null the remote normal myocardium.(133) Post-contrast T1 mapping has also 
shown promise to detect acute MI in a small cohort of predominantly non-
reperfused acute (186) and chronic MI patients.(186, 187) Refinements of the 
T1 MOLLI prototype using IR images at different TIs initially designed to 
improve motion correction (188, 189), can also retrospectively create “synthetic” 
IR LGE images, namely MagIR, PSIR outputs. These synthetic read-outs have 
recently been shown to accurately detect chronic MI size in a small cohort of 17 
patients.(190) To date, no studies have assessed the performance of post-
contrast T1 mapping and synthetic LGE in quantifying MI size with full LV 
coverage in a cohort of reperfused STEMI patients.  
 
Therefore, the aim of this chapter was three-fold: 
1. To assess the performance of T1 mapping to quantify the AAR as 
delineated by T2 mapping at 1.5T and 3T in reperfused STEMI patients.  
2. To investigate the performance of T1 and T2 mapping to detect IMH and 
MVO within the first week in reperfused STEMI patients, using T2* 
mapping as the reference standard for IMH.(139, 150, 152, 153, 155, 
156)  
3. To investigate whether post-contrast T1 mapping and synthetic LGE 
images can quantify MI size (using conventional LGE as the reference).  
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5.2 Methods 
5.2.1 Study population 
5.2.1.1 T1 mapping versus T2 mapping for the AAR 
This sub-study included 2 cohorts: 
• 18 STEMI patients from the 3T cohort. 
• 30 STEMI patients from the 1.5T cohort. 
All patients had full LV coverage of T1 and T2 mapping as described in 
the methodology section.   
The T1 and T2 maps were acquired to match the short-axis cines and 
LGE and to cover the entire left ventricle as shown in Figure 5-1. 
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Figure 5-1: Matching T1 maps, T2 maps and LGE short axis 
CMR images at 3T from base to apex of a patient presenting with an 
acute inferior STEMI reperfused by PPCI.  
Both T1 and T2 maps delineate the AAR (black arrows) and the 
LGE images show a small subendocardial myocardial infarct (red 
arrows). 
 
5.2.1.2 T1 mapping versus T2 mapping for the detection of IMH 
The 48 patients with an acute CMR study from the 1.5T cohort as 
described in the methodology section were included for this sub-study.  
 
5.2.1.3 Post-contrast T1 mapping for acute MI size 
28 acute STEMI patients from the 1.5T cohort described in the 
methodology section based on the availability of full LV coverage of post-
contrast T1 mapping and the availability of the synthetic IR output dataset were 
included in this sub-study. 
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5.2.2 Imaging analysis 
All LV volumes, LV mass, LV ejection fraction and MI size were analysed using 
CVI42 software (Version 5.2.2[340], Calgary, Canada) as described in the 
methodology section. MI size was quantified following manual delineation of the 
endocardial and epicardial borders of the short axis slices and using 5-SD 
threshold above the mean remote myocardium.(57)  
5.2.2.1 T mapping versus T2 mapping for the AAR 
For the 3T cohort, AAR by T1 mapping and T2 mapping were quantified 
using an in-house macro written in ImageJ (Version 1.45s, National Institute of 
Health, USA). The endocardial and epicardial borders of matching LV short axis 
T1 maps and T2 maps were manually segmented (excluding the papillary 
muscles) to obtain the myocardium volume. All subsequent quantification was 
performed on the pre-segmented images. All patients were analysed twice by 
HB and SKW blindly and independently, and HB performed the analysis twice, 
3 months apart. The affected myocardium on the T1 maps and T2 maps were 
quantified using 3 analytical techniques namely manual delineation, 2SD above 
the mean remote normal myocardium, and the automated Otsu detection 
method (Otsu technique).(179) In brief, the Otsu technique uses an algorithm to 
automatically divide the signal intensity histogram into normal and enhanced. 
An exhaustive search for values that minimise the intra-class variance between 
two populations of signal intensities is used to establish the threshold.(269) The 
Otsu technique was not applied on maps that were visually normal based on 
the coloured look-up table and with normal wall motion on cines. Those maps 
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were manually marked as normal. Analysis was performed for all the slices for 
each patient to obtain the “enhanced” myocardium as a percentage of the 
whole LV (%LV). Regions of interest (ROIs) were drawn within the AAR 
(avoiding areas of MVO), and within the remote myocardium to obtain 
representative T1 and T2 values at 3T CMR. Manual correction was performed 
for hypo-intense areas within the MI zone (corresponding to areas of MVO) and 
areas of hyper-enhancement due to any obvious blood pool or pericardial 
partial volume effects and off-resonance artefacts in the remote myocardium. 
As shown in Figure 5-2, the hypo-intense area within the AAR depicted by the 
red arrows were manual included as part of the AAR using an option available 
on CVI42 for no-reflow zones. All slices were visually assessed and those with 
significant partial volume effects and susceptibility or motion artefacts 
overlapping with the affected myocardium were excluded by consensus. In 
cases of doubt or disagreement, the raw images were used to decide whether 
that slice was to be excluded or not as previously described by von 
Knobelsdorff-Brenkenhoff et al.(270) 
For the 1.5T cohort, the endocardial and epicardial borders were 
manually traced on the T2 maps and copied to the T1 maps with minimal 
manual adjustments using CVI42 (Version 5.2.2[340], Calgary, Canada). The 
same 3 techniques (Manual, 2-SD and Otsu) were used to quantify the AAR. As 
mentioned above, the Otsu technique was not applied on maps that were 
visually normal based on the coloured look-up table and with normal wall 
motion on cines. These maps were manually selected as normal. Areas of 
hypo-intense core of MVO or IMH were included as part of the MI zone and 
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AAR. ROIs were manually drawn in MI zone and the remote myocardium to 
obtain representative native and post-contrast T1 and T2 values.  
5.2.2.2 T1 mapping versus T2 mapping for the detection of IMH 
The 2-SD threshold was also used to identify the hypo-intense core 
(hypo-intense area within the hyper-enhanced area) on both T1 and T2 maps to 
identify the hypo-intense core (Figure 5-2) in the 1.5T cohort.  
 
Figure 5-2: semi-automated method used to identify the 
hypo-intense core on the T1 and T2 maps. 
 
So far, no studies have validated a cut-off threshold to detect IMH and 
MVO from these maps and we chose to use the same threshold used to 
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quantify the AAR to delineate the hypo-intense core as a semi-automated 
method to minimise bias (Figure 5-2). ROIs were manually drawn in the hypo-
intense core (expressed as T1Core and T2Core), the AAR (expressed as T1AAR 
and T2AAR) and the remote myocardium (expressed as T1Remote and T2Remote) on 
both maps. In cases when no hypo-intense core was identified, the ROI was 
drawn in the area of infarct. The T1 and T2 maps were also graded in a binary 
fashion to detect the presence or absence of a hypo-intense core (with the help 
of the semi-automated method as above).  
10 randomly selected patients were separately analysed by 2 
investigators (HB and EGL with >2½ years and 1 year experience in CMR 
respectively) 2 months apart for intra-observer and inter-observer variability.  
 
Definitions 
• IMH was defined as a hypo-intense core on the T2* maps with a T2* < 
20ms as previously validated in pre-clinical (152) and subsequently used 
in several clinical STEMI studies. (139, 150, 155, 156) 
• Early MVO was defined as areas of dark core within the infarcted territory 
visually detected (red arrow on the EGE image in Figure 5-3) on the EGE 
images, acquired 1-2 minutes post-contrast, as previously 
described.(146, 160, 261) 
• Late MVO was defined as areas of dark core within the areas of LGE 
(red arrow on the LGE image in Figure 2) acquired 10-15 minutes post 
contrast on the LGE images as previously described.(149, 160, 271) 
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Figure 5-3: Example of a patient with an acute inferior MI 
depicting the evidence of MVO on EGE and LGE scans with 
corresponding hypo-intense cores (red and black arrows) on 
the basal LV short axis T2*, T1 and T2 maps. 
 
5.2.2.3 Post-contrast mapping for acute MI size 
Both the native and post-contrast MOLLI T1 mapping automatically 
generated 2 sets of IR images (MagIR and PSIR) in-line by the scanner for the 
TI range of 200 to 975ms (increments of 25ms) as illustrated in Figure 5-4. 
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Figure 5-4: The MagIR and PSIR output from the MOLLI T1 
mapping prototype 
This is an illustration of the 2 additional outputs (with TI 
200ms to 975ms) that were obtained from the MOLLI T1 mapping 
prototype for a patient with an acutely reperfused inferior STEMI. 
For synthetic MagIR LGE, the image with the optimal TI was 
manually chosen retrospectively as illustrated by the red square. For 
the synthetic PSIR LGE, the corresponding image from the PSIR 
output was chosen (red square) and was manually windowed if 
required.  
 
For the synthetic MagIR LGE, the image with the optimal TI (remote 
normal myocardium nulled as black) was manually selected and the 
corresponding matching PSIR image was selected as the representative 
synthetic PSIR LGE image (Figure 5-4). A threshold of 5SD was also used to 
quantify synthetic MI size.  
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For the post-contrast T1 maps, we used 2 semi-automated techniques, 
namely a threshold of 2-SD below the mean remote myocardial post-contrast 
T1 and the Otsu technique (which identifies the intensity threshold from the 
signal intensity histogram using the value with minimal intra-class variance 
between low and high intensities).(179) MI size was expressed as: by 
conventional LGE (reference standard) as MIConv; MagIR synthetic LGE as 
MISynthMagIR; PSIR synthetic LGE as MISynthPSIR; post-contrast T1 MI size by 2-SD 
as MIT1Post2SD; and by Otsu as MIT1PostOtsu. 
 
5.2.3 Statistical analysis 
Pearson’s correlation coefficient expressed as its square (R2) was used 
to assess inter-method correlation and inter-method agreement was assessed 
using ICC with 95% confidence intervals (95%CI). ROC analyses were used to 
assess the diagnostic performance for T1 and T2 maps for detecting IMH on the 
acute scans and were compared using the method described by Delong et al 
(272) Inter-observer and intra-observer variability for T1 and T2 values of the 
hypo-intense core were assessed in 10 patients and expressed as ICC (95% 
CI). Cohen’s Kappa was used to assess inter-observer and intra-observer 
agreement for the binary assessment of the maps. Bland-Altman analysis was 
performed to assess agreement and bias detection between methods and 
presented as average difference ± 2SD. Firstly, a per-slice and per-patient 
comparison was performed on the 3T cohort patients. Inter-observer and intra-
observer variability was assessed for all 18 patients in the 3T cohort using ICC 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
107 
and mean difference between inter-observer and intra-observer measurements 
of T1 and T2-derived AAR. Secondly, a per-patient comparison was performed 
on the 1.5T cohort. All statistical tests were two-tailed, and P-values of less than 
0.05 were considered statistically significant. 
 
5.3 Results  
5.3.1 T1 mapping versus T2 mapping for the AAR 
The patients’ demographics and coronary angiographic and CMR 
characteristics are detailed in Table 5-1. The majority were male and two-thirds 
of the patients presented with a left anterior descending territory STEMI and 
one-third with a right coronary artery territory infarct. Figure 5-5 and Figure 5-6 
show examples of T1 maps, T2 maps and LGE in patients from both cohorts. 
 
Table 5-1: Patients’ demographics, coronary angiographic and 
CMR characteristics. 
Details 3T cohort 1.5T cohort 
Number of patients 18 30 
Male 15 (83%) 23 (77%) 
Age ± SD (years) 58 ±10 55 ±12 
Hypertension 5 (28%) 8 (27%) 
Smoking 9 (50%) 11 (37%) 
Dyslipidaemia 3 (17%) 8 (27%) 
Chest pain onset to balloon time 292 (116-800) 213 (131-385) 
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(minutes) 
Infarct artery and location  
LAD 
Proximal/ Mid/ Distal 
RCA 
Proximal/ Mid/ Distal 
Cx 
Proximal/ Mid/ Distal 
 
12 (67%) 
5 (42%)/ 6 (50%)/ 1 (8%) 
6 (33%) 
3 (50%)/ 2 (33%)/ 1(17%) 
0 
NA 
 
19 (63%) 
13 (68%)/ 5 (26%)/ 1 (5%) 
9 (30%) 
8 (89%)/ 0 (0%)/ 1 (11%) 
2 (7%) 
2 (100%)/ 0 (0%)/ 0 (0%) 
Pre-PPCI TIMI flow (%) 
0/ 1/ 2/ 3 
 
13 (72%)/ 4 (22%)/ 1 (6%)/ 
0 (0%) 
 
21 (70%)/ 1 (3%)/ 3 (10%)/ 
5 (17%) 
Post-PPCI TIMI flow (%) 
0/ 1/ 2/ 3 
 
1 (6%)/ 0 (0%)/ 2 (12%)/ 15 
(82%) 
 
1 (3%)/ 0(0%)/ 2 (7%)/ 27 
(90%)  
Days from PPCI to CMR 5 (4-6) 4±2 
Left ventricular ejection fraction (%) 49±11  52±8 
End diastolic volume (ml) 135±21  147±35 
Left ventricular mass (g) 151±50  121±27 
Presence of MVO (%) 8 (44%) 20 (67%)  
Infarct size by LGE, (% LV volume) 18.8±9.4 25.6±14.1 
AAR by T1 mapping, (% LV volume) 
Manual 
Otsu 
2-SD 
 
32.0±11.5 
32.3±11.5 
38.4±13.6 
 
41.1±11.7 
41.6±11.6 
42.2±11.9 
AAR by T2 mapping, (% LV volume) 
Manual 
Otsu 
2-SD 
 
31.8±11.7 
31.6±11.2 
38.7±15.0 
 
41.7±11.9 
41.9±11.9 
42.4±11.9 
SD: standard deviation; LAD: left anterior descending; RCA: right coronary artery; Cx: 
circumflex artery; TIMI: Thrombolysis in Myocardial Infarction; PPCI: primary percutaneous coronary 
intervention; CMR: cardiovascular magnetic resonance; MVO: microvascular obstruction; LGE: late 
gadolinium enhancement; AAR: area-at-risk; LV: left ventricle 
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Figure 5-5: Representative mid left ventricular short axis 
T1 maps, T2 maps and LGE short-axis images from three 
patients demonstrating varying degrees of myocardial salvage 
at 3T 
For patient A, both the T1 and T2 maps delineate a 
large area of myocardial oedema in the left anterior 
descending (LAD) territory (black arrow), corresponding to the 
AAR, with no significant MI on LGE image (red arrow), 
indicating complete myocardial salvage. For patient B, the T1 
and T2 maps again delineate an area of myocardial oedema 
in the LAD territory (black arrow), with a subendocardial MI on 
the LGE image (red arrow), indicating some myocardial 
salvage. For patient C, the T1 and T2 maps delineate an area 
of myocardial oedema in the right coronary artery territory 
(black), with a transmural MI containing some MVO (hypo-
enhancement on T2 map and LGE images) on the LGE image 
(red arrow), indicating minimal myocardial salvage. 
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Figure 5-6: Representative examples of the native T1 and T2 maps 
showing the AAR and the corresponding MI extent at 1.5T 
Patients D and F suffered from an acute anterior STEMI and 
Patient E suffered from an acute inferior STEMI – all were treated 
by PPCI. The black arrows indicate the territory of the AAR on the 
T2 and native T1 maps and the red arrows indicate the territory of 
the subendocardial MI (of different transmural extents) on the LGE 
images. All these patients had significant myocardial salvage and 
the areas of abnormality on the T2 and native T1 maps extended 
beyond the corresponding MI territory, indicating oedema in the 
salvaged myocardium. 
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5.3.1.1 Quality and acquisition times of T1 and T2 maps  
The acquisition times for T1 maps and T2 maps per patient were similar 
both at 3T (T1 maps: 5.6 ± 1.9 minutes, T2 maps: 5.5 ± 2.0 minutes) and at 
1.5T (T1 maps: 5.5 ± 1.1 minutes, T2 maps: 4.9 ± 0.7 minutes). 15% of the 
maps at 3T and 10% of the maps at 1.5T were excluded due to suboptimal 
image quality. At 3T, both T1 and T2 CMR were equally prone to susceptibility 
artefacts in the lateral wall. As we did not have any patients with a circumflex 
territory infarction, these artefacts were remote from the AAR and the slices 
(10/107 slices, 9%) were kept for analysis (manual correction was required). 
Both T1 and T2 maps were equally likely to be affected by MVO, requiring 
manual correction to include the core as part of the AAR at both scanner 
strengths. The total CMR scan time was on average 60 minutes and 90 minutes 
at 1.5T and 3T respectively. 
 
5.3.1.2 Inter and intra-observer variability (3T cohort) 
The AAR by the 3 techniques (manual/ Otsu/ 2-SD) were 31.8 ± 11.7%, 
31.6 ± 11.2% and 38.7 ± 15.0% by T2 mapping and were 32.0 ± 11.5%, 32.3 ± 
11.5% and 38.4 ± 13.6% by T1 mapping, respectively. The ICC for intra-
observer and inter-observer variability of the 3 analytical techniques were 
excellent, both for T1 and T2 mapping and was highest for the Otsu technique. 
The 2-SD technique had the largest differences both for intra-observer and 
inter-observer measurements for both mapping techniques ( 
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Table 5-2).  
Table 5-2: Intra-observer and inter-observer 
variability of the AAR by T1 and T2 at 3T (n=18). 
 ICC (95% CI) Mean difference ± SD (%) P 
Intra-observer variability (n = 107) 
T1 mapping 
Manual 
2-SD 
Otsu 
 
0.961 (0.943 – 0.973) 
0.948 (0.917 – 0.966) 
0.989 (0.984 – 0.993) 
 
1.5 ± 7.1 
2.6 ± 7.7 
0.7 ± 3.2 
 
0.04* 
0.001* 
0.03* 
T2 mapping 
Manual 
2-SD 
Otsu 
 
0.951 (0.928 – 0.966) 
0.965 (0.942 – 0.978) 
0.996 (0.995 – 0.998) 
 
0.8 ± 6.4 
2.4 ± 6.4 
0.2 ± 1.9 
 
0.18 
0.001* 
0.24 
Inter-observer variability (n = 107) 
T1 mapping 
Manual 
2-SD 
Otsu 
 
0.980 (0.972 – 0.987) 
0.948 (0.925 – 0.964) 
0.993 (0.990 – 0.995) 
 
0.3 ± 4.3 
3.7 ± 7.2 
0.2 ± 2.6 
 
0.52 
0.001* 
0.55 
T2 mapping 
Manual 
2-SD 
Otsu 
 
0.964 (0.947 – 0.975) 
0.960 (0.914 – 0.978) 
0.993 (0.989 – 0.995) 
 
0.3 ± 6.1 
3.5 ± 6.5 
0.7 ± 2.6 
 
0.59 
0.001* 
0.008* 
ICC: intraclass correlation coefficient; SD: standard deviation 
 
 
The 2-SD technique overestimated the AAR compared to manual delineation (as the 
reference standard) but there was no difference between Otsu and manual delineation 
for both T1 and T2 mapping (Figure 5-7). The Otsu derived T1 and T2 AAR was 
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therefore used for the analysis below.  
 
Figure 5-7: Performance of three different threshold techniques for 
delineating the AAR on T1 and T2 maps. 
The AAR by the 2 standard deviations (2-SD) technique was 
significantly larger than that delineated by the manual and Otsu threshold 
techniques. There was no difference between the manual and Otsu 
techniques for both T1 and T2 mapping in delineating the AAR. 
 * denotes significant statistical difference with P<0.001. 
 
 
5.3.1.3 Comparison of the AAR by T1 mapping against T2 mapping at 3T 
The mean MI size by LGE was 18.8 ± 9.4% of the LV, (range 2.0 - 
34.0%). Myocardial salvage (AAR subtract the MI size) was 12.8 ± 10.0% of LV 
(range 0 – 42.0%) by T2 mapping. The MSI (myocardial salvage / AAR) was 
0.40 ± 0.26 (range 0 – 0.89).  
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The T1 and T2 values in the AAR were significantly higher than those in 
the remote myocardium (T1AAR: 1524 ± 116ms, T1Remote: 1163 ± 78ms, P < 
0.001; T2AAR: 72 ± 7ms, T2Remote: 46 ± 3ms, P < 0.001).  
The Otsu technique failed in 4% of the maps with extensive MVO and 
transmural LGE and the AAR was manually delineated for these slices. On a 
per-slice analysis, there was an excellent correlation between the T1 mapping 
and T2 mapping with an R2 of 0.95 and a regression slope 0.97 (95%CI 0.93 – 
1.01). There was no bias on Bland Altman analysis (mean ± 2SD:  bias 0.0 ± 
9.6%) (Figure 5-8 a and b). On a per-patient analysis, the correlation and 
agreement remained excellent with no bias (R2 0.95, regression slope 0.95 
(95% CI 0.84 – 1.07), bias 0.7 ± 5.1%, Figure 5-8 c and d). The mean AAR 
(expressed as a % of the LV) quantified by T1 mapping was similar to that by 
T2 mapping (32.3 ± 11.5% of the LV, range 6% to 52% by T1 mapping, versus 
31.6 ± 11.2% of the LV, range 5% - 48% by T2 mapping, P = 0.25).  
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Figure 5-8: Correlation and agreement between T1 and 
T2 mapping to delineate the AAR. 
Both on a per-slice (a and b) and per-patient analysis (c and 
d), there was an excellent correlation and agreement between T1 
and T2 mapping technique to delineate the AAR. The interrupted 
lines in a and c represent reference lines with a slope of 1. 
 
 
5.3.1.4 Comparison of the AAR by T1 mapping against T2 mapping at 1.5T 
The mean MI size in this cohort of STEMI patients was 25.1±14.3%LV 
and the mean Manual AAR by T2 was 41.5±12.0%LV. The MSI in this cohort 
was 0.41±0.28.  
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T2 in the MI zone was significantly higher than in the remote myocardium 
(67±7ms versus 50±3ms, P<0.0001). Native T1 in the MI zone was also 
significantly higher than in the remote myocardium (1258±57ms versus 
1041±57ms, P<0.001).  
The Otsu technique failed in 8% of the maps with extensive MVO and 
transmural LGE and the AAR was manually delineated based on the transmural 
extension of the MI for these slices. There was an excellent correlation (R2 0.99) 
and agreement (ICC 0.983 and 0.996 respectively) between the Manual T2 
AAR and the 2-SD. The T2 AAR by Otsu was similar to Manual T2 AAR 
(41.7±12.2%LV versus 41.5±12.1%LV, P=0.38) with no bias (0.2±2.1%). 
However, the T2 AAR by 2-SD was significantly larger than Manual 
(42.2±12.1%LV versus 41.5±12.1%LV P=0.011) with a bias of 1.0±2.6%.  
The same pattern was observed for T1 mapping. The T1 AAR by Otsu 
was similar to Manual (41.6±11.9%LV versus 41.0±12.0%LV, P=0.17) with no 
bias (-0.6±4.2%), and the T1 AAR by 2-SD was significantly higher than Manual 
(42.1±12.2%LV versus 41.0±12.0%LV, P=0.005) with a small bias of 1.0±3.9%.  
T1 mapping performed as well as T2 mapping in delineating the AAR (T1 
Otsu 41.6±11.9%LV versus T2 Otsu 41.7±12.2%LV, P=0.72; R2 0.97; ICC 
0.986(0.969-0.993); bias -0.1±4.2%LV). Table 5-3 and Figure 5-9 provide 
further details of the comparison between T2 and native T1 mapping for the 
quantification of the AAR using the different techniques. Figure 5-10 shows the 
correlation and agreement of the AAR between T1 and T2 mapping at 1.5T.  
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Table 5-3: Comparison of acute MI size and AAR 
quantification by the different techniques 
Reference/ 
%LV 
Other 
Techniques/ 
%LV 
P 
value 
R2 ICC 
(95%CI) 
Bias±2SD/ 
%LV 
T2 mapping 
 
T2 Manual 
41.5±12.1 
T2 Otsu 
41.7±12.2 
0.38 0.99 0.983 
(0.964-0.992) 
0.2±2.1 
T2 2-SD 
42.2±12.1 
0.011* 0.99 0.993 
(0.980-0.997) 
1.0±2.6 
T1 mapping 
 
T1 Manual 
41.0±12.0 
T1 Otsu 
41.6±11.9 
0.17 0.99 0.995 
(0.990-0.998) 
-0.6±4.2 
T1 2-SD 
42.1±12.2 
0.005* 0.96 0.983 
(0.949-0.993) 
-1.0±3.9 
T2 mapping versus T1 mapping 
T2 Manual 
41.5±12.1 
T1 Manual 
41.0±12.0 
0.11 0.99 0.989 
(0.977-0.995) 
0.5±3.4 
T2 Otsu 
41.7±12.2 
T1 Otsu 
41.6±11.9 
0.72 0.97 0.986 
(0.969-0.993) 
-0.1±4.2 
T2 2-SD 
42.2±12.1 
T1 2-SD 
42.1±12.2 
0.86 0.97 0.985 
(0.967-0.993) 
0.1±4.3 
LV: left ventricle; SD: standard deviation 
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Figure 5-9: Comparison of MI size and AAR quantified by 
the different techniques 
This figure shows the comparison of the AAR by T2 
and T1 mapping using the 3 quantification techniques. NS 
denotes no statistical difference and * denote P<0.05. Data 
presented as mean ± 95%CI. 
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Figure 5-10: Comparison of the edema-based AAR by 
T2 and native T1 mapping 
There was an excellent correlation and minimal bias in 
edema-based AAR delineated by T2 mapping versus native T1 
mapping. 
 
5.3.2 T1 mapping versus T2 mapping for the detection of IMH 
Figure 5-11 provides the details of the patients’ screening and 
recruitment into the study. 48 patients with a mean age of 59±13 years and 88% 
(24/48) male gender completed the CMR study at 4±2 days post-PPCI. 
Patients’ clinical characteristics are listed in Table 5-4. The mean MI size was 
27.4±14.6% of the LV and the AAR was 42.7±11.9% of the LV. Early MVO was 
present in 79% (38/48) of patients and late MVO in 63% (30/48) of patients. The 
average scanning time was 59±4 minutes, longer than a clinical CMR scan as 
on average an additional 15 minutes were required for T1 and T2 mapping 
acquisition (full LV coverage) and an additional 3 minutes for 3 short axis T2* 
mapping acquisition. 
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Figure 5-11: Details of the screening and recruitment of 
patients entering this study 
 
 
Table 5-4: Clinical characteristics of STEMI patients 
Details Number 
Number of patients 48 
Male  40 (83%) 
Age  58 ±13 
Diabetes Mellitus 9 (19%) 
Hypertension 15 (31%) 
Smoking 15 (31%) 
Dyslipidemia 15 (31%) 
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Chest pain onset to PPCI time 
(minutes) 
182 [128-328] 
Infarct artery (%)  
              LAD 
              RCA  
              Cx  
 
28 (58%) 
18 (38%) 
2 (4%) 
Pre-PPCI TIMI flow (%)  
              0 
              1 
              2 
              3  
 
38(80%) 
1 (2%) 
4 (8%) 
5 (10%) 
Post-PPCI TIMI flow (%)  
              0 
              1 
              2 
              3 
 
1 (2%) 
0 (0%) 
10 (21%) 
37 (77%) 
Treatment – during PPCI 
Aspirin 
Clopidogrel 
Ticagrelor 
Heparin 
Bivalirudin 
Glycoprotein IIbIIIa inhibitors 
 
100(100%) 
26 (54%) 
24 (50%) 
40 (83%) 
17 (35%) 
14 (29%) 
Treatment – on discharge 
Dual antiplatelet therapy 
Beta blockers 
ACEI/ARB 
Statin 
MRA 
 
48 (100%) 
48 (100%) 
48 (100%) 
47 (98%) 
11 (23%) 
LAD: left anterior descending artery; RCA: right coronary artery; Cx: 
circumflex artery; TIMI: thrombolysis in myocardial infarction; ACEI/ARB: 
angiotensin converting enzyme inhibitor/ angiotensin receptor blocker; MRA: 
mineralocorticoid receptor antagonist. 
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Figure 5-3 shows an example of the different imaging modalities 
acquired. These are mid LV short axis images of a patient with an acute inferior 
STEMI with MVO and the corresponding maps showing IMH (arrows). 
 
5.3.2.1 T2* mapping for the detection of IMH  
 T2* maps were not interpretable in 19% (9/48) of the patients (due to 
motion, flow and off-resonance artefacts). In patients with a hypo-intense core 
on the T2* maps, the mean T2* value of the core was 13±3ms compared to 
33±4ms in the remote myocardium, P<0.001. IMH occurred in 67% (26/39) of 
the patients. As expected, patients with IMH were more likely to have larger MI 
size (33.4±11.3% of the LV versus 17.5±9.8% of the LV, P<0.001) and worse 
ejection fraction (47±7% versus 53±7%, P=0.04). Further details on the CMR 
findings are summarised in Table 5-5.  
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Table 5-5 CMR characteristics of STEMI patients 
divided into those with and without IMH.  
 With IMH  
(n=26) 
Without IMH 
(n= 13) 
P value 
EDV/ml 172±44 152±17 0.06 
ESV/ml 91±30 73±16 0.02* 
EF/% 47±7 53±7 0.04* 
LV Mass/g 117±44 111±23 0.66 
Infarct size/ % of LV 33.4±11.3 17.5±9.8 <0.001* 
Infarct size/ g 24.9±8.6 11.4±8.0 <0.001* 
AAR/ %LV 46.5±10.8 37.5±13.3 0.03* 
Late MVO/ % (n) 96 (25) 8 (1) <0.001* 
Early MVO/ % (n) 100 (26) 46 (6) 0.02* 
T1Core/ ms 997±79 1124±65 <0.001* 
T1Remote/ ms 1035±46 1014±55 0.03* 
T1AAR/ ms 1244±79 1267±65 0.43 
T2Core/ ms 50±4 57±4 <0.001* 
T2Remote/ ms 51±3 50±3 0.35 
T2AAR/ ms 66±6 66±7 0.85 
IMH: intramyocardial haemorrhage; EDV: end diastolic volume; 
ESV: end systolic volume; EF: ejection fraction; LV: left ventricular mass; 
AAR: area-at-risk; MVO: microvascular obstruction. 
*Denotes being statistically significant. 
 
 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
124 
5.3.2.2 Detection of IMH by T1 and T2 mapping 
In patients with IMH, T1Core was lower than both T1Remote (997±79ms 
versus 1035±46ms, P=0.02) and T1AAR (997±79ms versus 1244±79ms, 
P<0.001). T2Core was similar to T2Remote (50±4ms versus 51±3ms, P=1.0) but 
lower than T2AAR (49±4ms versus 66±6ms, P<0.001). In patients without IMH, 
T1Core and T2Core were higher than T1Remote and T2Remote as shown in Figure 
5-12 below. 
 
 
Figure 5-12: T1 and T2 values of the hypo-intense core, 
remote myocardium and the AAR.  
* Denotes statistically significant difference. 
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ROC analyses of the T1 and T2 values of the hypo-intense core showed 
that both mapping techniques performed equally well at detecting IMH on the 
acute scans (T1 maps: area under the curve (AUC) 0.86 [95%CI 0.72-0.99], 
cut-off value for T1Core: <1080ms; T2 maps: AUC 0.86 [95%CI 0.74-0.99]; 
P=0.94, cut-off value for T2Core: <54ms)(Figure 5-13). When using the binary 
assessment of either presence or absence of a hypo-intense core on the T1 
and T2 maps as a measure to detect IMH, T1 and T2 performed as well the 
quantitative assessment of the maps (T1: AUC 0.87 [95%CI 0.73-1.00], T2: 
AUC 0.85 [95%CI 0.71-0.99]; P=0.90). The presence of a hypo-intense core 
had a sensitivity of 88% and a specificity of 85% to detect IMH on the T1 maps 
and a sensitivity and specificity of 85% on the T2 maps. The accuracy by T1 
mapping was 87% and 85% by T2 mapping. The positive predictive value by T1 
and T2 mapping were both 92%. The negative predictive values were equally 
high by T1 mapping and T2 mapping at 87% and 85% respectively. 
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Figure 5-13: ROC curves for the diagnostic performance 
of T1 and T2 mapping to detect IMH on the acute scans when 
compared to T2* maps. 
 
5.3.2.3 Detection of early and late MVO by T1 and T2 maps 
The AUC for the presence of a hypo-intense core on the maps to detect 
early MVO was 0.83 (95% CI 0.70 – 0.97) for T1 (sensitivity: 76%; specificity: 
90%) and 0.82 (95% CI 0.69 – 0.97) for T2 (sensitivity: 77%; specificity: 90%). 
For the detection of late MVO the AUC was 0.79 (95% CI 0.64 – 0.95) for T1 
(sensitivity: 84%; specificity: 71%) 0.80 (95% CI 0.62 – 0.93) for T2 (sensitivity: 
80%; specificity of 72%). 
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Table 5-6 summarises further details on the diagnostic performances of 
T1 and T2 maps to detect IMH, early MVO and late MVO. 
Table 5-6: Summary of the diagnostic performances 
of T1 and T2 maps to detect IMH, early MVO and late MVO 
 Sensitivity/ 
% 
Specificity/ 
% 
Positive 
predictive 
value/ % 
Negative 
predictive 
value/ % 
Accuracy/ 
% 
IMH 
T1 map 
T2 map 
 
88 
85 
 
85 
85 
 
92 
92 
 
79 
73 
 
87 
85 
Early MVO  
T1 map 
T2 map 
 
76 
74 
 
90 
90 
 
97 
97 
 
50 
47 
 
79 
77 
Late MVO 
T1 map 
T2 map 
 
84 
80 
 
71 
72 
 
87 
86 
 
72 
68 
 
81 
79 
IMH: intramyocardial hemorrhage; MVO: microvascular obstruction. 
 
5.3.2.4 ROC comparison for the detection of IMH, early MVO and late MVO 
There was no significant difference in the diagnostic performance for T1 
and T2 mapping to detect IMH, early MVO and late MVO (P values for ROC 
curves comparison for IMH versus early MVO, IMH versus late MVO, early 
MVO versus late MVO for T1 mapping: 0.90, 0.43, 0.37 respectively; for T2 
mapping: 0.81, 0.58 and 0.42 respectively). 
 
5.3.2.5 Early MVO with and without IMH 
32 patients has analysable T2* maps and early MVO. 26/32 (81%) 
patients had early MVO with IMH and 6/32 (19%) patients had early MVO 
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without IMH. Both T1 and T2 values were significantly lower in patients with 
early MVO with IMH compared to those with early MVO without IMH (T1Core: 
998[954 – 1036] ms versus 1116[1085 – 1168], P<0001; T2Core: 50[48 – 53] ms 
versus 55[54 – 56] ms, P=0.005). The same comparison was not performed for 
late MVO as only 1 patient had late MVO without IMH. All patients with early 
MVO and IMH developed late MVO compared to 2/6 (33%) of those with early 
MVO without IMH had late MVO, P<0.0001.  
 
5.3.2.6 Inter-observer and intra-observer variability 
On the quantitative mapping analysis of the hypo-intense cores, for intra-
observer variability, the ICC for the quantification of the hypo-intense core for 
the T1 maps was 0.944 (0.792-0.986) and for T2 maps was 0.903 (0.637-
0.976). For inter-observer variability, the ICC for T1 maps was 0.935 (0.746-
0.984) and for T2 maps was 0.887 (0.528-0.972). On the qualitative mapping 
analysis for the hypo-intense core detection using the semi-automatic method, 
the inter-observer and intra-observer agreement was 100%, Cohen’s Kappa 
=1.0, P<0.0001.  
 
5.3.3 Post-contrast T1 mapping for acute MI size 
Baseline characteristics of the patients included for this analysis are 
listed in Table 5-7. The mean age of the STEMI patients were 57±13 years old 
and 22/28 (79%) were male. The mean MI size (MIConv) in the STEMI patients 
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was 25.1±14.3%LV and the mean oedema-based AAR by T2 (AART2Manual) was 
41.5±12.0%LV. The myocardial salvage index in this cohort was 0.41±0.28. 
Post-contrast T1 was significantly lower in the MI zone compared to the remote 
myocardium (441±48ms versus 625±22ms, P<0.001).  
Table 5-7: Patient characteristics and coronary 
angiographic details 
Details Number 
Number of patients 28 
Male  22 (79%) 
Age  57 ±13 
Diabetes Mellitus  8 (29%) 
Hypertension 8 (29%) 
Smoking 10 (36%) 
Dyslipidemia 8 (29%) 
Chest pain onset to PPCI time 
(minutes) 
216 [138-422] 
Infarct artery (%)  
              LAD 
              RCA  
              Cx  
 
17 (61%) 
9 (33%) 
2 (7%) 
TIMI flow Pre/ Post PPCI (%)  
              0 
              1 
              2 
              3  
 
19 (68%)/ 1 (4%) 
1 (4%)/ 0 (0%) 
3 (11%)/ 1 (4%) 
5 (17%)/ 26 (92%) 
LAD: left anterior descending artery; RCA: right coronary artery; 
Cx: circumflex artery; TIMI: thrombolysis in myocardial infarction; PPCI: 
primary percutaneous coronary intervention 
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Figure 5-14: Representative examples of the T2 and native T1 
maps showing the AAR and the corresponding LGE on the 
conventional, synthetic and post-contrast T1 maps. 
Patients A and C suffered from an acute anterior STEMI and 
Patient B suffered from an acute inferior STEMI – all were treated 
by PPCI. The red arrows indicate the territory of the subendocardial 
MI (of different transmural extents) on the conventional and 
synthetic LGE images and post-contrast T1 maps. All these patients 
had significant myocardial salvage. 
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Figure 5-14 illustrates examples from 3 patients with an acute MI size by 
conventional LGE, synthetic MagIR LGE, synthetic PSIR LGE, and post-
contrast T1 maps.  
 
5.3.3.1 Acute MI size quantification  
There was an excellent correlation (R2 0.96 to 0.99) and inter-method 
agreement (ICC 0.964 to 0.996) between conventional LGE and the other 
techniques. There was minimal bias between MIConv and MISynthMagIR (bias: 
0.2±2.2%LV, P=0.35); between MIConv and MISynthPSIR (bias: 0.4±2.2%LV, 
P=0.060); and between MIConv and MIT1Post2SD (bias: 0.3±1.8%LV, P=0.10), with 
the latter having the narrowest limits of agreement. However, MIT1PostOtsu 
underestimated MI size when compared to MIConv (bias -2.2±6.0%LV, P=0.001). 
Figure 5-15 shows the comparison of the various techniques used for MI size. 
Figure 5-16 illustrates the correlations and Bland-Altman analysis of MIConv 
against the 4 other techniques and further details are summarised in Table 5-8. 
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Figure 5-15: Comparison of MI size quantified by the 
different techniques. 
This figure illustrates MI size by the conventional LGE, 
synthetic LGE and post-contrast T1 mapping and AAR by T2 and T1 
mapping.  
NS denotes no statistical difference and * denote P<0.05. 
Data presented as mean ± 95%CI.
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Figure 5-16: Comparison of MI size by different methods against the reference standard. 
These are the correlations (a-d) and Bland-Altman analyses (e-h) of MI size by conventional LGE against each of the 
4 other techniques (synthetic MagIR LGE, synthetic PSIR LGE, post-contrast T1 2-SD and post-contrast T1 Otsu).  
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Table 5-8: Comparison of acute MI size quantification 
by the different techniques. 
Reference/ 
%LV 
Other 
Techniques/ 
%LV 
P 
value 
R2 ICC 
(95%CI) 
Bias±2SD/ 
%LV 
Acute MI size 
 
 
MIConv 
25.1±14.3 
MISynthMagIR 
24.9±13.8 
0.35 0.99 0.996 
(0.992-0.998) 
0.2±2.2 
MISynthPSIR 
24.7±13.9 
0.060 0.99 0.996 
(0.992-0.998) 
0.4±2.2 
MIT1Post2SD 
24.9±13.8 
0.10 0.99 0.996 
(0.991-0.998) 
0.3±1.8 
MIT1PostOtsu 
23.0±12.9 
0.001* 0.96 0.964 
(0.859-0.987) 
2.2±6.0 
ICC: intraclass correlation coefficient; SD: standard deviation; MI: myocardial infarction; 
Conv: conventional; SynthMagIR: synthetic magnitude reconstructed inversion recovery; 
SynthPSIR: synthetic phase sensitive inversion recovery. 
 
5.4 Discussion  
We have demonstrated that T1 mapping CMR can perform as well as T2 
mapping to delineate the AAR in reperfused STEMI patients. There was an 
excellent correlation and agreement between T1 and T2 mapping in delineating 
the AAR in both cohorts. This data confirms the findings of the pre-clinical study 
by Ugander et al (131) in the reperfused canine heart. Both T1 and T2 mapping 
CMR were equally prone to susceptibility artefacts at 3T and equally affected by 
MVO. The acquisition times for both mapping sequences were similar on both 
scanners. 
We have also shown that T1 and T2 maps obtained at day 4 following a 
reperfused STEMI detected the presence of IMH with high specificity and 
sensitivity compared to the reference standard method using T2* maps. The 
binary assessment of presence or absence of a hypo-intense core performed 
as well as the quantitative assessment of the actual T1 and T2 values of the 
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hypo-intense core. However, T2* maps are still the modality of choice when 
available as the accuracy for T1 and T2 maps to detect IMH was only 87% and 
85%, respectively. T1 and T2 maps provide an alternative option for the 
detection of IMH when T2* imaging is not available. T1 and T2 mapping 
performed equally well to detect early and late MVO.  
Lastly, we have also showed that acute MI size can be accurately 
quantified from the post-contrast T1 maps (2-SD) and the synthetic LGE images 
when compared to conventional LGE imaging.  
 
5.4.1 T1 mapping versus T2 mapping for the AAR 
Langhans et al (133) recent looked at the reproducibility of the AAR by 
T1 and T2 mapping against SPECT in 14 patients with reperfused STEMI at 
1.5T. Although good correlations with SPECT were reported (R=0.94 for T2 and 
0.91 for T1-derived AAR), direct comparison between the two mapping 
techniques was not performed in terms of per slice correlation, agreement and 
inter and intra-observer variability. 
We found that the Otsu threshold method performed best with excellent 
inter-observer and intra-observer variability for both mapping techniques. The 
algorithm automatically divides the signal intensity histogram into two classes 
and requires minimal user input compared to manual delineation, SD threshold 
and full width half maximum techniques. It automatically calculates an optimal 
threshold (179) and has previously been shown to be more accurate and 
reproducible for quantifying acute MI size by CMR.(180) However, this 
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technique fails in those with a higher burden of IMH (4% in our cohort) and in 
those situations manual input is required. Furthermore, normal slices (normal 
T1 and T2 values, no wall motion abnormalities on cines) need to be manually 
selected as normal. 
Currently, it would appear that T1 and T2 mapping could be used 
interchangeably to assess the AAR in reperfused STEMI patients. In studies 
investigating post-contrast T1 and ECV in acute MI patient, there is the 
possibility of shortening the scanning time by omitting T2 maps as the T1 maps 
would be available for AAR quantification. However, T1 mapping may not be 
suitable in acute myocardial infarction patients who also have a chronic infarct 
in the remote myocardium. T1 mapping CMR has recently been shown to 
identify chronic infarct with high diagnostic accuracy (273) in a canine model, 
and using this technique in these patients would require taking into account 
areas of chronic infarct in the remote myocardium. Our study excluded patients 
with previous infarct and therefore we cannot comment on the performance of 
T1 mapping over T2 mapping in patients with co-existing chronic infarcts. From 
an MR physics point of view, these two techniques are assessing different 
properties of the myocardium and may explain the limits of agreement of 
around 10% on a per-slice comparison and of around 5% on a per-patient 
comparison and more work remains to be done to establish the advantage of 
one mapping sequence over the other.  
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5.4.2 T1 mapping versus T2 mapping for the detection of IMH 
T1 and T2 mapping performed equally well to detect early and late MVO. 
This is not surprising for late MVO as most patients with late MVO also had IMH 
in our cohort. Although numerically the AUCs were higher for the detection of 
early MVO than late MVO, ROC curves comparison did not show a statistical 
significance. T1 and T2 mapping could differentiate between early MVO with 
and without IMH and predominantly those with IMH displayed late MVO. Early 
MVO likely represents a spectrum of aetiologies for microvascular injury and 
late MVO with IMH representing the most severe form. A recent study (274) 
using a porcine model of MI showed that T2-STIR imaging could not 
discriminate between IMH and MVO but imaging was performed at 8 days and 
no T2* data were acquired. Given the recent evidence of the dynamic nature for 
the detection of the paramagnetic properties of IMH (112), it is not possible to 
put the results of that study into context with our findings. 
T1 of the infarct core was recently shown to be more prognostic than LV 
ejection fraction, infarct core T2 and IMH in a large cohort of STEMI 
patients.(156) Carrick et al (139) also showed that IMH was more closely 
associated with adverse LV remodelling than late MVO but their timing of CMR 
was a mean of 2.1 days and 87% of their patients with MVO had IMH. They 
also demonstrated the dynamic nature of MVO and IMH peaked at 2.9 
days.(139) Whether performing CMR ≥ 3 days post PPCI (our study: mean of 4 
days – 96% with MVO had IMH) may reveal more patients with MVO with IMH, 
which would have more prognostic significance, remains to be tested in future 
adequately powered studies.  
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The hypo-intense core on the T2 maps in reperfused STEMI patients has 
been thought to be due to IMH in previous studies.(98, 138) Pedersen et al 
(233) previously showed that T1-weighted inversion recovery images could 
detect IMH with high sensitivity and specificity in a porcine model of acute 
STEMI. However, in this work, we direct compared the diagnostic performance 
of T1 and T2 mapping to detect IMH against T2* mapping in the clinical setting.  
The mechanism of the low signal within the areas of IMH has previously 
been attributed to the paramagnetic properties of haemoglobin breakdown 
products.(146) However, degradation of the extravasated erythrocytes to 
oxyhaemoglobin, deoxyhaemoglobin, and methaemoglobin (strongly 
paramagnetic) is dynamic and would exhibit different T1 and T2 properties at 
various stages as previously described by Bradley et al (158) in brain imaging. 
T2 is better at identifying deoxyhaemoglobin, whereas T1 is better at detecting 
methaemoglobin (158) and this may explain the small difference in sensitivities 
for T1 and T2 maps to detect IMH in our study. Breakdown of the erythrocyte 
membrane eventually leads to ferritin and haemosiderin deposits within 
macrophages.(146) Although T2* is the most sensitive to detect IMH, it is prone 
to motion artefacts due to relatively long breath-hold duration and this has led to 
the development of free-breathing T2* mapping using motion corrected 
averaging.(157) However this is not widely available yet and therefore T1 and 
T2 mapping, which is increasing becoming available in most centres performing 
STEMI research may be an alternative option to detect IMH and minimise 
patients dropping out of studies when T2* mapping was not acquired or were 
not interpretable. 
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The mechanism for a hypo-intense core on the T1 and T2 maps in 
patients without IMH but with MVO is not clear. It has been postulated that this 
may be due to a localized reduction in tissue water content due to obstruction of 
the capillaries by distal micro-thrombi embolisation and plaques and cellular 
debris and compression from extrinsic oedema.(98, 139) The alternative 
explanation could be that the hypo-intense core on the T1 and T2 maps may 
still represent IMH but the haemoglobin degradation products are not 
paramagnetic yet to be detected by T2* if imaged too early and more work 
remains to be done. 
 
5.4.3 Post-contrast T1 mapping for acute MI size 
Messroghli et al (186) has previously shown that post-contrast T1 
mapping could detect both acute and chronic MI in a cohort of 24 patients but 
not all patients underwent coronary angiography prior to CMR and only 21% 
showed evidence of reperfusion. Bauner et al (187) had subsequently shown 
that post-contrast T1 could accurately detect chronic MI in 26 patients.  
For MagIR synthetic LGE images, the negative values occurring at short 
TIs are reconstructed as positive and are used to reconstruct the single shot 
LGE images.(244) As a result, in situations when the TI is too short, the loss of 
polarity in the MagIR image will appear as an artifact. The PSIR technique 
preserves polarity and is therefore less sensitive to the TI. For PSIR synthetic 
LGE images, the polarity is restored and the window level can be 
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retrospectively leveled to display the normal myocardium as black while the MI 
will appear white.(263) 
Synthetic LGE has also been shown to accurately quantify chronic MI 
size in a small cohort of patients (190), but in this study only one short-axis LV 
image was analysed. A previous conference abstract showed that synthetic 
PSIR LGE agreed well with conventional PSIR LGE in a small cohort of 17 
patients with ischaemic and non-ischaemic scars.(275) In our study we 
performed full LV coverage and we have shown that post-contrast T1 maps can 
accurately quantify acute MI size (using the semi-automated 2-SD threshold) 
when compared to the reference standard in a cohort of reperfused STEMI 
patients. Using the SD technique for quantification can be variable depending 
on where the reference ROI is drawn. To minimise the error associated with 
this, we have used the automated ROI delineation option with minimal manual 
adjustment when required. Furthermore, we have also shown that the additional 
sets of IR images that can be obtained from the post-contrast MOLLI T1 maps 
can be used to obtain synthetic LGE images (both MagIR and PSIR) and can 
accurately quantify acute MI size. PSIR LGE is T1-weighted with retrospective 
nulling of the remote myocardium, thus being insensitive to the TI used for 
acquisition.(276) With the PSIR technique, the tissue with the longest TI nulls 
first, irrespective of the TI used (post gadolinium, the remote myocardium has 
the longest TI) and this sequence has previously been shown to improve MI 
detection more accurately by LGE compared to conventional MagIR LGE 
images.(277) Both synthetic LGE and post-contrast T1 map would delineate the 
MI zone equally well but the T1 maps would have higher spatial resolution than 
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the single shot SSFP synthetic images and the MI zone could be quantified on 
a pixel-wise basis. However, the quality of the T1 maps may be affect if there is 
significant motion between the single shot images that may fail to align well 
despite motion-correction. However, as it stands, to acquire synthetic LGE, post 
contrast T1 maps would also need to be acquired and therefore the synthetic 
PSIR output could complement post-contrast T1 maps for MI size quantification 
without the need for conventional LGE images.  
 
5.4.4 Limitations 
We only included a small number of patients and did not have 
histological validation of the AAR. We found the Otsu technique to perform best 
against Manual both at 1.5T and 3T but manual input was required when no 
oedema was present (using visual assessment of the coloured maps and cine 
images as reference), and when extensive MVO was present on the maps. The 
AAR delineated by contrast-enhanced SSFP cines in a multivendor, multi-
centre setting, has been shown to perform well against T2-STIR imaging.(128) 
We did not acquire contrast-enhanced SSFP cines to compare against T1 and 
T2 mapping. The small sample size may account for the unusually high 
incidence of MVO (67%) when compared to the literature in the 1.5T cohort and 
could have been due to chance. A large number of the T2* maps were not 
interpretable in our study predominantly due to motion, flow and off-resonance 
artefacts and this highlights the challenge of performing a comprehensive CMR 
scan with multi-parametric mapping in acutely unwell STEMI patients (average 
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scanning time of 1 hour). The recent study by Carrick et al (139) also showed 
that 18% of T2* maps were not analysable either due to patient’s intolerance of 
the scan or T2* maps being not evaluable. Histological validation for the low T1 
and T2 of the hypo-intense core was not possible in this study and warrants 
further investigation. The large majority of our patients with MVO also had IMH. 
Therefore we could not assess whether the hypo-intense core on the T1 and T2 
maps could differentiate between late MVO with IMH and late MVO without 
IMH. However, we did find a difference in the T1Core and T2Core between those 
with early MVO with IMH and early MVO without IMH and this needs to be 
confirmed in future studies. The conventional LGE scan (acquired 10-15 
minutes post contrast) and post-contrast-T1 map (acquired 15-20 minutes post 
contrast) were acquired 5 minutes apart. But despite this, there was no 
difference in MI size. The TI range for the IR images generated in-line from the 
T1 maps was quite wide (200ms to 975ms and at 25ms increments). But off-line 
post-processing was not necessary and synthetic MagIR LGE images were 
interpretable and performed as well as conventional LGE for MI size 
quantification. Our sample size was small but still larger than previously 
published studies on synthetic LGE.(190) We used 2 different LGE read-outs 
(FLASH LGE in 22 patients and MOCO-FB LGE in 6 patients) for MI size 
quantification but both these sequences have been shown to perform equally 
well for MI size quantification.(278) Synthetic IR LGE is a single shot SSFP 
acquisition and therefore has lower spatial resolution than PSIR LGE. Therefore 
the synthetic IR LGE technique may be less useful in patients with small sub-
endocardial scars and mid-wall fibrosis. 
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5.5 Conclusion 
We have shown that T1 mapping CMR can accurately quantify the AAR 
delineated by T2 mapping in reperfused STEMI patients.  
Furthermore, the presence of a hypo-intense core on T1 or T2 maps 
provides an alternative approach for the detection of IMH in situations when T2* 
maps are not interpretable or available. However T2* mapping currently 
remains the reference standard in the clinical setting and T1 and T2 mapping 
therefore may play a complementary role in future studies targeting IMH. 
Finally, we have shown that post-contrast T1 mapping can accurately 
quantify acute MI size using post-contrast T1 maps or synthetic LGE outputs 
derived from those T1 maps. Therefore, conventional LGE imaging may be 
omitted in future studies when post-contrast T1 mapping is already being 
acquired. 
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6 Semi-automated quantification techniques for 
assessing acute and chronic myocardial infarction 
by CMR 
6.1 Introduction 
There is currently no established gold standard technique for quantifying 
MI size using LGE. Several different techniques have been proposed for 
quantifying acute and chronic MI size including manual contouring (176) and 
semi-automated threshold techniques such as a signal intensity threshold of 5-
SD (177) or 6-SD (178) above the normal remote myocardium, the Otsu 
technique (180), and the FWHM (182, 183) technique. The consensus 
document from the Society for Cardiovascular Magnetic Resonance Board of 
Trustees Task Force on Standardized Post Processing recommends the semi-
automated threshold technique of 5-SD for MI size quantification as it may 
improve reproducibility.(225) Manual contouring is considered the gold standard 
(57, 176) but may be time consuming (183, 184) and subjective. FWHM has 
emerged as the technique having the lowest variability (182, 183) but others 
have shown FWHM to underestimate acute and chronic MI size.(180, 185) 
Recently FWHM45% and 6SD were found to perform well in paired acute and 
follow-up scans at 3T.(185)  
By convention, the FWHM technique (181) uses a threshold of above 
50% of the maximal signal intensity of the ROI as the cut-off threshold and we 
hypothesized that areas previously occupied by MVO on the follow-up CMR are 
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likely to affect the highest signal intensity and impact on MI size quantification, 
compared to those without previous MVO. Therefore, the aim of our study was 
firstly to assess the impact of MVO on the performance of four most promising 
semi-automated techniques (5-SD, 6-SD, Otsu and FWHM) against manual 
contouring (referred to as Manual contouring throughout the chapter) as the 
reference standard (57, 176) in paired acute and follow-up CMR scans at 1.5T. 
Secondly, we aimed to assess the performances of acute MI size by these 
different techniques to predict the development of adverse LV remodelling 
(≥20% increase in end-diastolic volume).(197) 
 
6.2 Methods 
6.2.1 Study Population 
40 STEMI patients from the 1.5T cohort with paired acute and follow-up 
CMR as described in the methodology section were analysed for this chapter.  
 
6.2.2 Imaging acquisition 
All CMR scans were performed on a 1.5 Tesla scanner (Magnetom 
Avanto, Siemens Medical Solutions) using a 32-channel phased-array cardiac 
coil. The imaging protocol included full LV coverage for short axis cines and 
LGE and automated ECV maps were available for reference (30 patients had 
full LV coverage and 10 patients had base, mid and apical short axis slices) as 
described in the methodology section.  
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Late gadolinium enhancement 
LGE imaging was acquired using either a standard segmented ‘fast low-
angle shot’ (FLASH) two-dimensional inversion-recovery gradient echo 
sequence or a free-breathing, respiratory motion-corrected (FB MOCO) single 
shot steady state free precession averaged inversion recovery sequence (263) 
between 10-15 minutes after 0.1 mmol/kg of Gd-DOTA (Dotarem).  
 
6.2.3 Imaging analysis  
All imaging analysis was performed using CVI42 software (Version 5.2.2[340], 
Calgary, Canada).  
MI quantification 
The endocardial and epicardial borders were manually drawn on all the 
LGE images. MI size was quantified using Manual contouring by HB (2 and a 
half years experience in STEMI CMR scans analysis) and expressed as the 
%LV. Areas of hypo-intense core of MVO were included as part of the MI zone. 
Minimal adjustments were also performed if artefacts were present in the 
remote myocardium and these artefacts were manually excluded.  
Thresholds of 5-SD, 6-SD, Otsu and FWHM were applied on these LGE 
images with pre-drawn endocardial and epicardial borders to obtain 
corresponding MI sizes and expressed as %LV.  
For 5-SD and 6-SD (to identify signal intensities of 5-SD and 6-SD above the 
mean normal remote myocardium respectively), a ROI was identified in the 
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normal remote myocardium using the automatic option from CVI42, with 
minimal manual adjustment when required to minimise intra-observer variability.  
20 scans (10 acute and 10 follow-up) were randomly selected for intra-
observer variability (performed by HB, 3 months apart) of MI size quantification 
by Manual contouring. Furthermore, the reproducibility of MI size by 5-SD and 
6-SD when using manually drawn remote myocardial ROI and automatic remote 
myocardial ROI detection with minimal manual adjustment as illustrated in 
Figure 1 were compared. 
For the FWHM technique (to identify signal intensities that are above 
50% of maximal signal intensity of the reference ROI)(181), the automatic 
option was also used to delineate an ROI in the area of hyper-enhancement by 
LGE.  
The Otsu technique (to identify the intensity threshold from the signal 
intensity histogram using the value with minimal intra-class variance between 
low and high intensities)(179) did not require any additional ROIs but did require 
user input to identify slices with no LGE as normal.  
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Figure 6-1: Figure 1: Illustration of the steps used in the 
quantification of MI size.  
Endocardial and epicardial borders were first manually drawn (a to b). c 
illustrates the manual ROI delineation in the remote normal myocardium and Manual 
contouring of the MI (red arrows). d illustrates the automated ROI delineation. As 
shown by the red arrows in d, in this case, the ROIs need minimal manual adjustment 
(as shown in e by the red arrows) to make sure it was not in a segment containing 
LGE. Areas of MVO appears as a hypo-intense area (red arrow in f) and needed 
manual correction (red arrow in g) to include it as part of the MI. 
 
Automated ECV maps 
Manual ROI were drawn in the core of the MI zone (corresponding to 
areas of MVO in some patients with a hypo-intense core on the acute scan 
LGE) on the acute and matching ROIs were copied to the follow-up maps to 
obtained representative ECV values. 
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6.2.4 Statistical analysis 
SPSS version 22 (IBM Corporation, Illinois, US) was used for the 
majority of the statistical analyses and MedCalc for Windows Version 15.6.1 
(Medcalc Software, Ostend, Belgium) was used for ROC comparison using the 
technique described by Delong et al (272) Normality was assessed using 
Shapiro-Wilk test. Continuous data were expressed as mean ± SD or median 
(interquartile range). Groups were compared using paired Student t-test/ 
Wilcoxon signed rank test or unpaired Student t-test/ Mann-Whitney U test 
where appropriate. Categorical data were reported as frequencies and 
percentages.  
Intra-observer reproducibility for Manual contouring and for 5-SD and 6-
SD when using manual remote myocardial ROI delineation versus automatic 
remote myocardial ROI detection was assessed in 20 scans using ICC with 
95% confidence intervals (95%CI) and Bland-Altman analysis (expressed as 
bias ± 2 SD for limits of agreement).  
Inter-method precision and accuracy for MI size quantification was 
assessed as defined below: 
Precision: A semi-automatic technique was considered precise when 
the inter-method coefficient of variability (CoV) (279) was < 10% and the ICC 
was > 0.900 (arbitrary cut-offs to denote good precision in the absence of a 
reference standard).   
Accuracy: A semi-automatic technique was considered accurate when 
compared to Manual contouring if there was no statistically significant difference 
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between them on paired tests and no bias was present on Bland-Altman 
analysis. 
ROC analyses were performed to assess the diagnostic performance for 
MI size by Manual contouring, 5-SD, 6-SD, Otsu and FWHM on the acute scan 
to predict adverse LV remodelling. 
All statistical tests were two-tailed, and P<0.05 was considered 
statistically significant.  
 
6.3 Results 
The mean age of the STEMI patients was 59±13 years old and 88% 
were male. Further details regarding the patients’ clinical, angiographic and 
CMR characteristics are listed in Table 6-1. The mean acute MI size was 
25.0±13.7%LV (Manual contouring). The mean LVEF on the acute scan was 
49±8% and at follow-up was 53±10%. As expected, there was a significant 
regression in MI size between the acute scan and the follow-up scan 
(25.0±13.7%LV versus 17.3±10.1%LV, P<0.001, percentage of MI regression: 
32±20%). 26/40 (65%) patients had MVO on the acute scan. Figure 2 illustrates 
an example of MI size quantification by the 5 semi-automated techniques in a 
paired acute and follow-up LGE short-axis slice. 
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Table 6-1: Clinical, angiographic and CMR 
characteristics of the 40 STEMI patients.  
Details Number 
Number of patients 40 
Male (%) 35 (88%) 
Age (age) 59 ±13 
Diabetes Mellitus 8 (20%) 
Hypertension 14 (35%) 
Smoking 12 (30%) 
Dyslipidaemia 14 (35%) 
Chest pain onset to PPCI time 
(minutes) 
267 [122-330] 
Infarct artery (%)  
              LAD 
              RCA  
              Cx  
 
24 (60%) 
14 (35%) 
2 (5%) 
TIMI flow Pre/ Post PPCI (%)  
              0 
              1 
              2 
              3  
 
33 (83%)/ 1(3%) 
0 (0%)/ 0 (0%) 
3 (8%)/ 8 (20%) 
4 (10%)/ 31 (78%) 
CMR findings 
        LV EDV/ml 
                   Acute  
                   Follow-up 
        LV ESV/ml 
                   Acute  
                   Follow-up 
        LV EF/%                    
                   Acute  
                   Follow-up 
 
 
172±38 
182±49 
 
90±30 
88±38 
 
49±8 
53±10 
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         LV Mass/g 
                   Acute  
                   Follow-up 
        Reference MI size/ %LV 
                   Acute  
                   Follow-up 
        MVO/ % 
 
112±35 
104±26 
 
25.0±13.7 
17.3±10.1 
26 (65%) 
LAD: left anterior descending artery; RCA: right coronary artery; Cx: 
circumflex artery; TIMI: thrombolysis in myocardial infarction; CMR: 
cardiovascular magnetic resonance; LV: left ventricular; EDV: end 
diastolic volume; ESV: end systolic volume; EF: ejection fraction; MI: 
myocardial infarction; MVO: microvascular obstruction; AAR: area-at-
risk. 
 
 
 
Figure 6-2: Acute and follow-up MI size quantification by different 
techniques. 
This is an example of a paired acute (3 days) and follow-up (6 months) short axis 
LGE of a patient with an anterior STEMI reperfused by PPCI. This example highlights 
the presence of MVO on the acute scan (orange highlighted areas) and subsequent 
underestimation of MI size by FWHM on the follow-up scan. 
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6.3.1 Intra-observer variability 
There was excellent intra-observer reproducibility for Manual contouring 
with an ICC of 0.996 (0.988-0.998) and no bias (0.5±2.2%LV, P=0.07). 
There was also better intra-observer reproducibility for MI size 
quantification by the SD technique when automatic remote myocardial ROI 
delineation was used compared to manual drawing of remote myocardial ROI 
with a narrower 95%CI for the ICC and narrower limits of agreement on Bland-
Altman analysis [manual remote ROI: ICC of 0.990 (0.981-0.995), Bias:  
0.1±3.9%LV, P=0.09; automatic remote ROI: ICC of 0.999 (0.998-0.999), Bias: 
0.2±1.2%LV, P=0.87].  
 
6.3.2 Acute MI size quantification  
Both 6-SD [CoV: 5.1%; ICC: 0.982 (0.966-0.991); MI size: 24.9±14.0%LV, 
P=0.81; bias: 0.1±5.2%LV] and FWHM [CoV: 6.4%; ICC: 0.970 (0.943-0.984); 
MI size: 24.1±13.1%LV, P=0.066; bias: 1.0±6.2%LV] precisely and accurately 
quantified acute MI size when compared to Manual contouring (25.0±13.7%LV). 
In contrast, both 5-SD [CoV: 6.8%; ICC: 0.971 (0.811-0.990); MI size: 
27.4±14.6%LV, P<0.0001; bias: -2.4±5.0%LV] and Otsu [CoV: 8.4%; ICC: 
0.953 (0.441-0.987); MI size: 28.4±13.9%LV, P<0.0001; bias: -3.4±5.2%LV] 
were precise but not accurate as they both overestimated acute MI size (Figure 
3).  
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6.3.3 Chronic MI size quantification 
Only 6-SD [CoV: 6.0%; ICC: 0.952 (0.911-0.974); MI size: 17.2±9.7%LV, 
P=0.88; bias: -0.1±6.2%LV] precisely and accurately delineated chronic MI size 
when compared to Manual (17.3±10.1%LV). As on the acute scan, 5-SD [CoV: 
6.5%; ICC: 0.949 (0.752-0.982); MI size: 19.5±10.4%LV, P<0.0001; bias: -
2.2±5.1%LV) and Otsu [CoV: 7.4%; ICC: 0.934 (0.788-0.973); MI size: 
19.5±10.4%LV, P<0.001; bias -2.1±6.2%LV] were precise but not accurate as 
they overestimated chronic MI size. On the other hand, FWHM [CoV: 8.1%; 
ICC: 0.910 (0.755-0.957); MI size: 15.1±8.7%LV, P<0.001; bias: 2.2±7.1%LV) 
was precise but not accurate as it underestimated chronic MI size (Figure 6-3).  
 
 
Figure 6-3: Comparison of acute and follow-up MI size 
quantification by different techniques 
On the acute scan (red bars), MI size by FWHM and 6SD was similar to Manual 
whereas on the follow-up scan (blue bars), FWHM underestimated MI size and 6SD 
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remained similar to Manual. On the acute and follow-up scans, 5SD and Otsu 
overestimated MI size. 
 * Denotes statistically significant difference.  
 
6.3.4 Impact of MVO on MI size quantification 
All patients with MVO (26/40) had complete resolution of the dark core 
on the LGE images on the follow-up scan. The percentage of MI size regression 
was significantly greater for those without MVO (with MVO: 27±17%, without 
MVO: 42±22%, P=0.028). As was the case for the whole cohort, there was no 
significant difference between FWHM, Manual contouring and 6-SD both for 
those with and without MVO, and 5-SD and Otsu overestimated acute MI size.  
On the follow-up scan, FWHM remained similar to Manual contouring for 
those without previous MVO but underestimated chronic MI size only for those 
with previous MVO. The three other techniques maintained their previous 
relationship both for those with and without previous MVO: 6-SD was similar to 
Manual contouring but 5-SD and Otsu were significantly higher than Manual 
contouring. Further details for the comparison of MI size in those with and 
without MVO are available in Table 5-1 and the Bland-Altman plots in Figure 
6-4. 
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Figure 6-4: Bland-Altman plots of the chronic MI size using the 
4 semi-automated methods against manual and differentiated 
by the previous MVO or no MVO on the acute scan. 
The black dots represent patients with MVO on the acute scan and 
the red dots represent patients with no MVO on the acute scan. There 
was no bias between 6SD and Manual and all CoV were within 
acceptable limits. FWHM underestimated chronic MI size, especially in 
those with previous MVO. Both 5-SD and Otsu overestimated chronic MI 
size. 
 
On the acute scan, the median ECV in the infarct core was 59 (40-72) % 
in those without MVO and was significantly higher than those with MVO [34 (28-
40) %, P=0.02]. On the other hand, at follow-up, the median ECV in those with 
MVO on the acute scan was significantly higher than those without previous 
MVO. Figure 6-5 shows an example of 2 patients with paired acute and follow-
up LGE and corresponding ECV map (Patient A had no MVO on the acute scan 
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and Patient B had a large area of MVO. The corresponding area of MVO on the 
follow-up scan had a very high ECV of 85%). 
 
 
 
Figure 6-5: Paired LGE and automated ECV maps of 2 
patients with and without MVO 
Both patients presented with an inferior STEMI (red arrows). Patient A had no 
MVO on the acute scan and Patient B had a large area of MVO. The corresponding 
area of MVO on the follow-up scan had a very high ECV of 85% for Patient B 
compared to an ECV of 52 for Patient A. 
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6.3.5 Influence of LGE sequence on MI size quantification 
The quantification methods were also compared for each subset of the 
LGE sequences (FLASH: n=16; FB MOCO: n=24). As for the whole cohort, 5SD 
and Otsu was significantly higher than Manual and 6SD was similar to Manual 
contouring for both LGE sequences on the acute and follow-up scans. FWHM 
was significantly lower than Manual contouring for both LGE sequences on the 
follow-up scans. However, on the acute scans, FWHM was similar to Manual for 
FLASH but significantly lower for the FB MOCO sequence (FB MOCO: Manual: 
23.4±15.9%LV versus FWHM: 22.6±15.5%LV, P=0.001). Further details are 
shown in Table 6-2 and the Bland-Altman plots in Figure 6-6 below. 
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Table 6-2: MI size quantification using different LGE 
sequences 
Manual Other thresholds P value Manual 
Other 
thresholds P value 
FB MOCO LGE sequence (n=16) 
Acute MI size/ %LV Chronic MI size/ %LV 
23.4±15.9 
5SD 
26.3±17.4 
0.02* 
17.1±12.3 
5SD 
19.7±13.1 
0.001* 
6SD 
24.3±15.9 
0.13 
6SD 
18.0±12.2 
0.21 
Otsu 
25.9±16.8 
0.003* 
Otsu 
18.1±11.7 
0.03* 
FWHM 
22.6±15.5 
0.001* 
FWHM 
14.3±9.7 
0.005* 
FLASH LGE sequence (n=24) 
Acute MI size/ %LV Chronic MI size/ %LV 
 
 
 
26.0±12.2 
5SD 
28.1±12.8 
<0.0001* 
 
 
 
17.5±8.5 
5SD 
19.3±8.7 
0.001* 
6SD 
25.3±12.1 0.15 
6SD 
16.7±7.8 
0.25 
Otsu 
30.1±12.1 
<0.0001* 
Otsu 
20.3±9.7 
0.001* 
FWHM 
25.0±11.5 
0.24 
FWHM 
15.7±8.2 
0.033* 
FB MOCO LGE: free breathing and motion corrected late gadolinium 
enhancement; MVO: microvascular obstruction; MI: myocardial infarction; LV: left 
ventricle; SD: standard deviation; FWHM: full width half maximum; FLASH LGE: fast 
low angle shot late gadolinium enhancement. 
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Figure 6-6: Bland-Altman plots of the acute MI size using 
the 4 semi-automated methods against Manual and 
differentiated by the LGE sequence used. 
The blue dots represent patients with FLASH LGE sequence 
and the green dots represent patients with FB MOCO LGE 
sequence. There was no bias between 6SD and Manual and FWHM 
and Manual and all CoV were within acceptable limits. However, 
compared to Manual, FWHM was dependent of the LGE sequence 
used. Both 5-SD and Otsu overestimated acute MI size. 
 
 
6.3.6 Acute MI size quantification and adverse LV remodelling 
8/40 (20%) patients developed adverse LV remodelling. The diagnostic 
performances of Manual contouring, 5-SD, 6-SD, Otsu and FWHM were all very 
high with all 5 AUC of ≥ 0.90 as shown in Table 6-3 and Figure 6-7. ROC 
comparisons showed no significant differences between them (Manual 
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contouring versus: 5-SD, P=0.14; 6-SD, P=1.0; Otsu, P=0.14; FWHM, P=0.56). 
The sensitivities and specificities and cut-off values for acute MI size to predict 
adverse LV remodelling by the different techniques are listed in Table 6-3 
below. 
 
Table 6-3: Performance of the 5 techniques for 
quantifying acute MI size on predicting adverse LV 
remodelling at follow-up.  
Acute MI 
quantification 
AUC 
(95%CI) 
Sensitivity/ 
% 
Specificity/
% 
Acute MI 
cut-off 
value/ 
%LV 
Manual 
contouring 
0.93 
(0.82-1.00) 
88 91 37 
5-SD 
0.91 
(0.79-1.00) 
88 87 38 
6-SD 
0.90 
(0.83-1.00) 
88 95 35 
Otsu 
0.90 
(0.77-1.00) 
88 91 41 
FWHM 0.92 (0.80-1.00) 88 95 35 
MI: myocardial infarction; AUC: area under the curve; CI: confidence interval; LV: 
left ventricle; SD: standard deviation; FWHM: full width half maximum. 
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Figure 6-7: ROC curves for acute MI size by 5 
techniques to predict adverse LV remodelling. 
This is the ROC curves comparison to assess the diagnostic 
performance of the 5 quantification techniques to predict adverse LV 
remodelling. 
 
6.4 Discussion 
The main findings from this study are: (a) the 6-SD technique was as 
accurate as Manual contouring in quantifying acute and chronic MI size, 
irrespective of the LGE acquisition sequence used, whereas the FWHM only 
performed as well as Manual for FLASH and underestimated acute MI size by 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
163 
FB MOCO LGE sequence. (b) FWHM underestimated chronic MI size and this 
predominantly occurred in patients with MVO on the acute scan. These patients 
had very high ECV of the MI core that was previously occupied by MVO 
compared to those without previous MVO. (c) 5-SD and Otsu consistently 
overestimated both acute and chronic MI size when compared to Manual 
contouring; (d) All 4 semi-automated techniques were precise (all with 
acceptable CoV and excellent inter-method agreement), and on the acute scan, 
they all performed equally well to predict the development of adverse LV 
remodelling.  
There are several implications from our study. Firstly, 6-SD is the most 
suitable semi-automated technique in studies where accurate quantification of 
acute MI size is important (e.g. randomised controlled trials assessing the 
effectiveness of cardioprotective therapies on reducing acute and chronic MI 
size), as it performed as well as Manual contouring. Secondly, the performance 
of FWHM against Manual is influenced by the LGE sequence used and in 
studies requiring an accurate quantification of chronic MI size as an endpoint, 6-
SD would be preferred to FWHM given that the latter appeared to 
underestimate chronic MI size especially in patients who had MVO on the acute 
scan. Thirdly, for those clinical studies only requiring precise (good agreement 
but with some residual bias) MI size quantification, such as registries or 
prospective observational studies, and for those aiming to assess other 
surrogate markers such as LVEF or adverse LV remodelling, any of these 4 
semi-automatic techniques may be acceptable for quantifying MI size.  
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The reason for FWHM underestimating chronic MI size was due to the 
very high signal intensities on the follow-up scans in the location previously 
occupied by MVO on the acute scan. The likely explanation is that resorption of 
the MVO results in a relatively large interstitial space. These spaces are filled 
with contrast at a higher concentration than the surrounding scar tissues and 
displayed higher signal intensity than those without previous MVO as shown by 
the ECV maps. The “ECV” of the MVO on the acute scan was low but this was 
a reflection of the inability of LGE to penetrate areas of MVO and failure to 
achieve pseudo-equilibrium rather than a true MVO ECV value. As the FWHM 
uses the signal intensities that are above 50% of the maximal signal intensity 
within the scar, some of the scar tissue with “intermediate” signal intensities 
may have been classified as having signal intensities within “normal” range in 
these patients, resulting in an underestimation of chronic MI size.  
Several studies have investigated the optimal technique for MI size 
quantification and these are summarised in Table 9-1. Manual contouring is 
considered the reference standard (57, 176) and in experienced hands, has 
been shown to have the lowest variability.(176) However, the manual 
delineation of MI size can be time consuming.(183, 184) A semi-automated 
technique is highly desirable as this would improve workflow considerably and 
would be more objective. Although FWHM has consistently been shown to be 
more reproducible (176, 180, 182, 183), other studies have shown FWHM to 
underestimate acute and chronic MI size.(180) (185) Recently FWHM45% (185) 
instead was found to be similar to Manual in chronic MI. However, not all 
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specialist software for MI size quantification allows the adjustment of the signal 
intensity threshold for the FWHM technique.  
 
We showed that in patients with MVO on the acute scan, FWHM 
underestimates chronic MI size on the follow-up scan at 5 months and provided 
some mechanistic insights using automated ECV maps. Beek et al (178) 
previously showed that 6-SD had the highest accuracy to predict segment wall 
recovery in a cohort of chronic MI patients with hibernating myocardium. Flett et 
al (182) showed no difference between Manual contouring and 6-SD in both 
their acute and chronic MI cohorts and Dash et al (280) in a conference abstract 
showed that 6-SD was the most accurate to quantify MI size in a porcine model 
when compared to histology. Most recently, Zhang et al (185) have also shown 
that 6SD was similar to Manual contouring for both acute and follow-up MI size 
at 3T. However they did not compare Otsu in their study and they did not 
investigate the impact of MVO. We assessed the performance of the 4 most 
promising semi-automated techniques against Manual in paired acute and 
follow-up scans and our findings of the 6-SD technique being the most robust is 
consistent with some of the previous studies.(178, 182, 185, 280) McAlindon et 
al (176) recently showed that Manual contouring provided the lowest inter-
observer, intra-observer and inter-scan variability, but they did not assess 6-SD 
in their study. Of note, our intra-observer reproducibility for Manual contouring 
was similar to their study. However, Khan et al (183) recently showed 6-SD to 
be higher than Manual contouring in acute MI size quantification, but they only 
included 10 patients and the remote myocardial ROI was manually drawn. We 
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used the automatic option for ROI delineation with minimal user input when 
required and we showed that the reproducibility of the n-SD technique is 
improved when using this approach. 
 
6.4.1 Limitations 
We only compared 4 semi-automated techniques against Manual 
contouring but we specifically chose those techniques with the most promising 
results so far and that are widely available in most commercial software for MI 
size quantification. The automated method previously shown to be very 
promising and accounts for partial volume effect by Heiberg et al (281) is only 
available from one CMR analysis software and we were not able to include it in 
this study using CVI42. We did not perform intra-observer and inter-observer 
variability for all techniques as this has already been performed in several 
previous studies (176, 180, 182, 183, 185) and was not the main focus of our 
study. We used Manual contouring as the reference standard (176) given that 
histological validation was not possible in this study. We were underpowered to 
assess the performance of these different semi-automated techniques on 
clinical outcomes and this warrants further evaluation in larger studies. Despite 
using automated threshold techniques, user input was required if the automated 
reference ROIs in the remote myocardium were extending to the salvaged 
myocardium; when pixels with high signal intensity in the remote myocardium 
were enhanced due to artefact; or when the Otsu method were picking 
abnormalities in slices with no LGE. These user inputs would likely introduce 
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some intra-observer and inter-observer variability but would not affect the 
overall results in experienced hands. 
 
6.5 Conclusions 
The optimal semi-automated technique for the quantification of MI size 
depends on the research question. For randomised controlled trials requiring 
the accurate assessment of MI size, 6-SD would be preferred. However, for 
registries or observational studies where precise MI size quantification may be 
adequate, any one of the four techniques may be an acceptable semi-
automated option.  
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7 Multi-parametric mapping CMR to provide insights 
into the pathophysiology of adverse LV remodelling 
post-reperfused STEMI 
7.1 Introduction 
Although improvements in evidence-based therapies during PPCI have 
substantially reduced mortality following an acute STEMI, the onset of heart 
failure is on the rise.(3, 4, 282) MVO occurs in up to 50% of reperfused STEMI 
patients (61), and approximately 40% of STEMI patients develop IMH (139) 
detected by CMR. Both MVO and IMH are associated with larger MI size, 
adverse LV remodelling and worse clinical outcomes.(60, 61, 149, 159, 161, 
283, 284) 
IMH and its iron degradation products have been shown to result in 
residual myocardial iron within the MI zone and have been proposed to have 
cytotoxic and pro-inflammatory effects on the myocardium(207) (208). In some 
STEMI patients, T2 values in the surrounding myocardium have been shown to 
be elevated on CMR performed 6 months post-PPCI.(91, 209) The aetiology of 
the persistently elevated T2 signal and its relationship to adverse LV 
remodelling remains to be determined.  
Whether changes in the ECM in the non-infarcted remote myocardium in 
STEMI patients reperfused by primary PPCI is linked to adverse LV remodelling 
remains incompletely understood.(197, 210-213) Although native T1 mapping 
(197) and post-contrast T1 mapping (213) CMR have been used to interrogate 
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the remote myocardial ECM, the availability of automated ECV mapping CMR 
provides a more robust method for quantifying not only focal fibrosis but also 
diffuse interstitial expansion in the myocardium (216, 217) as the native and 
post-contrast T1 maps are co-registered and motion-corrected, thereby 
improving the quality of the generated automated maps.(218)  
We aimed to use multi-parametric mapping CMR to provide further 
insights into the pathophysiology of adverse LV remodelling in reperfused 
STEMI patients in order to identify potential future therapeutic targets. We 
hypothesized that patients with adverse LV remodelling were more likely (a) to 
have MVO/IMH on the acute scan; (b) to have residual iron at follow-up; (c) to 
have persistently high T2 around areas of residual iron that may suggest 
delayed infarct healing due to ongoing inflammation; (d) and have higher ECV 
in the remote myocardium due to remote compensatory changes. 
 
7.2 Methods 
7.2.1 Study Population 
40 STEMI patients reperfused by PPCI from the 1.5T cohort with paired 
acute and follow-up CMR scans described in the methodology section were 
included in the analysis for this chapter.  
20 age and sex-matched healthy volunteers served as control (all free of 
cardiovascular disease). All participants were scanned at the same centre and 
on the same scanner. 
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7.2.2 CMR acquisition 
CMR was performed on a 1.5 Tesla scanner (Magnetom Avanto, 
Siemens Medical Solutions) using a 32-channel phased-array cardiac coil as 
described in the methodology section.  
In the 1.5T STEMI cohort all patients had T2 maps acquired from base to 
apex during the acute scan. As for native T1 and post-contrast T1 maps, 30 
patients had full LV short axis coverage and the remaining 10 patients had 
three (basal, mid and apical) left ventricular short axis T1 maps acquired during 
both scans.  
The 20 healthy volunteers had one mid ventricular short axis native T1, 
T2 and post-contrast T1 maps acquired. All participants had full LV coverage for 
LV short axis cines and LGE acquired. 
Figure 7-1 shows an example of the basal short axis images acquire 
during the acute scan and at follow-up in a patient with an inferior STEMI. 
 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
171 
 
Figure 7-1: Multiparametric map acquisition. 
Basal left ventricular short axis of a patient with an acute 
inferior MI depicting MVO on LGE scans with corresponding hypo-
intense cores (red and white arrows) on the basal LV short axis T1, 
T2, T2* and ECV maps and the follow-up scan with corresponding 
maps and areas of residual myocardial iron on the T2* map. 
 
7.2.3 CMR analysis 
Imaging analysis was performed using CVI42 software (Version 5.2.2[340], 
Calgary, Canada) as described in the methods section.  
7.2.3.1 LGE and AAR quantification 
MI size was quantified as a percentage of the LV (%LV) using signal 
intensity threshold of 5-SD (57) above the mean remote myocardium. The 
presence of MVO (late MVO) was defined as areas of hypo-enhancement on 
the LGE images, and was quantified and expressed as %LV. Areas of MVO 
were included as part of the MI zone and AAR.   
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Once the above method was used to highlight the LGE area, the anterior 
and inferior RV insertion points were identified and using a dedicated tool on 
CVI42, the transmural extent of LGE was obtained quantitatively (by averaging 
the values from 100 chords from each slice, which was done automatically) to 
obtain the mean transmural extent of LGE for each of the 16 AHA segments 
(Figure 7-2). 
Adverse LV remodelling was defined as a ≥20% increase in LV end-
diastolic volume (LVEDV) between the acute and follow-up scans.(193, 194, 
197) 
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Figure 7-2: Example of generated bull’s eye plots with 
AHA segments from the maps and LGE images. 
 
7.2.3.2 Analysis of IMH and residual iron  
A hypo-intense core on the T2* maps with a T2* value of <20ms was 
used to identify the presence of IMH on the acute scans and “residual 
myocardial iron” on the follow-up scans.(150, 153, 156, 285, 286)  The extent of 
IMH and residual iron was quantified using manual ROI delineation around the 
hypo-intense core on the basal, mid and apical slices and expressed as %LV. 
For the follow-up T1 and T2 maps, a ROI was manual drawn in hyper-
enhanced areas using a signal intensity threshold of 2SD from the remote 
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myocardium (using the LGE images as reference) and was denoted as T1Infarct 
and T2Infarct respectively.  
A second ROI was copied from the hypo-intense core of the T2* map on 
to the T1 and T2 maps and denoted as T1Core and T2Core as illustrated in Figure 
7-3. 
In cases when there were no areas of hyper-enhancement on the follow-
up maps using a 2SD threshold, a ROI from the areas of LGE was copied on to 
the maps for representative values. An ROI was also drawn in the remote 
myocardium and expressed as T1Remote and T2Remote.  
 
 
Figure 7-3: Quantification of follow-up T2 maps. 
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Method used to detect the area of high T2 (T2Infarct) around 
the area of residual myocardial iron (T2Core) and the remote 
myocardium (T2Remote) using a threshold of 2SD from the remote 
myocardium. 
 
7.2.3.3 Analysis of the T1, T2 and ECV maps 
The endocardial and epicardial borders were manually delineated on the 
native T1 maps and T2 maps and copied on the ECV maps. The left ventricular 
outflow track and apical LV short axis slices were excluded and a 10% erosion 
of the wall thickness was applied to the endocardial and epicardial borders to 
minimise partial volume effects. Mean segmental T1, T2 and ECV values were 
then generated and displayed as a Bull’s eye plots using the 16 AHA segments 
(Figure 7-2). For assessing inter-method agreement, in 10 patients, manual ROI 
were also drawn with care to avoid partial volume effects in the remote 
myocardium and the infarcted segments for comparison with mean segmental 
values for ECV. The remote myocardium was defined as the AHA segment 
180o from the infarct territory with normal wall motion and no LGE. T1, T2 and 
ECV values in the remote myocardium were represented by T1Remote, T2Remote 
and ECVRemote. T1 values of the core (T1Core) of the infarct were obtained by 
manually drawing the ROI within the hypo-enhanced regions inside areas of 
hyper-enhancement within 2SD of the remote myocardium on the T1 maps and 
were represented as T1Core. Mean segmental ECV of the infarcted segments 
was represented as ECVInfarct.  
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7.2.4 Statistical analysis 
Statistical analysis was performed using SPSS Version 22 (IBM 
Corporation, Illinois, US). Continuous data was expressed as mean ± SD or 
median [interquartile range] and categorical data was reported as frequencies 
and percentages. Normality was assessed using Shapiro-Wilk test. 
Independent groups (those with and without IMH; with and without paired CMR 
scan; with and without residual iron at follow-up; with and without adverse LV 
remodelling; without adverse LV remodelling but with and without residual iron) 
were compared with unpaired Student t-test for normally distributed parameters 
and with Mann Whitney U test for non-normally distributed parameters. 
Comparison between paired acute and follow-up scans were performed using 
paired Student t-test for normally distributed parameters and Wilcoxon signed 
rank test for non-normally distributed parameters. To compare T1 and T2 
values in the remote, core and infarct territories between patients and divided 
between those with and without residual iron, a linear mixed model was used 
with the patients as a random factor and the territory within patients (remote, 
core, infarct) being a fixed factor. Comparison of 3 independent groups (no 
residual iron, residual iron only, residual iron and adverse LV remodelling) was 
performed using Kruskal-Wallis test and post hoc pairwise comparisons. 
Categorically variables such as incidence of MVO or IMH were compared using 
Chi square test or Fisher’s exact test. Pearson rho correlation coefficient was 
assessed between MVO, acute MI size, IMH and adverse LV remodelling as a 
continuous variable respectively and their correlations were compared. ROC 
curve was also used to compare the diagnostic performance of MVO, acute MI 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
177 
size and IMH to predict adverse LV remodelling. All statistical tests were two-
tailed, and P <0.05 was considered statistically significant.  
 
7.3 Results 
The 40 patients with paired acute and follow-up CMR from the 1.5T 
cohort were used for this chapter and their characteristics are listed in Table 
7-1. CMR details of these 40 patients are shown in Table 7-2. The median 
chest pain onset to PPCI time was 267 (122-330) minutes. The MI size was 
27.4±14.6%LV. MVO was present in 65% (26/40) of patients (mean MVO size 
among those with MVO was 13.6±7.2%LV).  In 24% of the patients, the paired 
T2* maps (acute and follow-up) had to be excluded as they were not 
interpretable due to motion and off-resonance artefacts. 
 
Table 7-1: Clinical characteristics of STEMI patients. 
Details Number 
Number of patients 40 
Male (%) 35 (88%) 
Age (age) 59 ±13 
Diabetes Mellitus 8 (20%) 
Hypertension 14 (35%) 
Smoking 12 (30%) 
Dyslipidaemia 14 (35%) 
Chest pain onset to PPCI time 267 (122-330) 
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LAD: left anterior descending artery; RCA: right coronary artery; 
Cx: circumflex artery; TIMI: thrombolysis in myocardial infarction; 
ACEI/ARB: angiotensin converting enzyme inhibitor/ angiotensin receptor 
blocker; MRA: mineralocorticoid receptor antagonist. 
 
Table 7-2: CMR characteristics of STEMI patients 
 Controls 
(n=20) 
Acute Scan 
(n=40) 
Follow-up Scan 
(n=40) 
P value 
EDV/ml 148±34 172±38 182±49 0.027 
ESV/ml 55±16 90±30 88±38 0.60 
EF/% 63±5 49±8 53±10 0.001 
LV Mass/g 108±21 112±35 104±26 0.051 
LV wall thickness in remote 
myocardium – diastole/mm 
7.2±0.7 7.1±1.3 6.7±1.3 NS 
LV wall thickness in remote 
myocardium – systole/mm 
12.0±1.3 12.0±1.8 11.2±1.8 NS 
LV wall thickening in remote 
myocardium / % 
66±14 77±40 75±26 NS 
LV wall motion in remote 
myocardium/mm 
7.7±2.5 9.2±2.6 8.9±2.6 0.04† 
0.10* 
(minutes) 
Infarct artery (%) 
LAD 
RCA 
Cx 
 
24 (60%) 
14 (35%) 
2 (5%) 
Treatment – on discharge 
Dual antiplatelet therapy 
Beta blockers 
ACEI/ARB 
Statin 
MRA 
 
40 (100%) 
40 (100%) 
40 (100%) 
39 (98%) 
10 (25%) 
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Infarct size/ % of LV NA 27.4±14.6 19.5±10.5 0.0001 
Infarct size/ g NA 20.2±13.6 14.4±9.4 0.0001 
AAR/ % of LV NA 42.0±12% - NA 
MVO/ n (%) NA 26 (65) - NA 
MVO (n=26)/ %LV NA 5.1±3.5  NA 
IMH (n=15)/%LV NA 14.0 (6.0-21.2) - NA 
Residual iron (n=13)/ %LV NA - 9.0 (4.0-10.3) NA 
T2Remote/ ms 
T2*<20ms (n=15) 
T2*≥20ms (n=13) 
50±4  
51 (48-53)  
49 (48-51) 
 
49 (46-51) 
47 (45-48) 
 
0.056 
0.060 
T2Infarct/ ms 
T2*<20ms (n=15) 
T2*≥20ms (n=13) 
NA  
64 (62-68) 
64 (62-69) 
 
60 (58-64) 
53 (51-55) 
 
0.017 
0.001 
T2Core/ ms 
T2*<20ms (n=15) 
T2*≥20ms (n=13) 
NA  
50 (46-53) 
55 (52-59) 
 
47 (45-50) 
47 (45-49) 
 
0.111 
0.001 
T1Remote/ ms 
T2*<20ms (n=15) 
T2*≥20ms (n=13) 
1000±25 
 
 
1051 (1023-1094) 
990 (968-1018) 
 
1015 (989-1020) 
1007 (966-1039) 
 
0.002 
0.74 
T1Infarct/ ms 
T2*<20ms (n=15) 
T2*≥20ms (n=13) 
NA  
1232 (1163-1338) 
1262 (1198-1286) 
 
1162 (1132-1216) 
1113 (1092-1140) 
 
0.014 
0.001 
T1Core/ ms 
T2*<20ms (n=15) 
T2*≥20ms (n=13) 
NA  
1016 (949-1061) 
1140 (1086-1160) 
 
1004 (990-1028) 
1042 (1015-1140) 
 
0.78 
0.11 
T2*Remote (n=28) NA 32 (30-35) 34 (31-35) 0.52 
T2*Infarct (n=13) NA 29 (24-36) 33 (28-35) 0.80 
T2*Core (n=15) NA 10 (11-13) 15 (13-17) 0.013 
ECVRemote/ %  
Whole cohort (n=40) 
 
 
26.4±2.1 
 
 
27.9±2.1 
 
 
27.0±2.1 
 
 
0.01† 
0.30* 
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With adverse LV      
remodelling (n=8) 
Without adverse LV 
remodelling (n=32) 
NA 
 
NA 
29.5±1.4 
 
27.4±2.0 
28.6±1.5 
 
26.6±2.1 
0.27 
 
0.02 
ECVInfarct/ % NA 69.2±9.6 70.4±19.9 0.71 
EDV: end diastolic volume; ESV: end systolic volume; EF: ejection fraction; LV: 
left ventricle; AAR: area-at-risk; MVO: microvascular obstruction; IMH: intramyocardial 
haemorrhage; NA: not applicable. 
† control versus acute scan; * control versus follow-up scan; NS: not statistically 
significant. 
 
 
7.3.1 IMH and oedema-based AAR 
Patients with IMH had lower T2Core (50[46-53] ms versus 55[52-49] ms, 
P=0.001) but similar T2Infarct (64[62-64] ms versus 64[62-69] ms, P=0.29) and 
T2 in the salvaged myocardium (65[61-68] ms versus 63[62-67] ms, P=0.43). 
However, in patients with IMH, oedema-based AAR was larger (46[40-55] %LV 
versus 31[24-43] %LV, P=0.009) and myocardial salvage index was smaller 
(0.24[0.16-0.43] versus 0.61[0.36-0.88], P=0.009), when compared to those 
without IMH. 
 
7.3.2 Residual myocardial iron on the follow-up scan in a subset of 
patients 
A subset of 28 patients who completed the follow-up scans had matching 
and interpretable T2* maps. There was no difference in the CMR parameters 
between those with paired T2* maps (n=28) and those without (n=12) (see 
Table 7-3). On the acute scan, 15/28 (54%) patients had IMH and 18/28 (64%) 
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had MVO.  15/18 (83%) patients had MVO with IMH. On the follow-up scan, 
13/15 (87%) patients had evidence of residual myocardial iron.  
Table 7-3: CMR characteristics patients with and 
without paired T2* maps. 
 Patients 
with paired 
T2* maps 
(n=28) 
Patients 
without 
paired T2* 
maps (n=12) 
P value 
EDV/ml 173±40 170±31 0.79 
ESV/ml 91±32 87±24 0.71 
EF/% 48±9 50±7 0.58 
Mass/ g 119±33 104±24 0.15 
Change in EDV/ ml 7±16 3±13 0.44 
Acute infarct size/ %LV 26.7±15.2 28.8±13.6 0.69 
Chronic Infarct size/ %LV 18.5±11.1 22.0±9.8 0.36 
AAR/ % of LV 42.7±12.3 40.3±11.8 0.56 
MVO/ n (%) 18 (64) 8 (67%) 0.59 
Adverse LV remodelling/ n (%) 6 (21%) 2 (17%) 0.55 
Acute scan 
T2 remote  
T2 core 
T2 infarct 
 
50 (48-52) 
52 (48-55) 
64 (62-68) 
 
50 (48-52) 
51 (48-54) 
65 (64-66) 
 
0.85 
0.96 
0.80 
Follow-up scan 
T2 remote  
T2 core 
T2 infarct 
 
48 (46-50) 
47 (45-49) 
57 (53-61) 
 
47 (45-49) 
47 (46-48) 
54 (52-57) 
 
0.63 
0.90 
0.25 
EDV: end diastolic volume; ESV: end systolic volume; EF: ejection fraction; LV: 
left ventricle; AAR: area-at-risk; MVO: microvascular obstruction. 
 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
182 
7.3.3 T1 and T2 of the core, infarct zone and remote myocardium at 
follow-up 
Using a linear mixed model to adjust for within patient interaction, in 
patients without residual myocardial iron, there was no difference between 
T1Core and T1Infarct (1042 [1015 – 1140] ms versus 1113 [1092 – 1140] ms, 
P=0.20) and T1Infarct was significantly higher than T1Remote (1113 [1092 – 1140] 
ms versus 1007 [966 – 1039] ms, P<0.001). However, T2Core was lower than 
T2Infarct (47 [45 – 49] ms versus 53 [51 – 55] ms, P=0.001) and similar to 
T2Remote (47 [45 – 49] ms versus 47 [45 – 48] ms, P=1.0) and T2Infarct was 
significantly higher than T2Remote (53 [51 – 55] ms versus 47 [45 – 48] ms, 
P<0.001) (Figure 7-4). 
In patients with residual myocardial iron, both T1Core and T2Core were 
similar to T1Remote and T2Remote (T1: 1004 [90 – 1028] ms versus 1015 [989 – 
1020] ms, P=1.0; T2: 47 [45 – 50] ms versus 49 [46 – 51] ms, P=1.0) but 
significantly lower than T1Infarct and T2Infarct (T1: 1004 [90 – 1028] ms versus 
1162 [1132 – 1216] ms, P<0.001; T2: 47 [45 – 50] ms versus 60 [58 – 64] ms, 
P<0.001) respectively (Figure 7-4). 
Patients with residual myocardial iron had lower T1Core, similar T2Core and 
higher T1Infarct and T2Infarct when compared to patients without. There was no 
difference in the T1Remote and T2Remote between these two groups as illustrated 
in Figure 7-4.  
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Figure 7-4: Box-plots of T1 and T2 values of the core, 
infarct and remote myocardium in patients with and 
without residual myocardial iron. 
 
Figure 7-5 shows an example of 3 patients with acute and follow-up CMR 
images showing MVO, IMH, residual myocardial iron and persistently elevated 
T2 in the surrounding myocardium within the infarct zone at follow-up. 
 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
184 
 
Figure 7-5: Acute and follow-up T2* maps. 
Examples of 3 patients (A, B and C) with acute and follow-up 
scans and the red arrows showing areas of MVO, IMH and residual 
myocardial iron and the black arrows showing areas of hyper-
enhancement on the T2 maps. 
 
7.3.4 IMH and adverse LV remodelling  
Eight out of forty (20%) patients developed adverse LV remodelling. 
Patients with adverse LV remodelling had larger MI size (30.1±7.3%LV versus 
16.9±9.8%LV, P=0.01), had an increased incidence (100% versus 50% P=0.10) 
and extent of MVO (8.0±3.2%LV versus 3.6±2.6%LV; P=0.001), and were more 
likely to have IMH (100% versus 60%, P=0.04) on the acute scans when 
compared to those without adverse LV remodelling.  
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7.3.5 Residual myocardial iron and adverse LV remodelling 
In patients with adverse LV remodelling, T2Infarct was significant higher 
than those without adverse LV remodelling and without residual myocardial iron 
(60 [54 – 64] ms versus 53 [51 – 56] ms, P=0.025), but similar to those with 
residual myocardial iron but no adverse LV remodelling (60 [54 – 64] ms versus 
60 [58 – 63] ms, P=1.0) as shown in Figure 7-6a.  
However, when looking at those patients that did not develop adverse LV 
remodelling, those with residual iron had a significantly higher change in EDV (8 
[-2 – 14] % versus -4 [-7 – 5] %, P=0.043), when compared to those patients 
without residual myocardial iron (Figure 7-6b).  
 
 
Figure 7-6: (a) T2 values in the infarct zone in patients 
with and without residual myocardial iron; (b) Change in EDV in 
patients with and without residual myocardial iron. 
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7.3.6 Relationship between acute MI size, MVO and IMH and adverse LV 
remodelling 
Acute MI size, extent of MVO and IMH correlated with the change in LV 
end diastolic volume (Pearson’s rho of 0.64, 0.59, and 0.66 respectively, P 
values of 0.18 and 0.62 respectively for correlation coefficient comparison), and 
performed equally well on ROC curve for predicting adverse LV remodelling 
(area under the curve: 0.99, 0.94, and 0.95 respectively, P=0.19 for ROC curve 
comparison). 
 
7.3.7 Intra-observer and inter-observer variability for ECV measurements 
There was less intra-observer and inter-observer variability when 
ECVRemote and ECVInfarct were assessed by mean segmental analysis when 
compared to manual ROI (Table 7-4). For intra-observer measurements, the 
limits of agreement for ECVRemote were ±1.22% when using mean segmental 
values compared to ±1.59% when using manual ROI. For inter-observer 
measurements, the limits of agreement for ECVRemote were ±0.99% when using 
mean segmental values compared to ±1.40% when using manual ROI. The 
limits of agreement for the two techniques were even wider for ECVInfarct (Table 
7-4). 
 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
187 
Table 7-4: Intra-observer and inter-observer 
variability for ECV using 2 different techniques (mean 
segmental values and manual ROI, n=10).  
ECV: extracellular volume fraction; ROI: region of interest. 
 
Changes in the remote myocardial ECV 
For both the acute and follow-up scans, there were no differences in LV 
diastolic and systolic wall thickness and LV wall thickening in the remote 
myocardium between the STEMI patients and controls (Table 7-2). However, on 
the acute scan, LV wall motion in the remote myocardium was higher in the 
STEMI patients when compared to controls (9.2±2.6mm versus 7.7±2.5mm, 
 Intra-class correlation 
coefficient  (95% CI) 
Bias ± limits of 
agreement (%) 
Intra-observer variability (n = 10) 
ECVRemote 
Mean segmental values 
Manual ROI 
 
0.994 (0.976-0.998) 
0.981 (0.922-0.995) 
 
0.11 ± 1.22 
0.42 ± 1.59 
ECVInfarct 
Mean segmental values 
Manual ROI 
 
0.992 (0.967-0.998) 
0.972 (0.886-0.993) 
 
0.53 ± 2.44 
0.13 ± 5.02 
Inter-observer variability (n = 10) 
ECVRemote 
Mean segmental values 
Manual ROI 
 
0.996 (0.984-0.999) 
0.989 (0.958-0.997) 
 
0.10 ± 0.99 
0.18 ± 1.40 
ECVInfarct 
Mean segmental values 
Manual ROI 
 
0.991 (0.949-0.998) 
0.963 (0.850-0.991) 
 
0.81 ± 2.21 
0.10 ± 5.96 
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P=0.04) but there was no statistically significant difference between them on the 
follow-up scan (8.9±2.6 mm versus 7.7±2.5mm, P=0.10). 
There were no significant differences in the T2Remote values between the 
STEMI patients and controls on either the acute scan or the follow-up scans. 
Native T1Remote and ECVRemote were both significantly higher in the STEMI 
patients when compared to controls on the acute scan (T1: 1032±51ms versus 
1000±25ms, P=0.001; ECV: 27.9±2.1% versus 26.4±2.1%, P=0.01), but this 
difference was not present on the follow-up scan (T1: 1004±39ms versus 
1000±25ms, P=0.66; ECV: 27.0±2.1% versus 26.4±2.1%, P=0.30) (Table 7-2).  
  
7.3.8 LV remodelling and remote myocardial ECV 
Out of 40 STEMI patients who had a follow-up scan, 8 (20%) patients 
had adverse LV remodelling. In these 8 patients, the ECVRemote was higher 
acutely when compared to those 32 patients without adverse LV remodelling 
(29.5±1.4% vs. 27.4±2.0%; P=0.01) and this difference in ECVremote persisted 
on the follow-up scan (28.6±1.5% vs. 26.6±2.1%; P=0.02). There were no 
significant differences in T2Remote between those with and without adverse LV 
remodelling both on the acute and follow-up scans (Figure 7-7).  
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Figure 7-7: T2 and ECV of the remote myocardium in 
STEMI patients with (n=8) and without LV remodelling (n=32). 
 
7.3.9 Multi-parametric CMR prediction of remodelling 
Percentage increase in LVEDV as a continuous variable was used as a 
surrogate for adverse LV remodelling for univariable and multivariable linear 
regression analysis. MI size quantified by LGE (R2 0.36, coefficient 0.64, 95% 
CI 0.37-0.9, P=0.0001) was the single most significant predictor of adverse LV 
remodelling after adjusting for T1Remote, MVO and LVEDV on the acute scan in a 
multivariable analysis. In order to account for both MI size and AAR, MSI was 
used in the regression model instead of MI size. T1Remote and ECVRemote, T1Core, 
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MSI and MVO on the acute scan were significantly associated with adverse LV 
remodelling on univariable analysis and these were then included in a 
multivariable analysis. MSI and then ECVRemote were most associated with 
adverse LV remodelling after adjusting for T1Remote, T1Core and MVO on the 
acute scan (Table 7-5 below). 
 
Table 7-5: Univariable and multivariable associates of LV 
remodelling (n=40). 
 Univariable analysis Multivariable analysis 
 Regression slope R
2
 P Regression slope P 
MSI -29 0.25 0.001 -25 0.008 
ECVRemote 3.5 0.24 0.001 2.6 0.03 
MVO/g 2.7 0.26 0.001  NS 
T1 remote 0.13 0.20 0.03  NS 
T1Core -0.06 0.14 0.001  NS 
NS: not statistically significant. 
 
7.4 Discussion 
Our study confirms that MVO is a strong precursor for the development 
of adverse LV remodelling. The majority of patients with MVO also had IMH 
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(83%). A large proportion of those with IMH had residual iron at follow-up 
(87%). Those with residual iron had higher T2 in the surrounding infarct areas 
suggestive of delayed resolution of oedema in these patients. All patients with 
adverse LV remodelling had residual iron and higher T2 in the surrounding 
infarct areas. Furthermore, those with residual iron but not meeting the 
definition for adverse LV remodelling had larger percentage increase in LVEDV 
than those without residual iron. Although T1 values were also higher in the MI 
zone surrounding areas of residual iron compared to those without, this 
difference in T1 may have been due to the complex interplay between fibrosis, 
oedema and the development of early fatty metaplasia (287) in the 
convalescent phase of a STEMI. We also showed that ECVRemote in STEMI 
patients was acutely elevated and this elevation persisted in those who 
developed adverse remodelling at 5 months, suggesting that remote 
compensatory changes in the ECM occurred in this subset of patients. There 
was no difference in T2 values observed in the remote myocardium of the 
STEMI patients when compared to the controls suggesting that the increased 
ECVRemote on the acute scan was unlikely due to oedema in the remote 
myocardium. As expected, those with adverse LV remodelling had significantly 
more infarct regression predominantly due to MVO resorption as demonstrated 
by the very high ECV of 82±8% at follow-up in regions previously occupied by 
MVO. 
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7.4.1 IMH, residual iron and adverse LV remodelling 
It is recognised that IMH is associated with larger MI size, adverse LV 
remodelling and poor clinical outcomes (160, 161, 261) and residual iron may 
be a source of prolonged inflammation (207) and may be pro-arrhythmic.(206) 
Although our study was purely based on tissue characterisation, these findings 
add to the current literature that residual iron may play a role in the 
inflammatory phase of adverse LV remodelling. Using T2* imaging, Kali et al 
(207) have recently shown in a small cohort of 15 STEMI patients that the 
presence of IMH on the acute scans was associated with residual iron at 6 
months. They also used immuno-histochemical analysis of canine heart models 
of acute MI to show evidence of localized accumulation of macrophages at the 
sites of residual iron at follow-up suggesting a prolonged inflammatory response 
due to the residual iron.(207) Roghi et al (208) showed in a small cohort of 15 
STEMI patients that those with MVO and IMH had higher levels of non-
transferrin bound iron, which have previously been linked with cardiotoxicity in 
thalassemia major patients with iron overload. Although oedema has been 
shown to be present in some patients up to 6 months post reperfused STEMI, 
we have showed that the delayed resolution of oedema by T2 mapping was 
associated with residual iron due to IMH. 
 
7.4.2 Remote myocardial ECV and adverse LV remodelling 
In a murine model of acute MI, Tsuda et al (211) found molecular and 
immuno-histochemical evidence of interstitial fibrosis in the remote myocardium 
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as early as 72 hours post MI. Volders et al (210) provided post-mortem 
histological evidence of an increase in interstitial collagen in the remote 
myocardium of infarcted patients when compared to control. However, 
Marijianowski et al (212) showed that post-MI LV remodelling in patients with 
end-stage heart failure undergoing transplant was not associated with interstitial 
fibrosis in the remote myocardium. From the tissue characterization point of 
view, Chan et al (213) used post-contrast T1 in 25 acute STEMI patients and 
found evidence of early remote expansion of the ECM, which persisted in the 
chronic stage. Carrick et al (197) demonstrated that increased native T1 values 
in remote myocardium of reperfused STEMI patients were independently 
associated with adverse LV remodelling. We interrogated the remote 
myocardium using automated ECV maps and we have demonstrated that only 
in a subset of patients who developed adverse LV remodelling had increased 
ECVRemote as early as 4 days and persisted at 5 months. The cause of this 
expansion in ECVRemote acutely could due to increase in the intravascular 
compartment due to compensatory hyperaemia in the remote myocardium and 
at follow-up, there is compensation in the remote myocardium to maintain 
cardiac output and a subset of patients develop remote myocardial LV 
remodelling with left ventricular hypertrophy and increased interstitial fibrosis. 
Interestingly, Carberry et al (288) recently showed that change in ECV in 
remote myocardium, calculated from native and post contrast MOLLI T1 maps 
in 140 patients, was a multivariate associate of LV remodelling. However, due 
to lack of power, ECVRemote was not associated with all-cause death and heart 
failure. 
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7.4.3 Limitations 
A significant proportion of the T2* maps were not interpretable in our 
study and this partly highlights the challenge of performing a comprehensive 
CMR scan with multi-parametric mapping in patients with an acute STEMI. Of 
note, 18% of T2* data were not available in the large study by Carrick et al 
(139) either due to patient’s intolerance of the scan or T2* maps being not 
evaluable. We did not measure blood inflammation markers to support the 
notion of persistent inflammation due to residual iron in these patients. 
Histological validation to elucidate whether persistently elevated T2 may be due 
to inflammation around the areas of residual iron was beyond the scope of this 
work and needs to be confirmed in future animal studies of IMH and MVO. We 
only included a relatively small number of patients and therefore we were 
underpowered to determine the interplay between T1Remote (197), T1Core (156), 
IMH (139) and ECVRemote on major adverse cardiovascular events. Furthermore, 
the Fragility Index (described in section 3.5 on Sample size) of this analysis was 
low due to the small number of patients and we only showed an association 
rather than causality. These findings need to be confirmed in future adequately 
powered studies.  
 
7.5 Conclusion 
The majority of patients with IMH had residual iron at follow-up, which 
was associated with adverse LV remodelling. Adverse LV remodelling itself was 
associated with delayed resolution of oedema in the MI zone that may be 
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suggestive of ongoing inflammation. These patients also displayed expansion of 
the remote myocardial ECV as early as 4 days and persisted at 5 months. 
Therefore, patients with IMH or residual iron could be future potential targets for 
therapeutic interventions with anti-inflammatory agents or chelation therapy 
aiming to prevent adverse LV remodelling and improve clinical outcome in 
these patients (except in those with established heart failure where iron 
supplementation can improve outcomes (289)). 
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8 Redefining post-MI left ventricular remodelling by 
CMR 
8.1 Introduction 
Adverse LV remodelling following STEMI has been conventionally 
defined as ≥20% increase in LVEDV from baseline. This cut-off value was 
determined using echocardiography, and was based on the upper limit of the 
95% confidence interval of intra-observer variability for the %Δ in LVEDV 
following STEMI.(193, 194) Reverse LV remodelling has been defined as ≥10% 
decrease in LVESV by echocardiography following cardiac resynchronization 
therapy, and was derived using ROC curves for the optimal cut-off for the 
%ΔLVESV to predict mortality.(195) So far, no cut-off values for adverse and 
reverse LV remodelling following STEMI have been defined by CMR, and 
studies using CMR to assess post-STEMI LV remodelling have relied upon 
using these cut-off values defined by echocardiography for adverse (196, 197) 
and reverse LV remodelling.(198) 
Therefore, the first aim of this study was to perform intra-observer and 
inter-observer measurements of LV parameters in paired acute and follow-up 
CMR scans in reperfused STEMI patients, in order to determine the minimal 
detectable changes (MDCs) that could be used as cut-off values for defining 
post-STEMI remodelling.  
Secondly, we aimed to identify the cut-off values for clinically important 
%ΔLVEDV and %ΔLVESV to predict LVEF <50% at follow-up.(169)  
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Finally, cut-off values for %ΔLVEDV and %ΔLVESV would then be 
applied to a cohort of 146 STEMI patients with paired acute and follow-up scans 
to assess different patterns of post-STEMI LV remodelling. 
 
8.2 Methods 
Patients included in this study are those from cohorts 1 and 2 with paired 
acute and follow-up scans and from 2 published studies (117, 290) as 
summarised in Table 8-1. All patients provided informed consent at the time of 
recruitment and the studies were conducted according to the Declaration of 
Helsinki. Only patients with a paired acute CMR within the first week post PPCI 
and a follow-up CMR were included in this study. 
8.2.1 Cohort for inter-observer and intra-observer analysis 
Analysis was performed using CVI42 software (Version 5.2.2[340], Calgary, 
Canada). 15 STEMI patients reperfused by PPCI, with a minimum of 6 months 
between the acute and follow-up scan were randomly chosen from cohort 1 and 
were used for inter and intra-observer variability. Semi-automated contours 
were drawn on the short-axis cine images using the threshold segmentation 
option for the epicardial border and the automatic detection option for the 
endocardial border, with minimal manual adjustment when required. The 
LVEDV, LVESV, LV mass (LVM) and LVEF were quantified using 2 methods as 
shown in Figure 8-1. In method 1, we used rounded endocardial contours and 
excluded the trabeculae and papillary muscles (T&P) as part of the LVM and 
they were included as part of the LV volume.
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Table 8-1: CMR acquisition details of the 2 additional 
studies included together with Cohort 1 and 2. 
 Number of 
patients 
with paired 
CMR 
Aim Scanner and 
contrast 
MVO and MI 
size 
Outcome 
Ludman 
2011 
(290) 
29 patients, 
4 months 
apart  
(RCT) 
To assess 
benefit of 
erythropoiet
in during 
PPCI 
1.5T 
Siemens 
Dotarem 
0.2mmol/kg at 
10 minutes 
MVO: Hypo-
intense core on 
LGE images at 
10 minutes 
MI size: manual 
High dose of 
erythropoietin 
as an adjunct 
to PPCI failed 
to reduce MI 
size 
Crimi 
2013 
(117) 
65 patients, 
4 months 
apart  
(RCT) 
 
LAD only 
included 
To assess 
benefit of 
remote 
ischaemic 
post 
conditioning 
during PPCI 
1.5T 
Siemens 
Magnevist 
0.2mmol/kg at 
15 minutes 
Hypo-intense 
core on LGE 
images at 5 
minutes 
MI size: manual 
Remote 
ischaemic 
conditioning at 
the time of 
PPCI was 
associated 
with a 
reduction in 
enzymatic MI 
size but this 
study was 
underpowered 
for MI size by 
CMR 
 3T 
cohort 
12 patients, 
1 year apart 
(cohort 
study) 
 3T 
Siemens 
Dotarem 
0.1mmol/kg at 
10-15 minutes 
Hypo-intense 
core on LGE 
images at 10-15 
minutes 
MI size: Otsu 
 
1.5T 
cohort 
 
40 patients, 
5 months 
apart 
(cohort 
study) 
 
 1.5T 
Siemens 
Dotarem 
0.1mmol/kg at 
10-15 minutes 
Hypo-intense 
core on LGE 
images at 10-15 
minutes 
MI size: 5-SD 
 
RCT: randomised controlled trial; LGE: late gadolinium enhancement; MVO: 
microvascular obstruction; MI: myocardial infarction; PPCI: primary percutaneous coronary 
intervention; PET/MR: positron emission tomography/ magnetic resonance; SD: standard 
deviation. 
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In method 2, the T&P were included as part of the LVM and were 
excluded from the LV volume. The basal cine slice was included if at least 50% 
of the cavity circumference was surrounded by ventricular myocardium and this 
principle was used for both end-systole and end-diastole. %ΔLVEDV, 
%ΔLVESV, %ΔLVM and %ΔLVEF were calculated as the difference between 
the follow-up parameters and the corresponding baseline parameters and 
expressed as a percentage of the baseline parameters. All 15 acute and 
matching follow-up scans were analysed by 2 experienced CMR operators 
(twice by HB, 3 years’ experience in CMR, 2 months apart and blinded to 
previous results, and once by YYG, 1 and a half years’ experience in CMR).  
 
Figure 8-1: Quantification of LV parameters with T&P 
part of LV volume (method 1) and part of LV mass (method 2). 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
200 
8.2.2 Cohort for LV remodelling 
Patient level data were obtained from the 2 previous randomised 
controlled trials (117, 290) and from the 3T and 1.5T cohorts described in the 
methodology section as listed in Table 8-1. Only patients with paired acute and 
follow-up CMR scans were included. The LV parameters reported by the 
original studies were used for analysis. All cines were acquired using steady-
state free precession based cines as previously described in their respective 
publications.(117, 290) The CMR details for the acute MI size and MVO 
detection by the 4 different cohorts of patients included are summarised in 
Table 8-1. 
 
8.2.3 Statistical analysis 
Statistical analysis was performed using SPSS Version 22 (IBM 
Corporation, Illinois, US). Normality was assessed using Shapiro-Wilk Test. 
Continuous data was expressed as mean ± standard deviation (SD) or median 
(interquartile range) and categorical data was reported as frequencies and 
percentages. Groups were compared using paired Student t test/ Wilcoxon 
signed rank test or unpaired Student t test/ Mann Whitney U test where 
appropriate. One-way analysis of variance was used to obtain the mean 
squared error for each LV parameter for inter and intra-observer measurements 
and their corresponding square root provided their standard error of the 
measurement (SEM). The 95% confidence interval (CI) for each SEM was 
calculated as previously described.(291) Coefficient of variation (CoV) was 
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expressed as the standard deviation of the difference divided by the mean and 
expressed as a percentage and Levene’s test for homogeneity of variance was 
used to compare CoV between the 2 methods used for LV parameters 
quantification (T&P being part of the LV mass or LV volume). Bland-Altman 
analysis was performed for inter and intra-observer measurements of the LV 
parameters for comparison. The MDCs with 95% confidence (MDC95) for intra 
and inter-observer measurements for %ΔLVEDV, %ΔLVESV, % LVM and 
%ΔLVEF was calculated as 1.96 x SEM x square root of 2. ROC curve analysis 
was performed to predict an LVEF of <50% at follow-up to identify clinically 
significant cut-off values for %ΔLVEDV and %ΔLVESV. All statistical tests were 
two-tailed, and P<0.05 was considered statistically significant.  
 
8.3 Results 
The median age of the 15 STEMI patients used for intra-observer and 
inter-observer measurements were 57 (44-62) years old and 12 (80%) were 
male. Details of the paired acute and follow-up CMR scans are shown in Table 
8-2. The acute CMR scan was performed at 2±1 days post-PPCI and the follow-
up CMR scan was performed at 7±1 months.  
Table 8-2: CMR characteristics of STEMI patients for 
intra-observer and inter-observer study. 
 Acute Scan 
(n=15) 
Follow-up Scan 
(n=15) 
P value 
T&P part of the LV volume 
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LVEDV/ml 156±38 171±51 0.05 
LVESV/ml 78±24 82±34 0.48 
LVM/g 107 (81-121) 87 (82-106) 0.07 
LVEF/% 50±7 53±9 0.15 
T&P part of the LV mass 
LVEDV/ ml 141±39 156±49 0.09 
LVESV/ ml 64±20 68±31 0.44 
LVM/g 118 (98-135) 99 (94-128) 0.25 
LVEF/% 54±7 58±10 0.07 
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-
systole volume; LVM: left ventricular mass; LVEF: left ventricular ejection fraction. 
 
8.3.1 Variability of LV parameters between the acute and follow-up CMR 
scans 
Table 8-3 summarises the SEM (95%CI), CoV and Bland-Altman 
analysis of the LV parameters divided into acute and follow-up scans and 
quantification method. Comparison of CoV did not show any statistical 
difference for inter-observer or intra-observer measurements (LVEDV, LVESV, 
LVM, LVEF) on both the acute or follow-up scans between both LV 
quantification methods (T&P included as part of the LV volume or LV mass) (P 
values between 0.26 to 0.93).   
The LVEDV and LVESV were significantly higher and the LVM and LVEF 
were significantly lower both on the acute and follow-up scans when the T&P 
were included as part of the LV volume as shown in Figure 8-2. When they 
were included as part of the LVM, they contributed the same extent to the LV 
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mass on the acute and the follow-up scans (13.5±5.0% and 14.5±5.7% 
respectively, P=0.53). 
 
 
Figure 8-2: Comparison of LV parameters on the acute 
and follow-up scans with T&P as part of LV volume or as part 
of LV mass 
 
8.3.2 Variability of %Δ in LV parameters 
Details on the intra-observer and inter-observer measurements for 
%ΔLVEDV, %ΔLVESV, %ΔLVM and %ΔLVEF, both for when T&P was 
included as part of either LV volume or LV mass, are provided in  
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Table 8-4. The MDC95 values for these LV parameters were different for 
inter-observer and intra-observer measurements, and whether the T&P were 
included as part of the LV volume or mass.  
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Table 8-3: Intra-observer and inter-observer variability for LV parameters. 
 Intra- observer Inter-observer 
 SEM  (95% CI) CoV Bias ± limits of agreement SEM (95% CI) CoV Bias ± limits of agreement 
T&P included as part of the LV volume 
LVEDV 
Acute (n=15) 
Chronic (n=15) 
 
2.0 (1.5 to 3.2) ml 
3.4 (2.5 to 5.3) ml 
 
1.3 % 
2.0 % 
 
-0.5±5.8 ml 
0±9.6 ml 
 
4.6  (3.4 to 7.3) ml 
6.5 (4.7 to 10.2) 
ml 
 
2.9 %  
3.8% 
 
-2.9±13.0 ml 
0.7±18.2 ml 
LVESV 
Acute (n=15) 
Chronic (n=15) 
 
1.8 (1.3 to 2.9) ml 
1.4 (1.1 to 2.3) ml 
 
2.3 % 
1.8 % 
 
-0.3±5.2 ml 
-0.5±4.2 ml 
 
3.6 (2.6 to 5.7) ml 
2.7 (2.0 to 4.3) ml 
 
4.7 % 
3.3 % 
 
1.7±10.2 ml 
1.0±8.0 ml 
LVM 
Acute (n=15) 
Chronic (n=15) 
 
2.2 (1.6 to 3.5) g 
2.7 (1.9 to 4.2) g 
 
2.2 % 
2.8 % 
 
0.5±6.2 g 
0.5±9.2 g 
 
4.2 (3.1 to 6.6) g 
3.3 (2.4 to 5.1) g 
 
4.1 % 
3.3 % 
 
-2.7±11.8 g 
-1.5±9.8 g 
LVEF 
Acute (n=15) 
Chronic (n=15) 
 
1.3 (1.0 to 2.1) % 
1.2 (0.9 to 1.9) % 
 
2.6 % 
2.3 % 
 
0.1±3.8 % 
0.1±4.8 % 
 
1.9 (1.4 to 3.0) % 
1.7 (1.2 to 2.6) %  
 
3.8 % 
3.2 % 
 
-1.4±5.4 % 
0.1±8.4 % 
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Table 8-3 continued: Intra-observer and inter-observer variability for LV parameters. 
 Intra- observer Inter-observer 
 SEM  (95% CI) CoV Bias ± limits of agreement SEM (95% CI) CoV Bias ± limits of agreement 
T&P included as part of the LV mass 
LVEDV 
Acute (n=15) 
Chronic (n=15) 
 
3.0 (2.2 to 4.8) ml 
3.3 (2.4 to 5.2) ml 
 
2.1 % 
2.1 % 
 
0.1±8.6 ml 
0.7±9.4 ml 
 
4.2 (3.1 to 6.7) ml 
4.1 (3.0 to 6.5) ml 
 
2.9 % 
2.7 % 
 
-2.7±12.0 ml 
1.6±11.6 ml 
LVESV 
Acute (n=15) 
Chronic (n=15) 
 
1.4 (1.0 to 2.1) ml 
1.5 (1.1 to 2.4) ml 
 
2.1 % 
2.3 % 
 
0.5±3.8 ml 
0.7±4.4 ml 
 
3.1 (2.2 to 4.8) ml 
3.2 (2.3 to 5.0) ml 
 
4.7 % 
4.6 % 
 
-1.2±8.6 ml 
-0.5±9.0 ml 
LVM 
Acute (n=15) 
Chronic (n=15) 
 
3.0 (2.2 to 4.8) g 
3.3 (2.4 to 5.2) g 
 
2.6 % 
2.9 % 
 
0±8.6 g 
-0.7±9.4 g 
 
3.6 (2.6 to 5.6) g 
4.4 (3.2 to 7.0) g 
 
3.0 % 
3.9 % 
 
-2.3±12.4 g 
-0.5±12.4 g 
LVEF 
Acute (n=15) 
Chronic (n=15) 
 
1.5 (1.1 to 2.4) % 
1.3 (1.0 to 2.1)% 
 
2.8 % 
2.3 % 
 
-0.7±4.4 % 
0.3±4.2 % 
 
2.2 (1.6 to 3.5) % 
2.1 (1.5 to 3.3) % 
 
4.1 % 
3.6 % 
 
-0.4±6.4 % 
1.1±6.4 % 
SEM: standard error of the measurement; CoV: coefficient of variation; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-
systole volume; LVM: left ventricular mass; LVEF: left ventricular ejection fraction. 
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Table 8-4: Intra-observer and inter-observer variability for %Δ in LVEDV, LVESV, LVM and LVEF. 
 Intra- observer Inter-observer 
 SEM (95%CI) Bias ± limits of 
agreement 
MDC95 SEM (95%CI) Bias ± limits of 
agreement 
MDC95 
T&P included as part of the LV volume 
%ΔLVEDV 
(n=15) 
2.4  (1.8 to 3.8) % 0.2±6.8 % 7%  3.5 (2.6 to 5.6) 
% 
1.7±8.2 % 10% 
%ΔLVESV 
(n=15) 
3.5 (2.6 to 5.6) % 0.5±10.0 % 10%  4.8 (3.3 to 7.1) 
% 
-0.5±12.0% 13% 
%ΔLVM 
(n=15) 
3.4 (2.5 to 5.3) % 0.2±9.6 % 9%  4.1 (3.0 to 6.5) 
% 
0.4±11.6 % 11%  
%ΔLVEF 
(n=15) 
4.0 (2.9 to 6.3) % 
[Absolute change 
2.3(1.7 to 3.6)%] 
0.8±11.4 % 11%  
(5.5% absolute 
change from 
an acute LVEF 
50%) 
4.8 (3.6 to 7.7) 
% 
[Absolute 
change 2.7(2.0 
to 4.3)%] 
2.2±12.8 % 13% 
(6.5% absolute 
change from 
an acute LVEF 
50%) 
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          Table 8-4 continued: Intra-observer and inter-observer variability for %Δ in LVEDV, LVESV, LVM and LVEF. 
 Intra- observer Inter-observer 
 SEM (95%CI) Bias ± limits of 
agreement 
MDC95 SEM (95%CI) Bias ± limits of 
agreement 
MDC95 
T&P included as part of the LV mass 
%ΔLVEDV 
(n=15) 
2.8 (2.0 to 4.4) % 
 
0.8±7.8 % 8% 
 
4.3 (3.2 to 6.9) 
% 
4.2±12.2 % 
 
12% 
%ΔLVM 
(n=15) 
3.1 (2.3 to 4.9) % -0.5±8.8 % 9%  4.4 (3.2 to 7.0) 
% 
1.8±12.6  % 12% 
%ΔLVEF 
(n=15) 
3.7 (2.7 to 5.9) % 
[Absolute change 
2.0 (1.4 to 3.1) %] 
1.4±10.6% 10% 
(5% absolute 
change from 
an acute LVEF 
50%) 
4.3 (3.1 to 6.7) 
% 
[Absolute 
change 2.1 (1.5 
to 3.3) %] 
2.2±12.0 % 12% 
(6.0% absolute 
change from 
an acute LVEF 
50%) 
SEM: standard error of the measurement; MDC95: minimal detectable change in 95% confidence; LVEDV: left ventricular end-diastolic 
volume; LVESV: left ventricular end-systole volume; LVM: left ventricular mass; LVEF: left ventricular ejection fraction. 
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Irrespective of how the T&P were dealt with, the highest MDC95 was 8% 
for %ΔLVEDV and 10% for %ΔLVESV for intra-observer measurements. The 
corresponding values for inter-observer measurements were 12% and 13%, 
respectively. Further details for %ΔLVM and %ΔLVEF are provided in Table 
8-5. 
Table 8-5: Cut-off values for LVEDV and LVESV in 
STEMI patients in our cohort (irrespective of whether T&P 
considered as part of LV volume or LV mass). 
 MDC95 
 Intra-observer Inter-observer 
%ΔLVEDV 8% 12% 
%ΔLVESV 10% 13% 
%ΔLVM 9% 12% 
%ΔLVEF 
11% 
(5.5% absolute 
change) 
13% 
(6.5% absolute 
change) 
MDC95: minimal detectable change in 95% confidence; %Δ: 
percentage change; LVEDV: left ventricular end-diastolic volume; 
LVESV: left ventricular end-systole volume; LVM: left ventricular mass; 
LVEF: left ventricular ejection fraction. 
 
8.3.3 Clinically significant %Δ in LVEDV and LVESV 
A total of 146 STEMI patients had matching acute (mean of 4±2 days) 
and follow-up CMR scans (median of 4 months). 12/146 (8%) patients had their 
scans on a 3T scanner and the rest were acquired on 1.5T scanners. Table 8-6 
summarises the clinical and CMR details of these 146 patients.  
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Table 8-6: Total number of patients with paired acute 
and follow-up scan from 4 studies. 
Details Number 
Number of patients 146 
Ludman 2011 
Crimi 2013 
Cohort 2  
Cohort 1  
29 (20%) 
65 (45%) 
12 (8%) 
40 (27%) 
Male 129 (88%) 
Age (years) 59±12 
Diabetes Mellitus 15 (10%) 
Hypertension 67 (46%) 
Smoking 64 (44%) 
Dyslipidaemia 47 (32%) 
Chest pain onset to PPCI time 
(minutes) 
184 [135-282] 
Infarct artery (%) 
LAD 
RCA 
Cx 
 
            109 (75%) 
29 (20%) 
8 (6%) 
TIMI flow pre-PPCI 
0 
1 
2 
3 
 
129 (89%) 
7 (5%) 
4 (3%) 
4 (3%) 
TIMI flow post-PPCI 
0 
1 
2 
3 
 
2 (1%) 
2 (1%) 
23 (16%) 
117 (82%) 
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Timing of acute CMR 4±2 days 
Timing of follow-up CMR 4 (4-5) months 
CMR findings- acute 
LVEDV 
LVESV 
LVM 
LVEF 
MI size 
MVO 
 
156 (132-183) ml 
80 (64-103) ml 
121 (104-145) g 
47±9 % 
24.6±12.1 %LV 
96 (66%) 
CMR findings- follow-up 
LVEDV 
LVESV 
LVM 
LVEF 
MI size 
 
165 (141-201) ml 
82 (60-109) ml 
106 (90-132) g 
50±11 % 
17.8±10.1 %LV 
LAD: left anterior descending artery; RCA: right coronary artery; Cx: 
circumflex artery; TIMI: thrombolysis in myocardial infarction; LVEDV: left 
ventricular end-diastolic volume; LVESV: left ventricular end-systole volume; 
LVM: left ventricular mass; LVEF: left ventricular ejection fraction. 
 
As expected, ROC curve analysis showed that %ΔLVESV was a better 
predictor of LVEF of <50% at follow-up, with an AUC of 0.83 (95% CI 0.77 to 
0.90), when compared to an AUC of 0.75 (95% CI 0.67 to 0.83) for %ΔLVEDV, 
P=0.03 for ROC curves comparison (Figure 8-3). A %ΔLVEDV of 11% had a 
sensitivity of 72% and a specificity of 70%, and a %ΔLVESV of 5% had a 
sensitivity and specificity of 78%. 
These cut-off values were lower than the MDC95 for inter-observer 
measurements. Therefore, using the cut-off values for MDC95 for inter-observer 
measurements (given that the scans from different studies were by different 
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observers), an increase in LVEDV of 12% had a sensitivity of 73% and a 
specificity of 69% and an increase in LVESV of 13% had a sensitivity of 90% and 
a specificity of 60% to detect an LVEF of <50%.  
 
 
Figure 8-3: ROC curve comparison for %ΔLVEDV and 
%ΔLVESV to detect LVEF<50% at follow-up. 
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8.3.4 Relationship between %ΔLVESV, %ΔLVEDV, %ΔLVEF on post-
STEMI LV remodelling 
Figure 8-4 shows the relationship between %ΔLVESV and %ΔLVEDV. 
The dashed lines represent the cut-off values of +12 and -12% for %ΔLVEDV 
(vertical dashed lines) and of +13 and -13% for %ΔLVESV (horizontal dashed 
lines). Patients were divided into 3 groups for %ΔLVEF based on the MDC95 
cut-off of 13% for inter-observer measurements, namely: blue circles - no 
change in LVEF at follow-up; green circles - increase in LVEF at follow-up 
compared to acute scan; red circles - decrease in LVEF at follow-up compared 
to acute scan. Those with a reduction in LVEF at follow-up were more likely to 
have an increase in both LVEDV and LVESV, and tended to be in the right 
upper quadrant (RUQ) of the graph (adverse LV remodelling group). Those with 
an improvement in LVEF were more likely to have in improvement in LVESV 
and LVEDV and tended to be in the middle lower quadrant (MLQ) and left lower 
quadrant (LLQ) of the graph (reverse LV remodelling group). Some patients had 
an increase in LVEDV only with or without an improvement in LVEF, and 
tended to lie in the right middle quadrant (RMQ) of the graph (adverse LV 
remodelling with compensation). Those in the middle quadrant (MQ) of the 
graph had no change in LVEDV or LVESV and predominantly no change in 
LVEF (no remodelling group). 
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Figure 8-4: Relationship between %ΔLVEDV, %ΔLVESV 
and %ΔLVEF. 
The vertical dashed lines represent the cut-off values of +12 
and -12% change in LVEDV and the horizontal dashed lines 
represent +13 and -13% %ΔLVESV. Patients were divided into 3 
groups for %ΔLVEF based on the MDC95 cut-off of 13%, namely: 
blue circles - no change in LVEF at follow-up; green circles - 
increase in LVEF at follow-up compared to acute scan; red circles - 
decrease in LVEF at follow-up compared to follow-up. Those with a 
reduction in LVEF at follow-up were more likely to have an increase 
in both LVEDV and LVESV, and tended to be in the right upper 
quadrant (RUQ) of the graph (adverse LV remodelling group). 
Those with an improvement in LVEF were more likely to have in 
improvement in LVESV and LVEDV and tended to be in the middle 
lower quadrant (MLQ) and left lower quadrant (LLQ) of the graph 
(reverse LV remodelling group). Some patients had an increase in 
LVEDV only with or without an improvement in LVEF, and tended to 
lie in the right middle quadrant (RMQ) of the graph (adverse LV 
remodelling with compensation). Those in the middle quadrant (MQ) 
of the graph had no change in LVEDV or LVESV and predominantly 
no change in LVEF (no remodelling group). 
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Figure 8-5a provides a schematic representation for evaluating LV 
remodelling post-STEMI from %ΔLVEDV and %ΔLVESV, using a 2-step 
approach: firstly the %ΔLVEDV is evaluated (in this case a cut-off value of 12% 
was used) and secondly, the %ΔLVESV is assessed as shown in Figure 8-5b 
(in this case a cut-off value of 13% was used). Using this approach, 4 main 
patterns of post-STEMI LV remodelling were observed: Group 1: adverse LV 
remodelling (with LVEF unchanged or worsened, 30%); Group 2: adverse LV 
remodelling with compensation (with LVEF predominantly improved, 16%); 
Group 3: no LV remodelling (with LVEF predominantly unchanged, 20%); and 
Group 4: reverse LV remodelling (with LVEF predominantly improved, 27%).
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Figure 8-5: (a) Schematic representation of the 
different groups of remodelling; (b) The evaluation of LV 
remodelling using a 2-step approach. 
Based on the %ΔLVEDV and %ΔLVESV between the follow-up and 
acute CMR, patients would predominantly fall into these 4 main patterns of LV 
remodelling groups. Using a 2-step approach and a combination of %ΔLVEDV 
and %ΔLVESV, patients can be easily classified into these 4 groups.  
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8.3.5 Relationship between %ΔLVESV/ %ΔLVEDV, MI size and MVO 
The acute MI size was divided into quartiles as follows: <15%, 15 to 
<24%, 24 to <33% and ≥33%. Figure 6 shows the distribution of acute MI size 
divided by quartiles and between those without MVO (Figure 8-6a) and those 
with MVO (Figure 6b). Although those with larger MI size and MVO were more 
likely to have adverse LV remodelling (red box), there were also patients with 
small MI sizes and no MVO who went on to develop adverse LV remodelling 
(green dots within the red margins in Figure 6a) and adverse LV remodelling 
with compensation (green dots within the yellow margins). Likewise, there were 
also a notable number of patients with large MI size and MVO who developed 
reverse LV remodelling (black dots within the blue margins in Figure 8-6b).  
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Figure 8-6: Relation between %ΔLVEDV/ %ΔLVEV and 
different quartiles of acute MI size in (a) patients without MVO 
and (b) patients with MVO. 
Some patients with small MI and no MVO (green dots in 6a) 
developed adverse LV remodelling (falling within the red margin or 
yellow margin in 6a) with others with large MI and MVO (black dots 
in 6b) developed reverse LV remodelling or no remodelling (falling 
within the green or blue box in 6b). 
 
8.4 Discussion 
The main findings of this study are as follows: (a) The MDC95 in 
%ΔLVEDV and %ΔLVESV of 12% and 13% respectively, and was higher than 
the corresponding cut-off values for predicting LVEF<50% at follow-up (11% for 
%ΔLVEDV, and 5% for %ΔLVESV), providing cut-off values for assessing 
adverse and reverse LV remodelling following STEMI by CMR; (b) The minimal 
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detectable changes in %ΔLVM and %ΔLVEF from the acute to follow-up CMR 
scan were 12% and 13%, respectively, providing cut-off values for assessing 
changes in these LV parameters following STEMI by CMR; (c) By assessing the 
combined %ΔLVEDV and %ΔLVESV between the acute and follow-up CMR, 
we observed 4 different patterns of LV remodelling following STEMI. 
In this study, we measured both intra-observer and inter-observer 
variability, and as expected the MDC95s for all these LV parameters were 
greater for inter-observer than intra-observer measurements. Our analyses on 
the whole cohort mainly focused on the inter-observer rather than the intra-
observer measurements because different operators analysed the scans from 
each study. We found that the inter-observer MDC95s for %ΔLVEDV and 
%ΔLVESV between the acute and the follow-up CMR were 12% and 13%, 
respectively. These provide cut-off values for defining LV remodelling following 
STEMI, and suggest that a combination an increase in LVEDV (≥12%) and in 
LVESV (≥13%) could be used to identify adverse LV remodelling, whereas a 
decrease in LVESV (≥13%) with or without a decrease in LVEDV (≥12%) could 
be used to identify reverse LV remodelling. However, further studies are 
required to investigate the prognostic implications of these proposed cut-off 
values for defining adverse and reverse LV remodelling following STEMI. 
Currently there is no consensus on whether T&P should be included as 
part of the LV volume or as part of LV mass during LVEF and LVM assessment 
by CMR. (57) We therefore provided MDC95 for %ΔLVEDV, %ΔLVESV, 
%ΔLVM, and %ΔLVEF using both approaches. It is already known that the T&P 
can significantly affect LV volumes, LV mass, and LVEF.(292, 293) We found 
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that LVEDV and LVESV were higher, and LVM and LVEF were lower when 
T&P were included as part of the LV volume and this is consistent with previous 
reports.(292-294) As their inclusion as part of the LV mass is not always 
practical depending on the software, both methods are currently considered 
acceptable.(57) Although the LV parameters differed depending on how the 
T&P were dealt with, there was no difference in the CoV both for inter or intra-
observer measurements for LVEDV, LVESV, LVM and LVEF when T&P were 
included as part of the LV volume or LV mass. However, the MDC95 for intra-
observer and inter-observer measurements for %Δ in LV parameters varied by 
1-2% depending on whether the T&P were included as part of the LV volume or 
LV mass. We therefore provided the highest MDC95 for each LV parameter in 
Table 5, irrespective of how the T&P were dealt with. 
Using LVEF <50% at follow-up as a clinically important surrogate marker 
for assessing adverse LV remodelling following STEMI, we obtained cut-off 
values for %ΔLVEDV and %ΔLVESV of 10% and 5%, respectively. The 
diagnostic performance of %ΔLVEDV and %ΔLVESV was not as high as 
expected and could be related to the fact that some patients have LV 
remodelling with compensation (group 3) and therefore would maintain LVEF 
above 50% despite an increase in %ΔLVEDV.  On the other hand, %ΔLVESV 
performed slightly better, which is not surprising as LVEF is calculated from the 
formula (LVEDV-LVESV)/LVEDV, and there was an element of mathematical 
coupling.(295) But the diagnostic performance for %ΔLVESV was not as high 
as expected as it is dependent on a change in %ΔLVEDV to lead to a reduction 
in LVEF. These cut-off values obtained were lower than that defined by our 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
221 
MDC95 cut-off values for %ΔLVEDV of 12%, and for %ΔLVESV of 13%. The 
minimal detectable change and the clinically significant change are independent 
of each other as they are derived in different ways and in our case, the former 
turned out to be larger than the later. Therefore we chose the cut-off values of 
MDC95 to define LV remodelling in the whole cohort. 
Westman et al (205) recently showed that there was an imperfect link 
between MI size and adverse LV remodelling (defined as >10ml/m2 increase in 
indexed LVEDV). Several studies have also shown that MVO was a strong 
predictor of adverse LV remodelling.(60) Using the definition in our study for 
adverse LV remodelling, we also showed that there was an imperfect link 
between acute MI size and adverse LV remodelling as well between MVO and 
adverse LV remodelling. Some patients with large MI size and MVO developed 
reverse LV remodelling and some patients with small MI size and no MVO 
developed adverse LV remodelling. As eluded by Westman et al(205),  the 
development of adverse LV remodelling is complex and multi-factorial, and 
more work is warranted in this field. 
We found the MDC95 in %ΔLVM between acute and follow-up scans to 
be ≥12%, suggesting that this would be the minimal change in LVM that is 
unlikely due to inter-observer measurement errors. However, the interpretation 
of changes in LVM following STEMI is complicated by the fact that on the acute 
scan, the presence of myocardial oedema also contributes to the changes in 
LVM acutely and therefore we did not investigate %ΔLVM in post-STEMI LV 
remodelling. However, it would be interesting to determine the MDC for 
assessing %ΔLVM in patients with LV hypertrophy (LVH) related to 
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hypertension or aortic valve disease, in order to provide cut-off values which 
can be used in studies assessing the regression of LVH.  
Finally, we found the MDC95 for %ΔLVEF to be ≥13% in STEMI patients 
when using CMR. This finding suggests that only a relative change in LVEF of 
13% or more can be reliably detected by CMR as being beyond inter-observer 
measurement errors. This is equivalent to an absolute change of 6.5% in a 
patient with an acute LVEF of 50%. This needs to be taken into consideration 
when planning future studies designed to investigate new treatments for 
improving LVEF following STEMI. 
 
8.4.1 Limitations 
Inter-observer and intra-observer measurements were performed in 15 
patients only (30 scans) but this is similar in numbers to the previous study 
providing the minimal detectable change in LVEF by echocardiography in 
patients undergoing chemotherapy (10 patients with echocardiography at 2 
time-points).(291) We only used one analysis tool and LV parameters were 
quantified using the semi-automated method. We did not have matching 
echocardiography data for comparison. Crimi et al (117) included LAD STEMIs 
only and there was an element of selection bias. However LAD STEMIs are 
associated with larger MIs and with poor prognosis (296) and therefore despite 
having only 146 patients with paired CMR scans, they represented a higher risk 
cohort with 75% presenting with LAD STEMI. We did not have a large enough 
cohort to provide information on clinical outcomes and therefore used an LVEF 
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at follow-up of <50% to be clinically important. There was heterogeneity in the 
performance of CMR for acute MI size and MVO (scanner strength, dosage and 
type of contrast, timing of LGE for MVO and MI, quantification technique used – 
Table 1) and our findings need to be confirmed by other studies. 
 
8.5 Conclusions 
The MDCs for %ΔLVEDV and %ΔLVESV of 12% and 13% respectively, 
between acute and follow-up CMR scans, may be used to help define adverse 
and reverse LV remodelling post-STEMI. Combining %ΔLVEDV and %ΔLVESV 
following STEMI may provide additional insights into the different patterns of LV 
remodelling, but their prognostic impact needs to be assessed in future studies. 
Finally, the MDC for %ΔLVEF of 13% relative to baseline provides the minimal 
effect size that needs to be taken into consideration when investigating 
treatments aimed at improving LVEF following acute STEMI. 
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9 General discussion 
In this thesis, we have shown that multi-parametric mapping CMR 
provides in-depth insight into the various components of an acute STEMI, 
namely the MI zone, the MI core, the AAR and remote myocardium. However, 
performing all these parameters can be time-consuming, especially in acutely 
unwell STEMI patients. Therefore, these multi-parametric mapping techniques 
should be used judiciously in order to obtain the maximum information with the 
least number of CMR sequences. 
 
9.1 T1 mapping for the delineation of the AAR, IMH and MI size 
A comprehensive CMR study in a reperfused acute STEMI patient 
requiring data on the AAR, IMH, MVO, MI size and ECV, would take on 
average, an hour to perform. Based on the results from Chapter 5, either native 
T1 mapping or T2 mapping and conventional LGE could be omitted. This 
approach would substantially shorten the scanning time by 15-20 minutes (see 
Figure 9-1 a and b) in centres performing comprehensive CMR studies, without 
compromising data acquisition. Furthermore, this would improve patient 
workflow, make the CMR scan more tolerable to acute STEMI patients, and 
may help minimise patient dropout in future clinical studies. If data on ECV were 
required, then native T1 mapping would be preferred over T2 mapping. By 
acquiring native (for AAR) and post contrast T1 mapping (for LGE), ECV maps 
can be derived (Figure 9-1d), and this process may also be accelerated if the 
synthetic or in-line ECV tool available on the Siemens platform is used.(297) 
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Alternatively, If only data on AAR and MI are required, then T2 mapping could 
be replaced by T1 mapping (Figure 9-1c).  
We would still recommend performing T2* weighted imaging or T2* 
mapping when available as the accuracy of T1 mapping and T2 mapping to 
detect IMH was only 85% and 87% respectively. However, in situations when 
T2* imaging is not interpretable or not available, T1 or T2 mapping could then 
be used as surrogates to identify IMH and this approach would minimise 
patients’ dropping out from future studies. The wider availability of free 
breathing and motion corrected T2* mapping (157) would make this modality 
more bearable for STEMI patients and full LV coverage (for accurate IMH 
quantification) would be possible with minimal discomfort to the patients.  
Last but not least, performing post-contrast cine as shown in Figure 9-1 
would provide an alternative modality for assessing the AAR. AAR from 
contrast-enhanced SSFP (CE-SSFP) cine has been shown to provide similar 
estimates of the AAR when compared to T2-STIR and CE-SSFP had 
significantly more images of diagnostic quality (97% versus 65%) in a large 
study of 215 STEMI patients.(114) 
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Figure 9-1: Duration of the CMR scan. 
Figure 6a and b illustrate the duration for a comprehensive 
STEMI CMR acquisition protocol providing data on AAR, IMH, MVO, 
MI size and ECV and on average takes around one hour to acquire. 
Based on the results from this study, T1 mapping may allow T2 
mapping and LGE to be omitted thereby shortening the scanning 
time by 15-20 minutes. Figure 6c and d illustrates the options of 
either doing T2 mapping and post-contrast T1 mapping or native T1 
mapping and post-contrast T1 mapping depending on the research 
question. 
 
Certain cardioprotective therapies such as ischaemic postconditioning 
(115) and remote ischaemic conditioning (using transient arm or leg ischaemia 
and reperfusion) (116, 117) have been shown not only to reduce MI size, but 
also reduced the extent of oedema delineated by T2 mapping and T2-weighted 
imaging, leading to an underestimate of the AAR in reperfused STEMI patients. 
Whether these therapeutic interventions also affect the AAR delineated by T1 
mapping needs to be investigated in future studies.  
It was previously believed that the AAR delineated by T2-weighted 
imaging is maximum and constant within the first week following an acute 
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myocardial infarction.(91, 164) A recent pre-clinical study using a porcine model 
of acute MI has suggested that myocardial oedema delineated by T2-weighted 
imaging vary over the first week and displays a bimodal phase of oedema.(110) 
However, recently Carrick et al (112) showed that although the T2 and T2* of 
the core of the MI followed a bimodal pattern and was more pronounced in 
those with IMH, the extent of myocardial oedema in the clinical setting followed 
a unimodal pattern and peaked at day 3. Nordlund et al (114) also recently 
provided some indirect evidence and no change in size or quality of the AAR 
over the first week in 215 STEMI patients. More work is warranted in this field to 
compare the performance and stability of CE-SSFP cines, T1 mapping and T2 
mapping to delineate the AAR within the first week of an MI and when is the 
optimal timing for CMR imaging. 
Although free breathing and motion corrected T2* mapping (157) sounds 
very appealing and promising for use in the setting of STEMI research, its 
performance against the conventional T2* mapping to detect and quantify 
different extents of IMH, remains to be tested. Furthermore, although IMH has 
been showed to peak on day 3 (112), whether those with IMH at a later stage 
(day 5 to 7) may be more prognostic remains to be tested in future studies. 
Advances in real-time cines for LVEF (298) and future refinements in MR 
fingerprinting techniques (299) (for robust and fast acquisition of simultaneous 
T1 and T2 mapping data per slice within one breath-hold) would further reduce 
scan time and would be highly desirable in the STEMI setting. 
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9.2 The optimal method for MI size quantification 
Several studies (177, 178) have investigated the optimal semi-automated 
method for quantifying MI size, but there is currently no established gold 
standard recommendation. Manual contouring is considered the reference 
standard (57, 176) but it can be time consuming (183) and may be subjective. 
Several semi-automated techniques have been proposed for quantifying acute 
and chronic MI size such as a signal intensity threshold of 5-SD (177) or 6-SD 
(178) above the normal remote myocardium, the Otsu technique (180), and the 
FWHM (182, 183) and the automated quantification accounting for partial 
volume effects (281) as summarised in Table 9-1. The consensus document 
from the Society for Cardiovascular Magnetic Resonance (SCMR) Board of 
Trustees Task Force on Standardized Post Processing (57) currently 
recommends the semi-automated threshold technique of 5-SD for MI size 
quantification, in the absence of clear gold standard semi-automated technique, 
as it may improve reproducibility. However, some studies have shown that 5-SD 
overestimates acute MI size (180, 280) and we showed a similar finding, as 
described in chapter 6.  6-SD was better that 5-SD, FWHM and Otsu to quantify 
both acute and follow-up MI size and this was most recently confirmed by 
Zhang et al at 3T.(185) Although FWHM has been shown to have the lowest 
variability (182, 183) and performed well for acute MI size in our cohort, it was 
dependent on the imaging sequence we used for LGE. Furthermore, we 
showed that in patients with MVO on the acute scan, FWHM underestimated 
the chronic MI size. However, we have also shown that acute MI size by all 4 of 
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these promising techniques performed equally well to predict adverse LV 
remodelling.  
Whether MI size quantified by the 4 different semi-automated techniques 
would perform equally well to predict clinical outcomes, needs to be tested in 
future studies. 
Table 9-1: Main studies comparing difference 
techniques for IS and AAR quantification. 
Study No of patients Techniques 
compared 
Software Result 
Zhang 2016 
 (185) 
114 AMI 
patients with 
matching 
follow-up scan 
at 6 months at 
3T 
Manual, 
FWHM (20 to 
50%), 1 to 9-
SDs 
Mass FWHM30% and 3-SD was 
closest to manual for total infarct 
size and FWHM45% and 6-SD 
was closest to manual for core 
MI size 
Dash 2015 
(280) 
(conference 
abstract) 
19 AMI 
porcine 
models 
FWHM 
5-SD 
6-SD 
CVI42 6-SD was more accurate to 
quantify MI size. FWHM and 5-
SD overestimated MI size when 
compared to histology 
McAlindon 
2015 (176) 
40 AMI 
 
Manual 
2,3,5 SDs 
Otsu 
FWHM 
CVI42  
Manual and FWHM provided the 
lowest inter, intra-observer 
variability for infarct size  
 
Khan 2015 
(183) 
10 AMI 1.5T 
and 10AMI 3T 
 
5-8 SDs 
FWHM 
Otsu 
CVI42 FWHM is accurate and 
reproducible. 
5-SD and OAT overestimates 
infarct size at both fields. FWHM 
correlated strongest with LV EF 
 
Vermes 
2013 (180) 
28 AMI 
30 myocarditis 
Visual 
2,3,5 SDs 
Otsu 
FWHM 
CVI42 Otsu and 5-SD did not differ. 
Otsu similar to visual 
5-SD and FWHM overestimated 
LGE compared to visual 
Varga- AMI in 6 2-6 SD, ImageJ 6-SD provided the most 
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Szemes 
2012 (300) 
swines FWHM, TTC accurate measure of MI size 
Flett 2011 
(182) 
20 AMI 
20 CMI 
20 HCM 
 
Manual 
2 - 6 SDs 
FWHM 
ImageJ 
(purpose-
written 
macro) 
No difference between FWHM, 
manual, 6-SD and 5-SD. 
FWHM similar to manual and 
more reproducible (reducing 
required sample size by one-
half) 
Beek 2009 
(178) 
38 CMI 
 
2-8 SDs 
FWHM 
Mass  6-SD showed the highest 
accuracy to predict segmental 
functional recovery 
Bondarenko 
2005 (177) 
15 CMI 2-6 SDs  No difference between visual 
analysis and 5-SD. 
Hsu 2006/ 
Hsu 2006 
(301, 302) 
11 canine - 
AMI 
11 AMI and 9 
CMI 
Manual 
2SD 
FWHM 
FACT 
Interactive 
Display 
Language/ 
Microsoft 
Visual C++ 
FACT accurately measured MI 
size in vivo and ex-vivo – more 
accurate than manual and SD. 
Manual and 2-SD overestimated 
infarct size compared to FACT 
Amado 2004 
(181) 
13 canine – 
AMI 
  
Manual 
1-6 SDs 
FWHM 
Cine tool, 
GE 
FWHM correlated best with post-
mortem data. 
No difference in MI between 6 
and 30 minutes after contrast 
AMI: acute myocardial infarction; SD: standard deviation; MI: myocardial infarction; 
FWHM: full width half maximum; FACT: feature analysis and combined thresholding; LGE: late 
gadolinium enhancement; CMI: chronic myocardial infarction; HCM: hypertrophic 
cardiomyopathy. 
 
9.3 IMH as a future therapeutic target to prevent adverse LV 
remodelling 
It is well recognised that IMH is associated with larger MI size, adverse 
LV remodelling and poor clinical outcomes (160, 161, 261, 283) and may be 
pro-arrhythmic. (206, 303) Although our study was purely based on tissue 
characterisation, these findings support the current literature (207, 208) that 
residual myocardial iron may play a role in the inflammatory phase of adverse 
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LV remodelling. We used T2 mapping for the detection of delayed resolution of 
oedema associated with residual myocardial iron in patients with IMH.  
Recently Carrick et al (139) performed serial scanning in 30 patients and 
elegantly described the time course of MVO and IMH. MVO was already 
present at 4 to 12 hours and remained stable up to a mean of 2.9 days and then 
reduced by day 10. IMH, on the other hand, peaked at a mean of 2.9 days and 
decreased by day 10. 13 patients had IMH on day 2.9 and only 4 patients 
displayed residual myocardial iron by 6 months. Based on brain imaging data 
(158), degradation of haemoglobin eventually leads to ferritin and hemosiderin 
deposits and the fact that the majority of their patients had no residual 
myocardial iron in their study may suggest that those patients had small areas 
of IMH that were rapidly cleared by the macrophages. They reported the 
presence of IMH in 41% of their total cohort of 245 patients with analysable T2* 
data and it is likely that this may be an underestimation of the true prevalence of 
IMH, as the CMR was performed at a mean of 2.1 days, which is earlier than 
the timing for peak IMH (2.9 days). Pooling the results of these 3 studies 
demonstrating residual myocardial iron following STEMI, Kali et al (207) (acute 
scan: 11 out of 15 patients with IMH; follow-up scan: 11 with residual 
myocardial iron), Carrick et al (139) (acute scan: 13 out of 30 patients with IMH; 
follow-up scan: 4 with residual myocardial iron) and our study (acute scan: 15 
out of 28 patients with IMH; follow-up scan: 13 with residual myocardial iron), 
the incidence of IMH by T2* mapping was 53% (39/73) and 72% (28/39) had 
residual myocardial iron at follow-up. Although IMH is likely to be confounded 
by larger infarct size, whether specifically targeting these patients with anti-
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inflammatory agents or chelation therapy needs to be investigated in future 
studies aiming to prevent adverse LV remodelling. 
9.4 Prognostic significance of the remote myocardial ECV  
Chan et al (213) used post-contrast T1 in 25 acute STEMI patients and 
found evidence of early remote systolic dysfunction and expansion of the ECM, 
which persisted in the chronic stage and their findings partly differs from ours. 
We did not find evidence of systolic dysfunction in the remote myocardium but 
paradoxically found an increase in wall motion in the remote myocardium on the 
acute scan only. These differences may partly be due to the smaller number of 
patients, and methodology used in their study (definition of a remote sector: any 
segment without LGE as defined in their study may potentially have included 
adjacent segments with oedema and stunning; they only analysed base, mid 
and an apical cine compared to full LV short axis analysis and we used 
averaged values of the mid ventricular segments in our study). Furthermore, not 
all STEMI patients showed persistence of ECVRemote expansion at follow-up 
when using automated ECV maps and this may be due to the fact that we 
included more patients with a wider range of MI size (acute MI size in our study 
27.4±14.6% versus 19.2±10.5% in their study) and the higher use of 
angiotensin converting enzyme inhibitors/ angiotensin receptor blockers 
(ACEI/ARB) and mineralocorticoid receptor antagonist (MRA) in our study 
(ACEI/ARB 92% versus 100%: MRA 16% versus 25%). 
Carrick et al (197) demonstrated that increased native T1 values in 
remote myocardium of reperfused STEMI patients were independently 
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associated with adverse LV remodelling after adjusting for LVEDV, MI size and 
MVO on the acute scan. In  a separate publication, Carrick et al (156) also 
showed that native T1 of the hypo-intense infarct core was inversely associated 
with the risk of all-cause mortality or hospitalization for heart failure in the same 
cohort of patients although they did not adjust for native T1 of the remote 
myocardium.  
 In our cohort, although the number of patients were significantly less, we 
showed that MI size was the single most significant predictor of adverse LV 
remodelling after adjusting for similar parameters including native T1 of the 
remote myocardium. Although MI size is known to be a strong predictor of 
outcome (58, 59), MSI is a more sensitive marker to assess the effectiveness of 
a reperfusion strategy (66, 67) in randomised controlled trials and it was 
recently shown that MSI significantly reduced sample size.(304) Therefore, we 
opted to use MSI instead of MI size expressed as a percentage of the LV. We 
found that acute ECVRemote together with MSI were also strongly associated with 
LV remodelling after adjusting for T1Remote, T1Core and MVO.  
Although the sample size was significantly smaller in our study, our 
findings may also differ from the studies by Carrick et al (156, 197) as we used 
mean segmental values for T1, T2 and ECV rather than manual ROI (The ICC 
for reliability of remote T1 in Carrick et al (197) was 0.92 and had quite a wide 
95% CI (0.80, 0.97)). Furthermore, the majority of our patients (>70%) had full 
LV coverage for the T1 maps and ECV maps. These maps were averaged to 
derive the mean segmental values as per the AHA classification and therefore 
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were more likely to be a better representation of the changes in the remote 
myocardium.  
Carberry et al (288) most recently showed in 131 STEMI patients that the 
change in remote zone ECV was a multivariable associate of the change in left 
ventricular end-diastolic volume at 6 months, but they were underpowered to 
show an association with clinical outcomes. Whether change in ECV in the 
remote myocardium can be used as a surrogate to predict those at high risk of 
adverse LV remodelling and poor clinical outcomes needs to be assessed in 
future adequately powered studies.  
9.5 Redefining LV remodelling by CMR 
Conventionally, adverse LV remodelling post-STEMI has been defined 
by %ΔLVEDV and CMR studies have used the echocardiography derived cut-
off value of 20%.(196, 197) Other groups have used an arbitrary cut-off of ≥15% 
increase in LVESV to define adverse LV remodelling by CMR.(63, 199) We 
found that the cut-off values for %ΔLVEDV and %ΔLVESV between the acute 
and the follow-up CMR were 12% and 13%, respectively.  
As expected, the cut-off value of 12% or more for %ΔLVEDV to define 
adverse LV remodelling obtained in our cohort is significantly lower than that 
defined by echocardiography. This is due to the better spatial resolution of 
CMR, with results in lower intra-observer and inter-observer variability.(191) On 
the other hand, the cut-off value for defining reverse LV remodelling as ≥13% 
ΔLVESV from our study is higher than the 10% cut-off value currently proposed 
by echocardiography (195), although the MDC95 for intra-observer 
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measurements by CMR was identical at 10%. The echocardiography-based 
method was derived using ROC curve for the optimal cut-off for decrease in 
ESV to predict mortality in patients undergoing cardiac resynchronization 
therapy and they did not perform inter-observer and intra-observer variability for 
%ΔLVESV. It is highly likely that the inter-observer and intra-observer for 
%ΔLVESV by echocardiography in STEMI patients would be higher than the 
CMR cut-off value we obtained.  
Our data, suggests that assessing both %ΔLVEDV and %ΔLVESV 
provides further insights into different patterns of LV remodelling following 
STEMI, and this approach may allow one to customise heart failure therapy to 
prevent adverse LV remodelling or promote reverse LV remodelling. Orn et al 
(149) described 3 patterns of LV remodelling based on the presence and 
persistence of MVO by CMR within the first week of an acute STEMI in a serial 
CMR study of 42 patients. Most LV remodelling occurred by 2 months and 
continued to at least 1 year. Those with no MVO had a normal pattern of wound 
healing; those with MVO on day 2 only dilated their ventricle but adapted 
functionally; and the last group were those with persistent MVO at 1 week and 
they dilated their ventricle without the ability to adapt functionally. These 3 
groups bear some resemblance to the groups of LV remodelling we identified 
but we did not have serial CMR data on MVO for comparison. Other factors that 
determine the pattern of LV remodelling post-STEMI also require further study. 
We also found that in STEMI patients, only a relative change in LVEF of 
13% or more can be reliably detected by CMR as being beyond inter-observer 
measurement errors. This is equivalent to an absolute change of 6.5% in a 
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patient with an acute LVEF of 50%. This needs to be taken into consideration 
when planning future studies designed to investigate new treatments for 
improving LVEF following STEMI. 
We have provided new definitions to define LV remodelling post-STEMI 
by CMR. Combining %ΔLVEDV and %ΔLVESV following STEMI may provide 
additional insights into the different patterns of LV remodelling, but their 
prognostic impact needs to be assessed in future studies.  
 
9.6 Summary of major findings 
1. T1 mapping can quantify the AAR as well as T2 mapping in STEMI 
patients both at 1.5T and 3T. T1 mapping provides a reliable alternative 
method to quantify the AAR. 
2. A hypo-intense core within the AAR on a T1 or T2 map can be used to 
detect IMH in cases when T2* mapping is not available or is not 
interpretable. 
3. Post-contrast T1 maps and the post-contrast T1 mapping derived 
synthetic LGE can be used to accurately delineate the acute MI size and 
by acquiring post-contrast T1 maps may obviate the need for 
conventional LGE imaging. 
4. When accurate MI size quantification is required (e.g. randomised 
controlled trials), 6-SD is the optimal semi-automatic threshold method 
both in the acute and follow-up setting. However, when precise MI size 
quantification is required (e.g. registries or observational studies), any 
                                    PhD thesis: Tissue Characterisation in Myocardial Infarction by CMR, Dr H Bulluck, UCL 
 
 
237 
one of these 4 semi-automated techniques (5-SD, 6-SD, FWHM or Otsu) 
may be suitable. 
5. A proportion of reperfused STEMI patients with IMH go on to have 
residual myocardial iron at 5 months and is associated with persistently 
elevated T2 in the areas of the chronic MI surrounding the residual iron. 
IMH and residual myocardial iron are potential future therapeutic targets 
to prevent adverse LV remodelling.  
6. The remote ECV is increased within the first few days of a reperfused 
STEMI but only remains persistently elevated in a subset of patients who 
develop adverse LV remodelling.  
7. The cut-off values to define %ΔLVEDV and %ΔLVESV in paired acute 
and follow-up STEMI patients are 12% and 13% respectively. These cut-
off values could be used to define LV remodelling post STEMI by CMR. 
Combining %ΔLVEDV and %ΔLVESV would provide additional insights 
into the different patterns of LV remodelling. 
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